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Abstract 
 
Fatty acid amides are an emerging family of bioactive lipids that consists of 
N-acylethanolamines, N-acylarylalkylamides, N-acylglycines, N-acyl amino acids, 
N-monoacylpolyamides, and primary fatty acid amides.  Short chain fatty acid amides are 
products of inactivated biogenic amines such as dopamine, histamine, octopamine, and 
serotonin, whereas long chain fatty acid amides have been implicated in a number of 
physiological process such as the perception and inhibition of chronic pain through binding to 
their specific receptors.  The most famous; therefore, the most studied long chain fatty acid 
amide is anandamide or also known as N-arachidonylethanolamine.  The biosynthesis of 
anandamide is well defined; however, other long-chain fatty acid amides, such as the 
N-acyldopamines, N-acylserotonins, N-acylglycines, N-acyl amino acids, and primary fatty acid 
amides have remained elusive to date.  Understanding the complete biosynthetic pathway for 
these cell signaling lipids, may yield new exciting molecular targets for human health and 
disease.  Discovery of the long-chain fatty acid amide biosynthetic enzymes has proven to be 
challenging due to the low biologic abundance of the respective metabolites found in organisms, 
the interconnection of the pathways, and expense of using mammalian cells and/or organisms.  
This led to the transition of studying these metabolites and their respective biosynthetic enzymes 
in Drosophila melanogaster.  D. melanogaster is an ideal system to study fatty acid amide 
biosynthesis because the respective metabolites have been identified, the cost of maintaining the 
organism is relatively low, and genetic manipulation (RNAi) is universally available.   
xi 
 
This dissertation is dedicated to defining enzymes involved in D. melanogaster 
N-acylarylalkyamide biosynthesis.  The biologically relevant long-chain N-acylarylalkylamides 
are comprised of long-chain N-acyldopamines and N-acylserotonins.  Very little is known for 
how these potent cell signaling lipids are biosynthesized in the cell.  One possible route is the 
N-acylation of the respective biogenic amine by an N-acyltransferase enzyme.  An enzyme 
known to catalyze this chemistry is arylalkylamine N-acetyltransferase (AANAT), which 
catalyzes the formation of N-acetylarylalkylamides from acetyl-CoA and the corresponding 
arylalkylamide.  The N-acetylation of biogenic amines is a critical step in Drosophila 
melanogaster for the inactivation of amine neurotransmitters, sclerotization of the cuticle, and to 
serve as the penultimate intermediate in the biosynthesis of melatonin.  Two AANAT(L) 
enzymes has been previously evaluated in D. melanogaster and six other putative AANATL 
enzymes have identified in the fly genome.  One AANAT is expressed as two biologically 
relevant isoforms, AANAT variant A (AANATA) and AANAT variant B (AANATB), where 
AANATA differs from AANATB by the truncation of 35 amino acids on the N-terminus.  The 
other AANATL enzyme to be previously studied is AANATL2, which was found to catalyze the 
formation of N-acetyltryptamine from acetyl-CoA and tryptamine.  Herein, we expressed six 
AANAT(L) enzymes (AANATA and AANATB, AANATL2, AANATL3, AANATL7, and 
AANATL8) and sought to define the acyl-CoA and amine substrates for each enzyme.  To 
accomplish this, we developed an activity-based screening assay to define acyl-CoA and amine 
substrates for AANATL2, AANATL3, AANATL7, and AANATL8.  Following this work, we 
defined the acyl-CoA and amine substrate specificity for AANATA, AANATL2, AANATL3, 
and AANATL7.  We have identified acetyl-CoA and arylalkylamines as substrates for 
AANATA, AANATL2, and AANATL3; whereas AANATL7 acetylates histamine and 
xii 
 
arylalkylamines.  AANATL2 was additionally shown to catalyze the formation of long-chain 
N-acyldopamines and N-acylserotonins.  Following these important set of results, we solved the 
kinetic mechanism for AANATA, AANATL2, and AANATL7 in which these enzymes were 
shown to catalyze the formation of N-acylarylalkylamides by an ordered sequential mechanism 
where the acyl-CoA substrate binds first followed by the corresponding amine substrate.  Finally, 
we evaluated the function of structural amino acids on regulating catalysis, structural features of 
substrates that effect binding and/or catalysis, and generated data leading to a proposed chemical 
mechanism by means of pH-activity profiles and site-directed mutagenesis of prospective 
catalytic residues.   
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Chapter One 
Introduction  
 
1.1 A historical perspective of cannabinoids and fatty acid amides  
 The origins for the field of fatty acid amide research, in particular, the N-acylserotonins 
and N-acyldopamines is firmly derived from cannabis research.  Cannabis has been cultivated for 
> 6000 years and its origins are suggested to reside in Eastern or Central Asia.
1-4
  It is commonly 
referred to as hemp, hashish, marijuana, and bhang.  Cannabis has been used by people 
throughout history for medicine, religious rituals, manufacturing of goods (strings, ropes, 
textiles, and paper), food, and recreational purposes.
3
  People of the ancient world used cannabis 
for medical purposes consisting of treating migraines, pain, malaria, constipation, tuberculosis, 
epilepsy, impotence, etc. 
3-5
  In the United States, the medical use of cannabis began in the 19
th
 
century; however, declined by the early 20
th
 century.
3
  Its use subsided mainly because of the 
difficulty with replicate effects from extracts and the discovery of other medical treatments, 
including vaccines, aspirin, and morphine.
3
  Another factor in the decline of the medical use of 
cannabis in the United States were the legal restrictions passed in various bills limiting its access 
and sale, beginning with various state prohibition laws and with the Marihuana Tax Act of 1937 
(federal law).
3, 6
  This act resulted in a tax placed on the sale of cannabis in the United States.  
Following this law, the Controlled Substance Act was passed as part of the Comprehensive Drug 
Abuse Prevention and Control Act of 1970, which created five “Schedules” or classifications for 
different control substances.
6-7
  To date, cannabis is considered a “Schedule I” control 
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substance.
7
  Being classified as a “Schedule I” control substance means that: (a) that the 
substance has a great risk of being abused, (b) there is not an accepted medical use for the 
substance, and (c) there is a lack of safety for the administration of the substance in a medical 
setting.
7
  Under this federal law, patients cannot obtain a prescription for the medical use of 
cannabis.
7
  In addition, most of the world still classifies cannabis as illegal.  However, recently 
there has been a push to legalize cannabis and related cannabinoids for medicinal purposes.  In 
fact, there are 23 States, in the United States, that have legalized “medical marijuana” to date 
(2014), with many more considering this type of legislation.
8-9
  In addition, there has been a 
larger push for “medical marijuana” and related cannabinoid research.  One major issue 
hindering the expansion of cannabinoids as medicinal therapeutics is the recreational use or the 
abuse of cannabis by the general population.  The National Institute on Drug Abuse (NIDA), as 
part of the National Institute of Health (NIH) published a series of statistics from 2013, showing 
that ~46% of people have used marijuana recreationally at some point in their life by the 12
th
 
grade.
10
  It is also reported that ~7% of people abuse marijuana daily for recreational use by the 
12
th
 grade, in 2013.
10
  Further studies and work are necessary to combat the recreational abuse of 
cannabis; however, at the same time elevating its potential as a medicinal therapeutic.    
 Medical research in cannabis and cannabis related compounds were first published in the 
1840s by an Irish physician, Sir William B. O’Shaughnessy.11-12  From O’Shaughnessy seminal 
work, it took until the 1930s for Thomas Wood
13
 and Robert Cahn
14
 to isolate and elucidate most 
of the structure for the first identified cannabinoid, cannabinol (Figure 1.1A).
11
  Subsequently, it 
took until 1940 for Roger Adams
15-19
 and Lord Alan Todd
20
 to synthesize cannabinol and 
complete a chemical elucidation of its structure.
11
  Following this work, Raphael Mechoulam and 
colleagues were the first group in 1964 to isolate and elucidate the structure of the major 
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psychoactive component of cannabis, (-)-Δ9-tetrahydrocannabinol (Δ9-THC) (Figure 1.1B).21-23  
In addition, the Mechoulam group continued the work started by Roger Adams and Alexander 
Todd, in which they elucidated the first complete structure of the major non-psychotropic 
cannabinoid in cannabis, cannabidiol (CBD) (Figure 1.1C).
24
  Following the structural 
elucidation of Δ9-THC, it took another ~24 years (1988) before the Howlett group identified its 
specific mammalian brain receptor, cannabinoid receptor 1 (CB1).
25
  The CB1 receptor is most 
abundant in the brain; however, it is also found in different peripheral tissues, including the 
gastrointestinal tract, heart, liver, kidney, eye, pancreas, prostate, testis, adipose tissue, and 
uterus.
26
  Then a second CB receptor was identified in 1993, cannabinoid receptor 2 (CB2),
27
 
which was initially identified in spleen and subsequently in the tissues of the immune system and 
low levels were found in the brain.
26
  Following the identification of the CB1 receptor, it was 
postulated that an endogenous ligand in mammalian brain must exist.
28
  At this time Bill Devane, 
who published the paper on the identification of the CB1 receptor, received his Ph.D. from Allyn 
Howlett’s group and joined the Mechoulam group as a post-doctoral fellow.28  As a post-doctoral 
fellow in the Mechoulam group,
28
 he discovered anandamide (N-arachidonoylethanolamine) 
(Figure 1.1D) from pig brains, as the first endogenous ligand for the CB1 receptor (Figure 
1.1D).
29
  The seminal discovery of anandamide in 1992
29
 marks the beginning of evaluating 
endocannabinoids and fatty acid amides as potent cell signaling lipids.  However, the discovery 
of fatty acid amides date back to the 1820’s, with the identification of hippurate 
(N-benzoylglycine) as an urine excreted metabolite that is derived from benzoic acid.
30-31
  In 
1957, N-palmitoylethanolamine was the first long-chain fatty acid amide discovered in egg 
yolk.
32-33
  Historically, most of the research on endocannabinoids and fatty acid amides has been 
with anandamide.  Ironically, this metabolite only accounts for ~10% of all the long-chain 
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N-acylethanolamines found in the brain.
30, 33-35
  Anandamide functions in a series of 
physiological processes including: (a) pain perception,
36-41
 (b) locomotion,
42
 (c) regulation of 
body temperature,
42
 (d) memory,
43-46
 (e) appetite,
47
 and (f) fear and anxiety,
48-49
 which arise from 
its binding to number of receptors including the CB1, 
29
 CB2,
50
 and the transient receptor 
potential vanilloid type 1 (TRPV1) receptors.
30, 33, 51
  The biosynthesis of anandamide has been 
extensively discussed in a series of publications and review articles.
30, 33, 52-56
          
Figure 1.1. Structures of different cannabinoids. (A.) Cannabinol. (B.) Δ9-tetrahydrocannabinol 
(THC). (C.) Cannabidiol (CBD). (D.) Anandamide (N-arachidonoylethanolamine).   
 
  
The field of fatty acid amide research expanded further with the discovery of oleamide, 
which was identified in mammalian cerebrospinal fluid and functions to induce sleep.
57
  
Subsequently, a series of fatty acid amides were systematically identified from mammalian brain, 
peripheral tissues, and other organisms (see reviews
30, 33, 39, 58-60
).
61-63
  This led to the 
classification of the fatty acid amides into different families consisting of the primary fatty acid 
amides, N-acylglycines, N-acyl amino acids, N-acylarylalkylamides, N-monoacylpolyamides, 
and N-acyltaurines.  The general structure of fatty acid amides is illustrated in Figure 1.2, where 
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the R1 group represents a varying length of an acyl group conjugated to a Y group, which is 
typically derived from a biogenic amine as shown in Table 1.1.  
Figure 1.2. General structure of fatty acid amides.  
 
Table 1.1. Structures of different fatty acid amides.
a, b 
Fatty acid amide family Structure 
N-acylethanolamines 
 
N-acylglycines 
 
N-acyl amino acids
c 
 
Primary fatty acid amides 
 
N-acylarylalkylamides
d 
 
N-monoacylpolyamides
e 
 
N-acyltaurines 
 
a
 R1 = acyl group of varying lengths, shown in red. 
b
 Blue represents the biogenic amine conjugated to the acyl group through an amide bond. 
c
 R2 group represent the various side chains of amino acids. 
d
 The N-acylarylalkylamide represented here is an N-acyldopamine. 
e
 The N-monoacylpolyamide represented here is an N-acylputrescine. 
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Currently, most fatty acid amides do not have a defined neurological function, their 
receptors are undefined, and the biosynthetic pathways have not been completely elucidated.
30, 33
  
There is a series of speculative proposals related to the possible function of these metabolites 
consisting of an “entourage effect”,64-65 serving as a chemical step to inactivate biogenic amines, 
biological intermediates to other cell signaling lipids, or possess a direct neurological function 
through binding to an orphan receptor.  The “entourage effect” is defined as: related fatty acid 
amides are biosynthesized to function as substrates to enzymes that degrade anandamide in order 
to stabilize the cellular concentration of anandamide. 
64-65
  For example, other N-acyldopamines 
such as N-palmitoyldopamine are biosynthesized to enhance the effect N-arachidonoyldopamine 
has with its endogenous receptor.  One interesting observation by Dr. Mechoulam is that these 
molecules must have a function, since the brain invests a considerable amount of energy in their 
biosynthesis.
28
  He continues to speculate that the subtle chemical differences of these molecules 
in the brain could be related to the differences observed in human personality, with different 
levels and/or ratios of these metabolites, could lead to an infinite amount of different 
personalities, which contributes to our individual differences.
28
  Further work is necessary to 
completely elucidate the physiological function for each of the fatty acid amides and define the 
receptors that disseminate these functions.  In addition, a significant amount of work is still 
required to discover all the possible fatty acid amides and elucidate the biosynthetic and 
degradative pathways for these important cell signaling lipids.  
 The research highlighted in this dissertation, sets to define enzymes involved in the 
biosynthesis of the N-acylarylalkylamides.  Therefore, the focus for the rest of this dissertation 
will be on the N-acylarylalkylamides; including characterization of possible biosynthetic 
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enzymes, defining the chemical mechanism for these enzymes, and understanding how enzyme 
structure affects its function.      
 
1.2 Function and biosynthesis of long-chain N-acylserotonins and N-acyldopamines  
There have been two groups of biologically relevant long-chain N-acylarylalkylamides 
identified from mammals
66-67
 and insects,
62, 68
 which are the N-acyldopamines and 
N-acylserotonins.  Long-chain N-acyldopamines were first synthesized in 2000 by the Di Marzo 
group, to be evaluated as inhibitors to anandamide hydrolysis that is catalyzed by fatty acid 
amide hydrolase (FAAH).
69
  In addition, they evaluated the affinity of the long-chain 
N-acyldopamines for the CB1 receptor by using a radiolabeled ligand displacement assay.
69
  
These data showed that long-chain N-acyldopamines (acyl group ≥ 18) can function to inhibit 
anandamide hydrolysis competitively, with N-pinolenoyldopamine and N-arachidonoyldopamine 
displaying the greatest apparent affinity (IC50 = 19.0 ± 4.5 µM and 22.0 ± 5 µM, respectively).
69
  
In addition, displacement experiments with a radiolabeled ligand demonstrated that 
N-arachidonoyldopamine has the greatest affinity (Ki = 250 ± 130 nM) for the CB1 receptors 
when compared to all other N-acyldopamines evaluated in this study.
69
  These data, in 
combination with a published hypothesis by Matysiak in 1998 that N-acyldopamines existed in 
vivo; led the Di Marzo and Walker groups to identify the first endogenous long-chain 
N-acyldopamine, N-arachidonoyldopamine (Table 1.2), from bovine brain.
66
  The highest 
concentration of N-arachidonoyldopamine was identified in the striatum, hippocampus, and 
cerebellum; which are at similar levels as the TRPV1 receptors.
66
  In addition, they showed that 
N-arachidonoyldopamine is an endogenous ligand for the human and rat TRPV1 receptors, by 
showing that it produced a significant increase of intracellular Ca
2+
 (EC50 = 40 ±6 nM and 48 ± 7 
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nM, respectively) in HEK293 cells that overexpress either receptor.
66
  The physiological 
functions identified for N-arachidonoyldopamine are similar to that produced by anandamide, 
likely mediated from having the same receptors.
66, 69
  These functions consist of pain perception, 
regulation of body temperature, and locomotion.
66, 69
  It also showed a dose-dependent protection 
of cultured cerebellar neurons, by functioning as an antioxidant and neuroprotectant.
70
  In 2003, 
the Walker group identified more long-chain N-acyldopamines from bovine brains, consisting of 
N-oleoyldopamine, N-palmitoyldopamine, and N-stearoyldopamine (Table 1.2).
67
  There is not 
much information on the function or the receptors for these other long-chain N-acyldopamines; 
except for some data published on N-oleoyldopamine.  N-oleoyldopamine was shown to bind to 
the human TRPV1 receptors (EC50 = 63.0 ± 5.5 nM) and weakly to the CB1 receptors (Ki = 16 
µM), while producing a dose-dependent response to thermal hyperalgesia in rats.
67
  Recently, 
N-oleoyldopamine was shown to bind weakly (EC50 = 4.4 µM) to human G coupled-protein 
receptor 119 (GPCR119), which is important to glucose homeostasis by stimulating insulin 
release and increasing the levels of cAMP and gastric inhibitory peptide in pancreatic cells. 
71
  In 
addition, N-oleoyldopamine was shown to possess a dose-dependent stimulation of locomotor 
activity,
72
 protect the heart against ischemia and reperfusion injury,
73
 decrease rat muscle rigidity 
(myorelaxant),
74
 and function in pain perception.
75-76
  The plasma concentration of 
N-oleoyldopamine were also shown to significantly decrease in individuals with post-traumatic 
stress disorder and might be used as a robust indicator for this disease.
77
  Currently, there are 
neither receptors nor a function defined for N-palmitoyldopamine and N-stearoyldopamine.  
N-palmitoyldopamine and N-stearoyldopamine were both evaluated as potential TRPV1 ligands; 
however, neither showed any increased in the intracellular concentration of Ca
2+
 in HEK cells 
overexpressing human TRPV1.
67, 78
  One proposed function for N-palmitoyldopamine and 
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N-stearoyldopamine is that they function as an “entourage effect”, essentially enhancing the 
effect of N-arachidonoyldopamine or anandamide on the TRPV1 receptors.
78
   
Recently our lab identified long-chain N-acyldopamines in D. melanogaster, consisting 
of N-arachidonoyldopamine, N-oleoyldopamine, and N-palmitoyldopamine.
62
  It is unclear what 
the endogenous receptors are or the physiological function is for these N-acyldopamines in D. 
melanogaster.  It has been suggested that the CB receptors are not found in D. melanogaster;
79-80
 
however, there is a report of TRVP receptors found in the fly, which might function as an 
endogenous receptor for these metabolites.
81
  
 
Table 1.2. Structures of endogenous N-acydopamines.
 
N-acyldopamine Structure
a 
N-arachidonoyldopamine
b, c 
 
N-oleoyldopamine
b, d 
 
N-stearoyldopamine
b 
 
N-palmitoyldopamine
b, c, d 
 
a
 References for structures include, Huang et al.,
66
 Chu et al.,
67
 and Farrell et al.
82
  
b
 References for in vivo identification in mammalian brain include, Huang et al.
66
 and Chu et al.
67
   
c
 References for in vivo identification in D. melanogaster brain include, Jeffries et al.
62
  
d
 References for in vivo identification in D. melanogaster thorax-abdomen include, Jeffries et al.
62
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 A biosynthetic pathway for the long-chain N-acyldopamines has not been completely 
elucidated.  Generally, there have been four pathways proposed in the literature for the 
biosynthesis of these metabolites (Scheme 1.1).
30, 33, 83-84
  The cognate metabolites in each of 
these pathways are tyrosine and the fatty acids.  Scheme 1.1A has the precursor metabolite as an 
N-acyltyramine that undergoes hydroxylation of the tyramine ring to generate an 
N-acyldopamine.  The N-acyltyramine is likely synthesized by a conjugation reaction catalyzed 
by an N-acyltransferase from tyramine and the corresponding activated fatty acid (acyl-CoA) 
substrate, by direct condensation of tyramine and the corresponding fatty acid, or from 
decarboxylation of an N-acyltyrosine.  Evidence for this pathway consists of when L-tyrosine 
and tritiated arachidonic acid is incubated with rat striatum, there is formation of tritiated 
N-arachidonyldopamine.
66
  In addition, endogenous levels of long-chain N-acyltyrosines were 
detected in mammalian brains.
61
   
Scheme 1.1B invokes the possibility that an N-acyl-L-Dopa is the direct precursor to the 
N-acyldopamines.  In this reaction, an N-acyl-L-Dopa is decarboxylated by a decarboxylase 
enzyme to generate an N-acyldopamine.  Evidence for this pathway consists of the identification 
of endogenous long-chain N-acyltyrosines,
61
  which could be the precursor metabolites to the 
N-acyl-L-Dopas.  The N-acyltyrosine would undergo hydroxylation on the aromatic ring to 
generate the corresponding N-acyl-L-Dopa.  In addition, after incubation of a tyrosine 
hydroxylase inhibitor (α-methyl-p-tyrosine) there was a time dependent decrease in the 
formation of the N-arachidonoyldopamine.
84
  Tyrosine hydroylase is the rate-limiting enzyme in 
the biosynthesis of dopamine, which could also function in the formation of N-acyl-L-Dopas.
85-87
  
The decrease in the N-arachidonoyldopamine from inhibiting tyrosine hydroxylase
84
 suggests 
that it functions in the biosynthesis of long-chain N-acyldopamines; however, does not prove that 
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it catalyzes the direct hydroxlyation of N-acyltyrosines.  The decrease in the endogenous levels 
of N-arachidonoyldopamine could also be attributed to the inhibition of general dopamine 
biosynthesis, by inhibiting the formation of L-Dopa.  In fact, the Walker group showed that 
N-arachidonoyltyrosine is a poor substrate for tyrosine hydroxylase, in an experiment comparing 
the hydroxylation of L-tyrosine to deuterated N-arachidonoyltyrosine.
84
  After a 10 min 
incubation time, it was shown that 24% of the L-tyrosine was converted to L-Dopa, whereas only 
0.23% of deuterated N-arachidonoyltyrosine was converted to deuterated 
N-arachidonoyl-L-Dopa.
84
  Subsequently, N-arachidonoyldopamine was not detected after 
injection of deuterated N-arachidonoyl-L-Dopa into the rat striatum.
84
  These data suggest that 
N-arachidonoyltyrosine → N-arachidonoyl-L-Dopa → N-arachidonoyldopamine is an unlikely 
biosynthetic pathway.   
Another proposed biosynthetic step in the chemical formation of N-acyldopamines is the 
direct condensation of a fatty acid and dopamine as shown in Scheme 1.1C.  The literature points 
to FAAH as the biosynthetic enzyme for this condensation reaction.
84
  FAAH is an amidase that 
has been shown to catalyze the hydrolysis of primary fatty acid amides and 
N-acylethanolamines.
88-91
  This proposal suggests that FAAH catalyzes the formation of 
N-acyldopamines in the reverse direction when compared to its hydrolase activity.  Evidence for 
this pathway is derived from the incubation of rat brain homogenates with 50 µM dopamine (or 
tyrosine), 50 µM tritiated arachidonic acid, and a catechol O-methyltransferase (COMT) 
inhibitor (OR-486), which resulted in the formation of tritiated N-arachidonoyldopamine.
66
  The 
COMT inhibitor was used to minimize the breakdown of N-arachidonoyldopamine, which is one 
of its major degradative products.
83
  A conflicting set of results were published by the Bezuglov 
group, which showed that N-arachidonoyldopamine is not generated in rat brain homogenates 
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from the incubation of tritium-labeled arachidonic acid and dopamine.
83
  This published work 
also analyzed numerous chemical steps for N-arachidonoyldopamine biosynthesis, by incubating 
different precursors with liver, spinal cord, or brain rat homogeneates.
83
  In addition, they 
analyzed the COMT catalyzed degradation of N-arachidonoyldopamine to 
3-O-methyl-N-arachidonoyldopamine for each tissue homogenate.  Interestingly, there was a 
considerable amount of 3-O-methyl-N-arachidonoyldopamine and arachidonic acid in the rat 
brain homogenates after 30 min incubation with tritium-labeled arachidonic acid and 
dopamine.
83
  This suggests that either the dopamine is rapidly methylated to 3-methoxytyramine 
by COMT before being N-acylated or N-arachidonoyldopamine is rapidly converted to 
3-O-methyl-N-arachidonoyldopamine after its initial formation.  The major experimental 
difference between the two groups (Benzuglov and Di Marzo groups) is that the Di Marzo group 
used a COMT inhibitor.
66, 83
  This likely allowed for the observation of N-arachidonoyldopamine 
in rat brain homogenates by inhibiting the formation of a major degradative product.  
3-O-methyl-N-arachidonoyldopamine is considered to be a major inactive degradative product of 
N-arachidonoyldopamine, where it was found to be ~10-fold less potent with the TRPV1 
receptors.
66
  In fact, after incubation of tritiated N-arachidonoyldopamine and S-adenosyl 
methionine with rat brain homogenates, ~40% of the tritiated molecule was converted to 
3-O-methyl-N-arachidonoyldopamine and ~11% was hydrolyzed to arachidonic acid.
83
  These 
results and the data published by the Di Marzo group, suggests that the pathway order is the 
following: arachidonic acid + dopamine →(→) N-arachidonoyldopamine → 
3-O-methyl-N-arachidonoyldopamine.
66, 83
  The second arrow, found in the parenthesis, indicates 
that it is still unknown if N-arachidonoyldopamine is generated by the direct condensation of 
arachidonic acid and dopamine or if arachidonic acid is activated to arachidonoyl-CoA prior to 
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its conversion to N-arachidonoyldopamine.  A summary for the precursor incubation conditions 
that contributed to the greatest observed formation of N-arachidonoyldopamine that was 
published by the Benzuglov group can be found in Table 1.3.
83
  This group showed that 
N-arachidonoyldopamine could be synthesized in every tissue homogenate analyzed, but the set 
of precursors that generated the greatest yield of N-arachidonoyldopamine varied for each 
tissue.
83
  Incubation of arachidonic acid and tyrosine generated more N-arachidonoyldopamine in 
the liver and spinal cord homogenates, whereas incubating arachidonic acid + tyrosine + 
tetrahydrobiopterin + NADPH + Fe
2+
 + Mg
2+
 generated the most N-arachidonoyldopamine in the 
brain homogenates.
83
  Three possible explanations for the differences seen in each tissue 
homogenate is: (a) the pathway for the formation of N-arachidonoyldopamine is tissue 
dependent, (b) there is a time-dependence in the formation and degradation of 
N-arachidonoyldopamine, and/or (c) N-arachidonoyldopamine could be biosynthesized by 
numerous pathways, in which the predominant pathway is tissue dependent.  The data generated 
by the Di Marzo,
66
 Walker,
84
 and Benzuglov
83
 groups suggest that a direct condensation of a 
fatty acid and dopamine (or tyrosine) is possible by FAAH.  The Walker group also evaluated 
the in vivo and in vitro role FAAH has in N-arachidonoyldopamine biosynthesis.
84
  Using a 
FAAH inhibitor (URB579) fed to rats or FAAH knockout rats, the level of anandamide and 
N-arachidonoyldopamine were evaluated and compared to a vehicle fed to rats or wild-type rats, 
respectively.
84
  Anandamide was chosen because it is a known FAAH substrate that is 
hydrolyzed to arachidonic acid and ethanolamine.
89
  In both of these experiments, the levels of 
anandamide increased, whereas the levels of N-arachidonoyldopamine decreased when compared 
to the controls.
84
  These data suggest that N-arachidonoyldopamine biosynthesis is directly 
related to FAAH activity.  The two possible functions FAAH can have in 
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N-arachidonoyldopamine biosynthesis is: (a) catalyzes the direct condensation of arachidonic 
acid and dopamine (tyrosine), or (b) functions to liberate arachidonic acid by hydrolysis of 
anandamide (or other fatty acid amides), which can shuttle it to other pathways such as 
N-arachidonoyldopamine biosynthesis.  Subsequently, the Walker group then evaluated 
recombinant FAAH as either a degradative or biosynthetic enzyme for 
N-arachidonoyldopamine.
84
  Hydrolysis of N-arachidonoyldopamine (at 30 mins, ~50% 
converted) was low compared to anandamide (at 10 mins, ~95% converted), suggesting that 
N-arachidonoyldopamine is a poor substrate for FAAH.
84
  Then they incubated FAAH with 
anandamide and deuterated dopamine, and monitored the formation of deuterated 
N-arachidonoyldopamine over a 30 min period.  The hypothesis was that liberation of 
arachidonic acid from anandamide hydroylysis could serve as a substrate for FAAH catalyzed 
condensation with dopamine to generate N-arachidonoyldopamine.
84
  Under these set of 
conditions used in this publication, they observed a rate of deuterated N-arachidonoyldopamine 
formation that is ~150 pmoles/min/mg.
84
  It is unclear from these published methods, if the 
substrates were held at a saturating concentration; however, with this in mind, the rate of 
N-arachidonoyldopamine biosynthesis
84
 is 180-fold less than the published Vmax of FAAH 
catalyzed hydrolysis of anandamine.
88
  Depending on the assay conditions, these data suggest 
that arachidonic acid and dopamine are poor substrates for a FAAH catalyzed condensation 
reaction.
84
  In addition, we are not sure why the authors did not evaluate arachidonic acid and 
dopamine, directly.
84
  It is unlikely that this reaction is biologically significant because it is 
thermodynamically unfavorable to generate an amide from a carboxylate and amine by an 
amidase.  FAAHs likely function in fatty acid amide biosynthesis and degradation is the 
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liberation of fatty acids, which can be shuttled to different fatty acid amide biosynthetic 
pathways.    
 
Table 1.3. A summary of data published by Akimov et al.
83
 showing the corresponding 
precursors that generated the greatest amount of N-arachidonoyldopamine from incubation with 
different rat tissue homogenates.
a, b 
Tissue Homogenate 
Precursor combination that produced greatest 
amount of N-arachidonoyldopamine 
Liver arachidonic acid + tyrosine 
Spinal Cord arachidonic acid + tyrosine 
Brain 
arachidonic acid + tyrosine + 
tetrahydrobiopterin+ NADPH + Fe
2+
 + Mg
2+ 
a
 Reference - Akimov et al.
83
 
b
 Other precursors used in various combinations were N-arachidonyltyrosine, dopamine, 
N-arachidonyldopamine, and S-adenosyl methionine. 
 
 Finally, the last proposed pathway (Scheme 1.1D) utilizes an activated fatty acid, in the 
form of an acyl-CoA in a conjugation reaction with dopamine.  This pathway is chemically more 
attractive than a FAAH catalyzed condensation reaction, since a thioester is thermodynamically 
more favorable; therefore, more susceptible for nucleophilic attack from the neutral amine of 
dopamine.  One piece of evidence for this pathway is that the incubation of arachidonic acid with 
either tyrosine or dopamine in mammalian brain homogenates will generate 
N-arachidonoyldopamine.
66
  In this case, tyrosine could be converted to dopamine through 
normal dopamine biosynthesis concurrently with the rapid conversion of arachidonic acid to 
arachidonoyl-CoA by an acyl-CoA synthetase.
92
  Then an N-acyltransferase enzyme can catalyze 
the formation of N-arachidonoyldopamine from dopamine and the newly generated 
arachidonoyl-CoA.  This chemistry has been well characterized for the N-acetylation of 
dopamine or serotonin, which is catalyzed by arylalkylamine N-acetyltransferase (AANAT) or 
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also known as serotonin N-acetyltransferase (SNAT) (further discussed in Section 1.3; Chapters 
2, 4, and 5).
93-101
  Therefore, it has been hypothesized that either AANAT or another AANATL 
enzyme with specificity for long-chain acyl-CoA substrates, could be the biosynthetic enzyme 
for the formation of long-chain N-acyldopamines.  Similar chemistry was recently observed from 
the Hunt group, which identified an N-acyltransferase enzyme, glycine N-acyltransferase like 2, 
could catalyze the formation of long-chain N-acylglycines, another class of fatty acid amides.
102
  
Evidence against this pathway, is after the rat striatal, midbrain, or hippocampal homogenates 
were incubated with 50 µM radiolabeled arachidonoyl-CoA and 50 µM dopamine, there was no 
detectable radiolabeled N-arachidonoyldopamine.
84
  This data could suggest that an 
N-acyltransferase enzyme is not involved in N-acyldopamine biosynthesis.  However, it is 
possible that N-arachidonoyldopamine was generated but rapidly degraded as shown by Akimov 
et al.
83
  In combination to degradation of N-arachidonoyldopamine, it is possible that the tritiated 
dopamine is rapidly degraded to either its methylated (3-methoxytyramine) or oxidized product 
(3,4-dihydroxyphenylacetic acid), yielding undetectable levels of tritiated 
N-arachidonyldopamine.
84
  It is also possible that the brain homogenates does not include the 
biosynthetic N-acyltransferase enzyme or could be inactivated under the published set of 
conditions.  These set of data are inconclusive and further work needs to be addressed to confirm 
or exclude this chemical step in the biosynthesis of long-chain N-acyldopamines. 
 The long-chain N-acylserotonins (Figure 1.3) are another group of endogenously found 
fatty acid amides.  N-arachidonoylserotonin was first synthesized as an inhibitor for FAAH, 
resulting in an IC50 = 12 µM.
103
  Following this work, N-arachidonoylserotonin was shown to 
have analgesic bioactivity, likely through duel mechanisms consisting of FAAH inhibition
103
 and 
serving as a TRPV1 antagonist.
104-105
  Subsequently, it was shown that N-arachidonoylserotonin 
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can function in regulating gastric emptying,
106
 inhibiting anxiety,
107
 and possess anti-allergic 
activity.
108
  N-arachidonoylserotonin, N-palmitoylserotonin, N-stearoylserotonin, and 
N-oleoylserotonin were the first long-chain N-acylserotonin identified in different regions of the 
porcine gastrointestinal tract.
109
  Subsequently, N-arachidonoylserotonin was identified in human 
and bovine brain samples.
110
  In addition to these fatty acid amides, N-eicosapentaenoylserotonin 
and N-docosahexaenoylserotonin were identified in the jejunum of mice after the feeding of fish 
oil over a six week period.
109
   
Scheme 1.1. Proposed biosynthetic enzymes in the formation of long-chain N-acyldopamines. 
(A.) Hydroxylase. (B.) Decarboxylase. (C.) Fatty acid amide hydroylase. (D.) N-acyltransferase.  
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Figure 1.3. General structure of N-acylserotonins. R1 = varying acyl chain lengths.  
 
Very little data has been generated for the biosynthesis of long-chain N-acylsertonins 
since their seminal discovery in 2011.
109
  What is known, (a) is that the N-acylserotonins are 
located in the mammalian gastrointestinal tract and brain,
110
 which is the region of the body that 
has the highest level of serotonin,
111
 (b) incubating porcine ileum segments with serotonin 
produced a concentration dependent increase in the N-acylserotonins, and (c) a dietary dependent 
increase in N-eicosapentaenoylserotonin and N-docosahexaenoylserotonin in the mouse jejunum 
after feeding high concentrations of the corresponding fatty acid in the form of fish oil over a six 
week period.
109
  A summary of these data suggest that a fatty acid and serotonin is a set of 
precursors to the long-chain N-acylserotonins.  Two pathways consistent with this chemistry are 
a FAAH catalyzed condensation reaction from the corresponding fatty acid and serotonin or a 
prerequisite formation of the activated fatty acyl-CoA, followed by a N-acyltransferase catalyzed 
conjugation reaction to generate the final N-acylserotonin product.  It is unlikely that FAAH is 
the biosynthetic enzyme in this pathway since a portion of the long-chain N-acylserotonins 
function as inhibitors to its enzyme catalyzed hydrolysis reaction.
109
  This leaves an unknown 
N-acyltransferase enzyme that could be the biosynthetic enzyme.  Further work defined in this 
dissertation will help answer this fundamental question (Appendix B). 
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1.3 Possible chemical mechanisms for N-acyltransferases 
N-acetylation is an important chemical reaction for the inactivation of biogenic amines, 
biosynthesis of melatonin, and cuticle sclerotization.
112-115
  In insects, the known biogenic 
amines are octopamine, serotonin, tyramine, dopamine, and histamine, which functions primarily 
as neurotransmitters.
116
  One major chemical step for the inactivation of these bioactive amines 
in D. melanogaster is the N-acetylation of the primary amine.  N-acetylation of serotonin is also 
the penultimate chemical step in the biosynthesis of melatonin.
117-121
  Melatonin is a metabolite 
of serotonin biosynthesis (Scheme 1.2), catalyzed by the N-acetylation of serotonin (AANAT or 
SNAT) followed by the methylation of the hydroxyl group (hydroxyindole 
O-methyltransferase).
117-121
  Melatonin is primarily found in the pineal gland of mammals and 
functions to regulate the sleep wake cycle.
122-124
  Concentration of melatonin in the pineal gland 
fluctuates during a 24 hour period, where high levels are synthesized at night and low levels 
during the day.
122-124
  AANAT is the rate-limiting enzyme in the formation of melatonin, which 
controls the day/night fluctuations of melatonin in mammals.
122, 125
  Very little work has been 
published for melatonin in D. melanogaster; however, it has been shown that its biosynthesis is 
similar to mammals (Scheme 1.2).
126-127
  Melatonin also regulates the life span of D. 
melanogaster, likely because of its antioxidant properties.
126
 
Scheme 1.2. Biosynthesis of melatonin. AANAT – arylalkylamine N-acetyltransferase, SNAT – 
serotonin N-acetyltransferase, HIOMT – hydroxyindole O-methyltransferase, SAM – 
S-adenosylmethionine, SAH – S-adenosylhomocysteine. 
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The N-acylation of biogenic amines is catalyzed from the corresponding acyl-CoA and 
amino donor substrates by an N-acyltransferase enzyme (NAT).  NATs can catalyze the 
formation of N-acylamides by one of the three proposed chemical mechanisms found in Scheme 
1.3.  In Scheme 1.3A, the thioester carbonyl of acyl-CoA undergoes nucleophilic attack by the 
amine substrate to generate a zwitterionic tetrahedral intermediate.  The newly formed 
intermediate is then deprotonated by an amino acid residue functioning as a general base.  Then 
the tetrahedral intermediate collapses by the protonation of coenzyme A by an amino acid 
residue functioning as a general acid, to generate the N-acylamide and CoA-SH products.  This 
chemical mechanism as been attributed to a number of NATs, such as aminoglycoside 
N-acetyltransferase,
128-129
 spermidine/spermine N
1
-acetyltransferase,
130
 and perosamine 
N-acetyltransferase.
131
   
The mechanism in Scheme 1.3B shows a base catalyzed initial deprotonation of the 
positively charged amino group of the amine substrate, followed by nucleophilic attack of the 
thioester carbonyl of acyl-CoA to generate a zwitterionic tetrahedral intermediate.  Then a 
collapse of the tetrahedral intermediate occurs with the protonation of CoA.  This chemical 
mechanism as been attributed to a number of NATs, such as histone N-acetyltransferases,
132
 
N-myristoyltransferase,
133-134
 QdtC N-acetyltransferase,
135
 and WlbB N-acetyltransferase.
136
  
 
Scheme 1.3C highlights a nucleophilic attack of the acyl-CoA thioester carbonyl by a 
nucleoplic residue (Cys) of the NAT enzyme.  Then the tetrahedral intermediate collapses by an 
acid catalyzed protonation of coenzyme A, yielding a stable covalently modified acyl*NAT 
intermediate.  Next, the amine substrate attacks the carbonyl of the acyl*enzyme intermediate to 
generate a zwitteriontic tetrahedral intermediate.  Finally, collapse of the intermediate occurs 
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with an acid catalyzed protonation of the nucleophilic amino acid residue and a base catalyzed 
deprotonation of the amine intermediate.  Arylamine N-acetyltransferase is an example of an 
NAT that utilizes this type of chemical mechanism.
137
   
Scheme 1.3. Possible chemical mechanisms for N-acyltransferases. (A.) Acid/base catalyzed 
breakdown of a zwitterionic tetrahedral intermediate.  (B). Base catalyzed deprotonation of 
positively charged amino group, with protonation of coenzyme A during breakdown of the 
zwitterionic tetrahedral intermediate.  (C.)  NAT catalyzed formation of N-acylamides through a 
stable covalently modified acyl-enzyme intermediate. 
 
N-acetylarylalkylamides is one set of acetylated metabolites catalyzed by 
N-acyltransferase enzymes in both mammals and insects.  This reaction is catalyzed by AANAT, 
which is an enzyme that is part of the Gcn5-related N-acetyltransferase family of enzymes 
(GNAT).
100, 138
  Currently, very little work has been done to characterize insect AANAT or 
AANATL enzyme(s).  The first identification of N-acetyltransferase activity in D. melanogaster 
was in 1972 by Dewhurst et al., which measured radiolabeled formation of N-acetyltyramine, 
N-acetylserotonin, and N-acetyldopamine from fly homogenates.
139
  Following this work, in 
1977 Maranda and Hodgetts characterized the first AANAT enzyme from D. melanogaster.
112
  
Subsequently, Brodbeck et al. identified two biologically relevant AANAT variants, AANAT 
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variant A (AANATA) and variant B (AANATB) in 1998.
140
  They discovered that the two 
AANAT variants differed by only 35 amino acids on the N-terminus, which AANATB is the 
larger variant.
140
  AANATA was identified in the adult fly and during late stage embryogenesis, 
and localized to the brain, midgut, and ventral nerve cord.
140
  AANATB was identified in the 
adult fly and during the late pupal stage, which its localization was in the brain.
140
  A second 
AANATL enzyme, AANATL2, was discovered in 2000 by Amherd et al. and was shown to 
catalyze the formation of N-acetyltryptamine from acetyl-CoA and tryptamine.
141
  No further 
work has been done to characterize this enzyme since its initial discovery.  In addition, Amherd 
et al. and our group have identified eight possible AANATL enzymes in the D. melanogaster 
genome.
141-142
  None of these other AANATL enzymes have been characterized to date.  Very 
little work has been done mechanistically on the fly enzymes until Cheng et al. published the 
AANATA crystal structure in 2012.
143
  Their work concluded that two serines, Ser-182 and 
Ser-186, function as the general base and acid in catalysis, respectively.
143
  In addition, they 
suggested that Glu-47 initiates catalyses by deprotonating Ser-182 to generate an alkoxide prior 
to it (Ser-182) functioning as a general base.
143
  We found this unlikely, because of it being 
thermodynamically unfavorable for a serine to function as a general acid to protonate a thiolate 
(see Chapter 2).   
Herein, the following chapters detail the characterization of four D. melanogaster 
AANAT(L) enzymes.  We compare the chemistry for AANATA and AANATB, two 
biologically relevant variants.  In addition, we describe a developed screening strategy (Chapter 
3) that utilizes the pooling of amines to define the substrates for D. melanogaster AANATL 
enzymes.  Finally, we define the kinetic mechanism, functional analysis of structurally different 
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substrates, functional analysis of different amino acid residues, and proposed a chemical 
mechanism for AANATA (Chapter 2),
142
 AANATL2 (Chapter 5),
68
 and AANATL7 (Chapter 4).       
 
1.4 Future perspective in the fatty acid amide field  
During our investigation of the fatty acid amide biosynthetic pathways, in addition to the 
Bradshaw group,
63
 we identified a significant amount of fatty acid amides in D. melanogaster, 
including long-chain N-acyldopamines and N-acylserotonins.
62, 68
  Since some of these 
metabolites have been suggested to be ligands to the cannabinoid receptors and their biosynthesis 
or degradation is catalyzed by FAAH, we find it amazing that these molecules are found in this 
organism.  It has been published that neither FAAH nor the CB receptors are found in D. 
melangaster, based off primary sequence identity.
79-80
  The lack of CB receptors in D. 
melanogaster is also derived from radioligand binding assays, in which binding of CB specific 
ligands was not observed in fly head tissue homogenates.
79
  One intriguing result from this 
published work is D. melanogaster sequence CG8839, which only has 25% sequence identity 
from 85% of human FAAH.
80, 144
  Albeit the low sequence similarity, the catalytic core of 
Lys-142, Ser-217 (or Ser-218), and Ser-241 is conserved with CG8839.
90-91, 145
  However, a 
proline rich SH3 binding domain shown to be important for rat FAAH activity is missing in 
CG8839, leading McPartland et al. to conclude that this enzyme and likely any enzyme in D. 
melanogaster will function with FAAH activity.
80, 146
  We also identified another FAAH like 
enzyme, CG5112, which the catalytic core is conserved, but the proline rich SH3 binding domain 
is missing.
146
  Both of these D. melanogaster enzymes have not been characterized to date and 
the only data published that corresponds to them is that both are found in lipid droplets, based off 
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proteomic profiling.
147
  It will be interesting to evaluate D. melanogaster CG8839 and/or 
CG5112 to determine if it has a similar function to FAAH. 
Next, some enzymes involved in biosynthesis and degradation of different fatty acid 
amides have been identified in either mammals or D. melanogaster.  One major question is if the 
biosynthetic (and degradative) pathways for the fatty acid amides are conserved between these 
two organisms?  Some examples of questions related to the metabolism of fatty acid amides are: 
(a) is there an AANAT(L) enzyme that will catalyze the formation of long-chain 
N-acylserotonins and N-acyldopamines in mammals, (b) is there secondary pathways for the 
biosynthesis of long-chain N-acylserotonins and N-acyldopamines, or (c) if there is a secondary 
pathway, what is the predominate chemical step in their biosynthesis?  Further evaluation of 
enzymes involved in fatty acid amide metabolism is necessary to determine if D. melanogaster is 
truly a model system.  
Finally, we have a large panel of fatty acid amides identified in both mammals and D. 
melanogaster; however, not many of these metabolites have a defined physiological function.  In 
addition, the receptors that potentiate their physiological function have not been completely 
defined.  Further work is necessary to identify the endogenous receptors for each of these lipids 
and to understand their physiological role.  There is still a substantial amount of work to be 
completed to fully understand the biological impact these molecules have on human health.  
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Chapter Two 
Mechanistic and Structural Analysis of Drosophila melanogaster Arylalkylamine 
N-acetyltransferases 
 
2.1 Note to reader 
 This chapter has been previously published in Biochemistry, 2014, 53: 7777-7793 and has 
been reproduced with permission from ACS Publications.  This work can be viewed in Appendix 
A.  
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Chapter Three 
AANATL Screening Method 
 
3.1 Introduction 
The N-acylation of a biogenic amine is an important chemical step in Drosophila 
melanogaster for the inactivation of neurotransmitters, cuticle sclerotization, melatonin 
biosynthesis, and biosynthesis of important cell signaling lipids.
1-4
  One set of enzymes, the 
arylalkylamine N-acetyltransferases (AANAT), are known to catalyze the formation of 
N-acetylarylalkylamides from acetyl-CoA and the corresponding arylalkylamide.  Recently, 
eight putative arylalkylamine N-acetyltransferase like enzymes (AANATL) were indentified in 
D. melanogaster based off their primary sequence identity.
5-6
  Only two (AANATA
3-4, 6-8
 and 
AANATL2
5
) of these enzymes have been previously characterized.  AANATA was shown to 
catalyze the formation of N-acetylarylalkylamides, consisting of N-acetyltyramine, 
N-acetyltryptamine, N-acetyldopamine, N-acetylserotonin, and N-acetyloctopamine.
3-4, 6-8
  
Previous work also showed that acetyl-CoA and tryptamine are substrates for AANATL2.
5
  Prior 
to our work, none of the other AANATL enzymes (AANATL3; CG10659, AANATL4; 
CG18607, AANATL5; CG10476, AANATL6; CG18606, AANATL7; CG13759, and 
AANATL8; CG15766) have been evaluted to define substrates each utlizes in their N-acylation 
reaction.  All eight AANATL enzymes belong to the Gcn5-related N-acetyltransferase 
superfamily (GNAT),
9-10
 which is a large family of enzymes (~10,000 members) that use 
acyl-CoA and amine substrates to generate an N-acylamide (Scheme 3.1).  One difficultly in 
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defining the chemistry for GNAT enzymes is that the primary sequence identity when compared 
to other N-acyltransferases is very low.
10
  This makes it challenging to define substrates for this 
family of enzymes solely from bioinformatics, whereas a developed screening method would be 
advantageous in classifying the chemistry each respective enzyme catalyzes. 
Herein, we report the successful development of an activity-based screening method for 
GNAT enzymes.  Our method employs a combination of two activity-based screening steps and 
a product identification step by liquid chromatography quadruple time-of-flight mass 
spectrometry (LC/QTOF-MS).  This high-throughput screening method was extremely 
successful at defining different substrates for four D. melanogaster AANATL enzymes 
(AANATL2, AANATL3, AANATL7, and AANATL8).  Additionally, this method was able to 
discover unconventional acyl-CoAs and/or amines that serve as AANATL substrates, giving new 
insight to the cellular functions for this family of enzymes from the fly.  
Scheme 3.1. General GNAT reaction. R – fatty acyl group. Y – amine substrate. 
 
3.2 Materials and methods 
3.2.1 Materials 
Ambion RETROscript® Kit, ProBond™ nickel-chelating resin, MicroPoly(A) PuristTM 
was purchased from Invitrogen.  Oligonucleotides were purchased from Eurofins MWG Operon.  
PfuUltra High-Fidelity DNA polymerase was purchased from Aglient.  BL21 (DE3) E.coli cells 
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and pET-28a(+) vector were purchased from Novagen.  NdeI, XhoI, Antarctic Phosphatase, and 
T4 DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG 
were purchased from Gold Biotechnology.  Acetyl-CoA and oleoyl-CoA were purchased from 
Sigma-Aldrich.  N-oleoylserotonin was purchased from Caymen Biochemical.  N-acetylagmatine 
and N
1
-acetylspermidine were custom synthesized from Cayman Biochemical.  AANATL2 and 
AANATL8 were codon optimized and purchased from Genscript.  All other reagents were 
purchased in high quality from either Sigma-Aldrich or Fisher Scientific.   
 
3.2.2 Cloning of recombinant D. melanogaster AANATL enzymes 
AANATL2 (CG9486) was cloned, over-expressed, and purified as previously reported 
(Appendix B).
11
  The AANATL8 (CG15766 – Accession No. NM_132040.2) gene was codon 
optimized and synthesized by Genscript.  The AANATL3 (CG10659 - NCBI reference sequence 
NM_136174.2) and AANATL7 (CG13759) genes were amplified by PCR using PfuUltra 
High-Fidelity DNA polymerase from a cDNA library generated from Drosophila heads, using 
the following primers: AANATL3 - forward 5’ 
TACGCATATGATGGCCTCAAGCATTAAAGAC 3’ and reverse 5’ 
TACGCTCGAGTCACAGTTTGATGAACATAATTCG 3’ or AANATL7 - forward 5’ 
TCAGCATATGATGGAGTACAAGATGATTGCACCC 3’ and reverse 5’ 
TCAGCTCGAGTTAAAGCGACTGCTTCTTCTCAT 3’.  The production of the D. 
melanogaster head cDNA library is described in Dempsey et al or also found in Appendix B.
11
  
The PCR conditions for the separate amplification of AANATL3 or AANATL7 were: initial 
denaturing step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), 
then a final extension step of 72°C for  10 min.  The following set of cloning procedures was 
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performed for each enzyme, separately.  The AANATL3 and AANATL7 PCR products, in addition 
to the codon optimized AANATL8 gene were then inserted into a pET-28a (+) vector using NdeI 
and XhoI restriction sites to generate AANATL3-pet-28a, AANATL7-pet-28a, and 
AANATL8-pet-28a expression vectors.  After the formation of the expression vectors, each one 
was transformed into E. coli XL-10 cells, spread onto a Luria Broth (LB) agar plate, and 
incubated overnight at 37°C.  A single colony from the LB agar plates containing the 
AANATL3-pet-28a, AANATL7-pet-28a, or AANATL8-pet-28a expression vector was then 
cultured overnight in LB media supplemented with 40 µg/mL kanamycin at 37°C.  The 
AANATL3-pet-28a, AANATL7-pet-28a, and AANATL8-pet-28a plasmids were purified from the 
final cultures using the Promega Wizard® Plus SV Minipreps DNA purification kit.  Each pure 
plasmid was sequenced by Eurofins MWG operon and then transformed into E.coli BL21 (DE3) 
cells for protein expression.      
 
3.2.3 Expression and purification of AANATL enzymes 
The BL21(DE3) E. coli cells containing the AANATL3-pet28a, AANATL7-pet-28a, or 
AANATL8-pet28a vectors were cultured separately in LB media supplemented with 40 µg/mL 
kanamycin at 37°C.  All three cultures were induced at an OD600 of 0.6 with 1 mM isopropyl 
thio-β-D-galactoside.  The cells were then culture for another 4 hrs at 37°C before being 
harvested separately by centrifugation at 5,000 g for 10 min at 4°C.  The following set of 
purification procedures was performed for each enzyme, separately.  The supernatant from the 
centrifugations were discarded and the pellets were resuspended in nickel affinity purification 
binding buffer (20 mM Tris pH 7.9, 500 mM NaCl, 5 mM imidazole), lysed by sonication, and 
then centrifuged at 10,000 g for 15 min at 4°C.  The supernatant was collected, whereas the 
pellet was discarded.  The supernatant was then loaded on a ProBond™ nickel-chelating column 
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containing 6 mL of resin, washed with 60 mL of binding buffer, and then washed with 60 mL of 
20 mM Tris, pH 7.9, 500 mM NaCl, 60 mM imidazole to remove any non-specifically bound 
proteins.  Then each protein was eluted in 1 mL fractions using 20 mM Tris, pH 7.9, 500 mM 
NaCl, 500 mM imidazole.  The purified fractions of AANATL3 and AANATL8 were dialyzed 
into 20 mM Tris pH 7.4, 200 mM NaCl for 16 hr at 4°C, separately.  Purified AANATL7 was 
dialyzed into 50 mM HEPES pH 8.2, 500 mM NaCl, 1 mM EDTA for 16 hr at 4°C.  The purity 
of each protein was assayed by a 10% SDS-PAGE gel and their respective concentrations were 
determined by the Bradford binding assay.  
 
3.2.4 Enzyme screening assay 
The activity-based screening for each AANATL enzyme for acyl-CoA and amine 
substrates were evaluated in two separate steps.  The first step was to evaluate each enzyme 
using either acetyl-CoA or oleoyl-CoA separately, with seven different groups of pooled amines.  
The corresponding amines in each group are found in Table 3.1.  The assay conditions were 300 
mM Tris pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and pooled amines at 22°C.  The final 
concentrations of the amine substrates for the screening assay were the following: Groups 1, 2, 3, 
4, and 6, were 60 mM, whereas groups 4, 5, and 7 were 20 mM.  The initial velocities were 
determined using Ellmans reagent (molar extintion coefficent = 13,600 M
-1
cm
-1
), by measuring 
the rate of coenzyme A release at 412 nm.
12
  The reported initial velocities are represented as the 
background hydrolysis rate subtracted from the observed velocity.   
The second step was to individually evaluate each amine from groups that had significant 
velocities above the background hydrolysis rate, with the corresponding acyl-CoA substrate.   
“Significant velocity” is defined herein as any rate (µmoles/min/mg) that was ≥ 0.1 
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µmoles/min/mg above the background rate.  The assay conditions were the same as the pooled 
amine screening step, including the concentration of each amine substrate evaluated.  After all 
the amine and the corresponding acyl-CoA(s) substrate(s) were indentified, then the final 
reaction products were analyzed by LC/QTOF-MS. 
 
Table 3.1. Pooled amines for initial substrate screening. 
Group Amino Donors 
1 Lysine, threonine, glycine, histamine 
2 Alanine, arginine, histidine, tyramine 
3 Serine, proline, methionine, serotonin 
4 Glutamate, asparagine, valine, ethanolamine 
5 Aspartate, isoleucine, tryptophan, glutamine 
6 Leucine, phenylalanine, γ-aminobutyric acid, taurine 
7 Spermidine, agmatine, cadaverine, putrescine, β-alanine 
  
3.2.5 Identification of N-acylamide product by LC/QTOF-MS 
Following the activity-based screening method, we confirmed the presence of the 
predicted N-acylamide product by LC/QTOF-MS.  The products for each reaction were 
generated by incubating the specific enzyme (AANATL2; 36 µg, AANATL3; 69 µg, 
AANATL7; 9.3 µg, or AANATL8; 36 µg) for one hour in 300 mM Tris pH 8.0, 500 µM 
acyl-CoA substrate, and 60 mM or 20 mM amine substrates.  The amine concentration was the 
same as that evaluated in the activity-based screening section.  The resulting reaction mixture 
was passed through a 10 kDa ultrafilter (Millipore) to remove the AANATL enzyme and the 
protein-free solution was then injected on an Agilent 6540 LC/QTOF-MS.  The LC/QTOF-MS 
method used and the data analysis is described in the Dempsey et al. publication or also found in 
Appendix B.
11 
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3.2.6 Enzyme assay for defining the AANATL3 steady-state kinetic constants  
AANATL3 activity was analyzed using Ellman’s reagent12 by measuring the release of 
coenzyme A at 412 nm under the following assay conditions: 300 mM Tris, pH 8.0, 150 µM 
DTNB, while holding one substrate at a constant saturating concentration and varying the 
concentration of the other substrate at 22°C.  Initial velocities of CoA-SH release were measured 
using a Cary 300 Bio UV-Visible spectrophotometer.  The resulting initial velocity kinetic data 
were fit to equation 3.1 using Sigma Plot 12.0, where vo is the initial velocity, [S] is the substrate 
concentration, Vmax is the maximal velocity, and Km is the Michaelis constant.  Assays were 
performed in triplicate and reported as ± the standard error.  The uncertainty for the kcat,app, 
(kcat/Km)app, and the relative (kcat/Km)app values were calculated by using equation 3.2, which σ is 
the standard error.      
 
Equation 3.1 
   
        
      
 
 
Equation 3.2 
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3.3 Results and discussion 
3.3.1 Expression and purification of AANATL enzymes 
AANATL2,
17
 AANATL3, AANATL7 and AANATL8 from D. melanogaster were 
overexpressed and purified successfully to yield 7.5 mg/L, 11 mg/L, 27 mg/L and 7.5 mg/L of 
purified protein per liter culture, respectively.  Purity was analyzed and shown to be ≥ 90% by a 
10% SDS-PAGE gel (Figure 3.1 or Appendix B).
11
  Successful expression and purification of 
each protein allowed for the further evaluation of potential substrates by a pooling strategy 
discussed in subsequent sections.   
Figure 3.1. SDS-Page analysis. (A) AANATL3, (B) AANATL7, (C) AANATL8. 
 
3.3.2 Pooling strategy for identification of AANATL enzymes 
We developed a three step substrate screening method which includes two activity-based 
screening methods and one product identification step.  Specifically, our GNAT screening 
strategy is composed of (a) a amine pooling strategy that is screened with either a short-chain 
(acetyl-CoA) or long-chain (oleoyl-CoA) acyl-CoA by measuring the rate of CoA-SH release 
using Ellmans reagent,
12
 (b) followed by individual screening of each amine in the group(s) with 
the corresponding acyl-CoA that produced a velocity above the background hydrolysis rate, and 
finally (c) confirming the presence of the N-acylamide product in the final reaction mixture by 
LC/QTOF-MS.  The first step in the identification of novel AANATL substrates is the initial 
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screening of amine substrates that are pooled into specific groups.  A general approach for how 
the first six groups of pooled amines (Group 1 – 6) were assembled consists of:  (a) if there is in 
vivo evidence for the predicted N-acylamide product, (b) combining amines that are structurally 
diverse, and (c) the solubility
13
 of the amine in water.  Amines were chosen for the first six pools 
based off previous reports of endogenous levels of N-acyl amino acids,
14-15
 N-acetylhistamine,
16
 
N-acetyltyramine,
17
 N-acylethanolamines,
14-15
 N-acylserotonins,
17-18
 and N-acyl GABAs.
14
  
Therefore, we evaluated AANATL2, AANATL3, AANATL7, and AANATL8 to determine if 
these enzymes could function to catalyze the formation of these endogenous fatty acid amides.  
In addition, we made an effort to pool structurally diverse amines into different groups in order 
to minimize any inhibition effects from other amines that may occur in the enzymatic assay.  The 
concentration of amines in the pooled enzymatic screening assay were held at high 
concentrations since some GNAT enzymes are known to have high Km,app values for the amine 
substrate.   For example, mouse glycine N-acyltransferase (GLYAT) has a Km,app value of 6 mM 
for glycine.
19
  The amine concentrations for the pooled screening method were either 60 mM (10 
× the Km,app value for GLYAT; Groups 1, 2, 3, and 6)  or 20 mM (3 × the Km,app value for 
GLYAT; Groups 4 and 5), yielding assay conditions that are saturating for most GNAT 
enzymes.  Groups 4 and 5 were analyzed at 20 mM, because of the solubility of glutamate (~65 
mM),
13, 20
 tryptophan (~60 mM),
13, 21-22
 and aspartate (~38 mM)
13, 20
 in water.  Following the 
evaluation of the first six pooled amine groups (Table 3.2), we decided to add Group 7 because 
of the low velocities observed for AANATL3 and AANATL8.  Group 7 is predominantly 
composed of polyamines and was evaluated at a concentration of 20 mM for each amine (Table 
3.1).  Some polyamines have been identified to serve as substrates for N-acetylation by different 
GNAT enzymes.  The Km value for polyamine N-acetyltransferase enzymes range from the 
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micromolar (human spermidine/spermine N
1
-acetyltransferase: spermidine – 22 µM)23 to low 
millimolar concentrations (rat acetyl-CoA 1,4-diaminobutane N-acetyltransferase: putrescine – 3 
mM).
24
  Therefore, the assay conditions for the amine concentration would produce a worst case 
scenario of 7-fold higher than the Km,app value for rat acetyl-CoA 1,4-diaminobutane 
N-acetyltransferase,
24
 suggesting we are likely close to saturating conditions for most GNAT 
enzymes.  Tyrosine and cystine were not evaluated in this study. Tyrosine has a low solubility in 
water (~2.5 mM)
13, 20
 when compared to the other amino acids, while cystine will interfere with 
Ellman’s reagent by inducing an absorbance increase at 412 nm.  Ellman’s assay measures the 
free release of thiol groups, in our case, the free release of the coenzyme A product from the 
AANATL-catalyzed reaction.
12
  Since, cystine has a free thiol as its side chain, it will induce a 
color change that is non-specific to the enzyme-catalyzed reaction.  We did not use a pooling 
strategy for the acyl-CoA substrates because of numerous reports that long-chain acyl-CoAs 
serve as inhibitors to GNAT enzymes;
6, 19, 25-26
 therefore, we screened each acyl-CoA 
individually.  Our screening method wanted to encompass a broad range of acyl-CoA substrates, 
with an emphasis on the length of the acyl-chain.  Acyl-CoAs will serve as substrates for GNAT 
enzymes, with most using acetyl-CoA.  There are reports of GNAT enzymes using oleoyl-CoA 
as a substrate;
27
 therefore, we used acetyl-CoA and oleoyl-CoA to represent the short- and 
long-chain acyl-CoAs in the screening method, respectively.   
The first step of the screening method was the amine pooling strategy for D. 
melanogaster AANATL2, AANATL3, AANATL7, and AANATL8 (Table 3.2).  These set of 
experiments identified significant hits for each enzyme, wherein we define significance as any 
velocity shown in Table 3.2 that is at least 0.1 µmoles/min/mg greater that the observed 
background hydrolysis activity.  We decided to incorporate velocities that are small compared to 
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the background rate because long-chain fatty acid amides are found in low abundances in 
biological samples, in particular the fly and they function as potent cell signaling lipids.
2, 28
  This 
indicates that their biosynthesis could be catalyzed by enzymes that function with small 
velocities as observed for D. melanogaster AANATL2 (Appendix B)
11
 and human glycine 
N-acyltransferase like 2.
27
  From our data (Table 3.2), we identified significant hits for 
AANATL2 (acetyl-CoA: Group 1, 2, 3, 4, and 7; oleoyl-CoA: Group 3), AANATL3 
(acetyl-CoA: Group 2 and 3), AANATL7 (acetyl-CoA: Group 1, 2, 3, 4, and 7), and AANATL8 
(acetyl-CoA: Group 1, 2, and 7).  These data directed us to further screen each amine from the 
respective group that was assigned as a “hit” individually, with the corresponding acyl-CoA. 
 
Table 3.2. Pooled screening method for the AANATL-catalyzed reaction. 
Acyl-CoA 
Velocity 
(µmoles/min/mg) 
Group
 
1
a
 2
a
 3
a
 4
b
 5
b
 6
a
 7
b
 
AANATL2 – CG9486 
Acetyl-CoA 2.5
c 3.8
c 
2.5
c 
1.5
c 
0.05 0.0 0.18
c 
Oleoyl-CoA 0.02 0.05 0.20
c 
0.05 0.02 0.0 0.0 
AANATL3 – CG10659 
Acetyl-CoA 0.03 0.38
c 
0.40
c 
0.0 0.02 0.05 0.03 
Oleoyl-CoA 0.01 0.0 0.0 0.0 0.0 0.01 0.0 
AANATL7 – CG13759 
Acetyl-CoA 28
c 13
c 
11
c 
13
c 
0.04 0.0 4.2
c 
Oleoyl-CoA 0.0 0.05 0.0 0.01 0.0 0.01 0.0 
AANATL8 – CG15766 
Acetyl-CoA 0.57
c 0.24
c 
0.03 0.05
 
0.0 0.0 29
c 
Oleoyl-CoA 0.0 0.0 0.0 0.0 0.01 0.0 0.0 
 a
 Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 60 mM 
Group X (pooled amines). 
b
 Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 20 mM 
Group X (pooled amines). 
c
 Classified as a “hit” (≥ 0.1 µmoles/min/mg when compared to background hydrolysis rate) 
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3.3.3 Indiviual screening of amine and acyl-CoA substrates that yielded a “hit” from pooling 
method 
A summary of the data from the individual screening of every amine from pools that 
were classified as “hits” can be found in Table 3.3.  Amine substrates in decreasing order of 
velocity identified for AANATL2 were tyramine > serotonin > histamine > ethanolamine >> 
putrescine > agmatine > cadaverine > spermidine, with acetyl-CoA as the corresponding 
acyl-CoA substrate.  AANATL2 was also identified to catalyze the formation of 
N-oleoylserotonin from serotonin and oleoyl-CoA.  These data highlight an enzyme, for the first 
time that will catalyze the formation of long-chain N-acylserotonins.  Serotonin and tyramine, in 
combination with acetyl-CoA, were found to be substrates for AANATL3 with similar velocities.   
Individual amine screening for AANATL7 identified in decreasing order of velocity: 
histamine > tyramine > serotonin > putrescine > agmatine > ethanolamine > cadaverine with 
acetyl-CoA as the corresponding acyl-CoA substrate.  These data feature an enzyme that can 
catalyze the formation of N-acetylhistamine, N-acetylagmatine, and N-acetylethanolamine, 
which are unknown or understudied metabolites,
16, 29
 with very few reports of an enzyme that 
can catalyze their direct biosynthesis.
30-33
   
Finally, the individual screening of amine substrates for AANATL8 showed a decreasing 
order in velocity: agmatine >> putrescine > spermidine > cadaverine > histamine > tyramine 
with acetyl-CoA as the corresponding acyl-CoA substrate.  These data indicate that AANATL8 
will catalyze the formation of polyamines; therefore, functioning as a polyamine 
N-acetyltransferase (PNAT).  Agmatine generated the highest velocity, which is an understudied 
amine substrate for GNAT enzymes.
33
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Table 3.3. Summary of data from the individual screening method for AANATL enzymes.
a 
Enzyme Group 
Amine 
Substrate 
Acyl-CoA 
Substrate 
Velocity 
(µmoles/min/mg) 
Retention 
Time 
(min) 
[M + H]
+
 
(m/z) 
AANATL2 
1
b 
Histamine 
Acetyl-CoA 
2.2 0.317 154.0982 
2
b 
Tyramine 4.0 0.687 180.1030 
3
b 
Serotonin 3.1 0.715 219.1140 
4
c 
Ethanolamine 0.85 0.220 104.0710 
7
c 
Spermidine 0.1 0.230 188.1753 
Agmatine 0.13 0.323 173.1389 
Cadaverine 0.11 0.318 145.1335 
Putrescine 0.16 0.345 131.1183 
3
b 
Serotonin Oleoyl-CoA 0.21 6.126 441.3463 
AANATL3 
2
b 
Tyramine 
Acetyl-CoA 
0.45 0.694 180.1030 
3
b 
Serotonin 0.47 0.713 219.1142 
AANATL7 
1
b 
Histamine 
Acetyl-CoA 
23 0.320 154.0975 
2
b 
Tyramine 7.7 0.687 180.1019 
3
b 
Serotonin 5.8 0.719 219.1133 
4
c 
Ethanolamine 1.7 0.345 104.0695 
7
c 
Agmatine 3.3 0.318 173.1393 
Cadaverine 1.0 0.317 145.1335 
Putrescine 3.9 0.345 131.1179 
AANATL8 
1
b 
Histamine 
Acetyl-CoA 
0.51 0.318 154.0972 
2
b 
Tyramine 0.24 0.694 180.1031 
7
c 
Spermidine 0.67 0.232 188.1758 
Agmatine 32 0.322 173.1395 
Cadaverine 0.59 0.324 145.1329 
Putrescine 5.1 0.329 131.1182 
a
 Data in table represents each the acyl-CoA and amine that produced a positive “hit” in velocity above 
the background hydrolysis rate (≥ 0.1 µmoles/min/mg).  All other amines from the respective pools did 
not produce a velocity above the background hydrolysis rate. 
b
 Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 60 mM 
amine substrates. 
c
 Enzyme reaction conditions – 20 mM Tris, pH 8.0, 150 µM DTNB, 500 µM acyl-CoA, and 20 mM 
amine substrates. 
 
3.3.4 High resolution LC/QTOF-MS identification of the N-acylamide product generated from 
individual screening method 
The screening data was extremely successful at identifying substrates for each AANATL 
enzyme evaluated.  We wanted to further evaluate each enzyme by identifying if the predicted 
N-acylamide product is present in the final reaction mixture.  We compared commercial 
N-acylamide standards to the AANATL final reaction mixture using high resolution 
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LC/QTOF-MS.  The N-acylamide product from the AANATL final reaction mixture (Table 3.3) 
and commercially available standards (Table 3.4) were compared by the retention time and the 
m/z value of the [M + H]
+
 peak using high resolution LC/QTOF-MS.  The data in Tables 3.3 and 
3.4 confirms the presence of the predicted N-acylamide product in the AANATL-catalyzed 
reaction sample for each enzyme evaluated in this study.  All data represented herein is 
consistent for retention time (± 0.1 reported error for LC/QTOF-MS) and the [M + H]
+
 peak 
when compared to commercially available standard.  
 
Table 3.4. N-acylamide LC/QTOF-MS standards. 
Standard 
Retention Time 
(min) 
[M +H]
+
 
(m/z) 
N-acetylhistamine 0.256 154.0976 
N-acetylserotonin 0.726 219.1131 
N-acetylethanolamine 0.299 104.0710 
N-acetylputrescine 0.345 131.1172 
N-acetylagmatine 0.316 173.1424 
N
1
-acetylspermidine 0.233 188.1758 
N-oleoylserotonin 6.145 441.3509 
 
3.3.5 Steady-state kinetic analysis of AANATL3 
 AANATL3 was further evaluated to determine the substrate specificity for biologically 
relevant arylalkylamines found in the fly (Table 3.5).  The order for the specificity of the 
biogenic arylalkylamines is as follows: serotonin > tyramine > octopamine.  Dopamine was also 
evaluated at a concentration of 10 mM, but did not yield a velocity above the background 
hydrolysis of acetyl-CoA, suggesting that it is either not a substrate or has a significantly higher 
Michaelis constant (Km,app > 10 mM;) for AANATL3 when compared to the other 
arylalkylamines in Table 3.5.       
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Table 3.5. AANATL3 kinetic constants.
a 
Substrate 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
Relative (kcat/Km)app 
Acetyl-CoA
b 
46 ± 3 0.202 ± 0.003 (4.4 ± 0.3) × 10
3
 N/A
d
  
Tyramine
c 
760 ± 80  0.23 ± 0.01 310 ± 40 1.7 ± 0.4
e 
Serotonin
c 
550 ± 30  0.229 ± 0.004 410 ± 20 2.3 ± 0.4
e
  
Octopamine
c 
1300 ± 200  0.23 ± 0.01 180 ± 30 1.0 ± 0.2
e 
a
 Kinetic constants are reported with the standard error (n = 3). 
b 
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 7.5 mM tyramine, and varying concentration 
of acetyl-CoA. 
c 
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying 
concentration of arylalkylamine. 
d 
N/A – not applicable.  The second order rate constant for acetyl-CoA was not indexed to any other 
substrate. 
e 
Relative (kcat/Km)app was normalized to octopamine [(kcat/Km)app = 180 ± 30]. 
 
3.3.6 Discussion 
There are over 10,000 GNAT superfamily enzymes identified in all kingdoms of life,
10
 
which makes this one of the largest known superfamilies.  Methods used to define a cellular 
function for previously uncharacterized enzymes consist of genome sequencing and 
bioinformatics,
34-35
 identifying the sub-cellular localization of the protein,
36
 substrate docking 
methods,
37-38
 and activity-based individual screening of substrates.
39-41
  Using bioinformatics to 
define the chemistry of a GNAT enzyme is challenging because of the very low primary 
sequence identity for this family of enzymes.
10
  For example, D. melongaster AANATA was 
reported to have ≤ 12% sequence identity with its mammalian ortholog.7  In addition, using 
bioinformatics to solve the function of uncharacterized proteins can be misleading, in that many 
predicted proteins in public databases are missannotated
34, 42-43 or are classified as a “hypothetical 
proteins”.44-45  In fact, it has been reported that up to 40% of known proteins are not annotated in 
public databases and their define functions are still pending.
44-45
  Sub-cellular localization has 
been successful in giving insight to the chemical environment an enzyme performs its function; 
however, it will not confirm the exact in vivo reaction(s) the enzyme will catalyze.  Protein 
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docking strategies have been immensely successful in defining substrates for uncharacterized 
enzymes.
46
  As the public databases grow with solved crystal structures, defining the chemistry 
of these enzymes have become easier and cheaper by using computational methods.  However, 
this method requires a solved crystal structure for the protein being studied or a structurally 
similar protein that can be evaluated by a homology model.
47
  In 2012, the PDB database 
contained > 2,000 non-redundant crystal structures that were annotated with unknown 
functions.
48
  This suggests that even with a solved crystal structure, it can still be extremely 
challenging to define the biological function of a protein just from a crystal structure.  In all, we 
identified a need to develop a high-throughput screening strategy, to define the function for 
enzymes that have not been previously characterized. 
Very few screening methods have been developed to discover substrates for an 
uncharacterized enzyme.  There are examples of published screening methods that utilize 
substrate pooling strategies, individual substrate screening methods, or enzyme pooling methods 
to define the cellular function of enzymes.  The report by von Buhler et al.
39
 uses a substrate 
pooling strategy to measure percent conversion by GC/MS and LC/MS for cytochrome P450s.  
Kuznetsova et al.
40
 used a 96-well plate reader to annotate functions for a broad class of different 
enzymes (phosphodiesterases, esterases, proteases, dehydrogenases, and oxidases), using 
individual and pooling strategies.  Kuhn et al.
41
 also used a 96-well plate reader to individually 
screen possible amine substrates with acetyl-CoA for different GNAT enzymes.  Our method is a 
hybrid of these methods; where we incorporate a pooling strategy, followed by individual 
screening, and finally analyzing the N-acylamide product by LC/QTOF-MS.   Our screening 
strategy is similar to that developed for bacterial GNAT enzymes by Kuhn et al.,
41
 whereas the 
differences are that we used an initial amine pooling step and a final LC/QTOF-MS N-acylamide 
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product confirmation step.  Also, with recent evidence that long-chain fatty acid amides can be 
biosynthesized by GNAT enzymes,
2, 27
 we decided that our screening method should incorporate 
long-chain acyl-CoA substrates, in addition to acetyl-CoA.  In addition, we evaluated the 
activity-based screening steps with Cary 300 Bio UV-vis spectrophotometer, whereas Kuhn et 
al.
41
 used a 96-well plate reader to measure free release of CoA-SH at 412 nm using Ellman’s 
reagent.
12
  We believe our pooling method could also be translated to a 96-well plate reader in 
the future.  One major advantage to our method is the successful use of an initial high-throughput 
amine pooling strategy, instead of individually evaluating every amine.  Screening different 
substrates for an enzyme could be laborious and expensive, especially GNAT enzymes that use 
an expensive acyl-CoA substrate [currently acetyl-CoA is ~150-fold > the price of gold (as of 
12/23/2014)].  Our method can minimize the cost and time in defining substrates for GNAT 
enzymes.  For example with one enzyme, if we pool together 5-10 amine substrates into seven 
groups, in combination with screening a short-chain (acetyl-CoA) and long-chain acyl-CoA 
(oleoyl-CoA) substrate separately, we can initially screen 70-140 combinations in only 14 
experiments.  This method totals to 5-10 fold less experiments when compared to individually 
screening each substrate.  Therefore, this method would significantly decrease the overall cost 
and time when compared to screening each substrate, separately. 
In our study, we report the successful expression and purification of four D. 
melanogaster AANATL enzymes (AANATL2, AANATL3, AANATL7, and AANATL8) and 
the novel discovery of substrates for each enzyme by our screening strategy.  AANATL2 was the 
first enzyme to be evaluated, which generated excitement for our method.  We identified that it 
will catalyze the formation of N-oleoylserotonin (Table 3.3).  These data led to the first report of 
an enzyme that will catalyze the formation of long-chain N-acylserotonins and N-acyldopamines 
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(Appendix B).
11
  These data also corroborate the original report by Amherd et al.
5
 that 
AANATL2 will catalyze the formation of N-acetylarylalkylamides.  The second enzyme studied, 
AANATL3, was shown to catalyze the formation of N-acetylserotonin and N-acetyltyramine 
(Table 3.4).  Following this work, we showed that histamine, arylalkyamines, ethanolamine, 
agmatine, putrescine, and cadaverine will serve as substrates for AANATL7, whereas agmatine, 
histamine, tyramine, and other polyamines will serve as substrates for AANATL8.  Histamine is 
known to function as a neurotransmitter for photoreceptors in the D. melanogaster nervous 
system,
16
 whereas agmatine is an unknown metabolite in the fly.  However, agmatine is known 
to exist in mammals, with the highest concentration found in the stomach and brain, where it 
functions as a neurotransmitter.
49
  These enzymes could function in the inactivation of these 
neurotransmitters.  Very few reports are published for enzymes that can catalyze the formation of 
N-acetylhistamine or N-acetylagmatine, especially with the higher velocities observed for 
agmatine (AANATL8) and histamine (AANATL7).
30-33
  We must express some caution with 
these data, in which the high velocities observed for substrates is not completely indicative of 
substrate specificity.  We would need to determine the second order rate constant (kcat/Km) for all 
substrates in order to rank the “best substrate(s)” for that particular enzyme, as shown with 
AANATL3 (Table 3.5).  Regardless, these are exciting results that need to be followed up with a 
more compressive characterization of each enzyme (AANATL2 – Chapter 5 and AANATL7 – 
Chapter 4). 
 In conclusion, we were able to successfully develop and implement a screening method 
for the general identification of substrates for GNAT enzymes found in D. melanogaster.  Using 
the method described herein, we were able to annotate acyl-CoA and amine substrates to each 
enzyme evaluated in this study.  We were able to discover enzymes which catalyze well known 
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N-acetylamide products, such as N-acetyltyramine
17
 and N-acetylserotonin.
17-18
  We also were 
able to define enzymes that catalyze the formation of understudied or undiscovered N-acylamide 
products, such as or N-acetylhistamine,
16
 N-oleoylserotonin,
11, 50
 and N-acetylagmatine.
29
  We 
believe this method could be translated to GNAT enzymes in other organisms and to other 
classes of enzymes that have an activity-based assay (ex. dehydrogenases, proteases, 
phosphodiesterases, etc…).40  The subsequent chapters in this dissertation will discuss the 
characterization of AANATL7 and AANATL2, which evolved from the work defined in this 
chapter.  
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Chapter Four 
Mechanistic and Structural Analysis of a Drosophila melanogaster Enzyme, Arylalkylamine 
N-acetyltransferase Like 7, that Catalyzes the Formation of N-acetylarylalkylamides and 
N-acetylhistamine 
 
4.1 Introduction 
The N-acetylation of biogenic amines is a critical chemical step in the inactivation of 
potent neurotransmitters.  In Drosophila melanogaster, the biogenic amines are composed of 
dopamine, serotonin, tyramine, octopamine, and histamine.
1
  Biosynthesis of these biogenic 
amines and the corresponding N-acetylamide product are derived from their cognate amino acid 
precursor.  Tyramine, dopamine, and octopamine are products of tyrosine metabolism; serotonin 
is generated from tryptophan, whereas histamine is derived from histidine.  Complete 
biosynthesis of the arylalkylamine biogenic amines and the corresponding 
N-acetylarylalkylamide has been discussed immensely;
2-6
 however, there has been very little 
discussion for the N-acetylation of histamine as a degradative pathway in the fly.  Histamine has 
been predominantly localized to the fly nervous system,
7-10
 in which the highest amount in the 
head was identified in the eye,
11
 where it functions as a neurotransmitter for photoreceptors.
12
  
Histamine is biosynthesized (Scheme 4.1) by the decarboxylation of histidine by a histidine 
decarboxylase.
12-14
  Degradation of histamine can occur by three different pathways, which 
consists of either an oxidation reaction or two conjugation reactions (N-acetylation or β-alanine 
conjugation) in D. melanogaster.   The oxidation pathway is proposed to deaminate histamine by 
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two subsequent steps catalyzed by a diamine oxidase (histaminase)
15
 and an aldehyde 
dehydrogenase
16-19
 to generate the respective products, imidazole-4-acetaldehyde and 
imidazole-4-acetic acid.  These enzymes have not been characterized in D. melanogaster, 
however the product imidazole-4-acetic acid has been identified in the fly head.
12
  Another 
pathway for histamine degradation is the conjugation with β-alanine to generate carcinine 
(β-alanylhistamine),20-21 which is catalyzed by N-β-alanyl dopamine synthase.22-23  This pathway 
has been attributed as the major pathway for recycling histamine in the fly head through which 
carcinine can be subsequently hydrolyzed to regenerate histamine, by the enzyme N-β-alanyl 
dopamine hydrolase.
23-24
  Finally, histamine can be inactivated by an N-acetyltransferase enzyme 
that catalyzes the formation of N-acetylhistamine.   Evidence for each of these pathways has 
been provided in insects, where the final products of N-acetylhistamine,
12
 imidazole-4-acetic 
acid,
12
 and carcinine
23
 have been identified in the D. melanogaster head.  We report herein, an 
enzyme that catalyzes the formation of the N-acetylhistamine and N-acetylarylalkylamide 
products, or known as arylalkylamine N-acetyltransferase like 7 (AANATL7). 
AANATL7 is a member of the GCN5-related N-acetyltransferase (GNAT) family of 
enzymes.
25-26
  AANATL7 catalyses the formation of N-acetylarylalkylamides and 
N-acetylhistamine from acetyl-CoA and the corresponding amine substrate. The N-acetylation of 
biogenic amines was first identified in D. melanogaster by Dewhurst et al. in 1972
4
 by 
measuring N-acetyltransferase activity of crude extracts with the substrates: acetyl-CoA with 
serotonin, tyramine, or dopamine.  Later N-acetylhistamine was identified in the fly head
12
 as a 
product of histamine metabolism.  Herein, we report an N-acetyltransferase enzyme that can 
catalyzed the formation of N-acetylarylalkylamides and N-acetylhistamine in D. melanogaster.  
Further studies solved the kinetic mechanism by dead-end inhibition, followed by pH-activity 
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profiling and site-directed mutagenesis experiments to delineate a proposed chemical mechanism 
for this enzyme.  Finally, we discuss some structure-function relationships identified for 
AANATL7 with respect to different substrates and amino acid residues involved in substrate 
binding and regulation of catalysis. 
 
Scheme 4.1. Proposed biosynthetic and degradative pathways for histamine metabolism. 
Reaction 1, Histidine decarboxylase (HDC). Reaction 2, Diamine oxidase (DAO). Reaction 3, 
Aldehyde dehydrogenase (AlDH).  Reaction 4, N-β-alanyl dopamine synthase (NBAD synthase).  
Reaction 5, N-β-alanyl dopamine hydrolase (NBAD hydrolase).  Reaction 6, Histamine 
N-acetyltransferase (HNAT) and arylalkylamine N-acetyltransferase (AANAT). 
 
4.2 Materials and methods: 
4.2.1 Materials 
 ProBond™ nickel-chelating resin was purchased from Invitrogen.  PCR primers were 
purchased from Eurofins MWG Operon.  PfuUltra High-Fidelity DNA polymerase was 
purchased from Agilent.  BL21 (DE3) E. coli cells, E. coli XL10 competent cells, and 
pET-28a(+) vector were purchased from Novagen.  NdeI, XhoI, Antarctic Phosphatase, and T4 
DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG 
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were purchased from Gold Biotechnology.  Acetyl-CoA, butyryl-CoA, hexanoyl-CoA, 
octanoyl-CoA, oleoyl-CoA, coenzyme A, and N
ω
-acetylhistamine were purchased from 
Sigma-Aldrich.  All other reagents were of the highest quality available from either 
Sigma-Aldrich or Fisher Scientific. 
 
4.2.2 AANATL7 transcript localization 
 We used the D. melanogaster cDNA library generated for the head and thorax-abdomen 
that was discussed in Dempsey et al.
27
 Amplification of AANATL7 and glyceraldehyde 
3-phosphate dehdrogenase (GAPDH) transcripts were completed by polymerase chain reaction 
(PCR) under the following conditions: initial denaturing step of 95°C for 2 min, then 45 cycles 
of 95°C for 30 s; varying annealing temperatures (45°C, 50°C, 55°C, and 60°C) for 30 s; 72°C 
for 1 min; then a final extension step of 72°C for 10 min.  The primers used to amplify the 268 
bp (AANATL7) and 449 bp (GAPDH) products were (AANATL7: forward - 
TTTCCGCAAGATTTTCGACT, reverse TGTAGGGTTGCTCCGAGAAG; GAPDH: forward - 
ATCGTCGAGGGTCTGATGAC, reverse - ACCGAACTCGTTGTCGTACC) were synthesized 
by Eurofins MWG Operon.  The amplified products were analyzed by a 1.3% agarose gel and 
the band was visualized by 0.5 µg/mL ethidium bromide under ultraviolet light.  Each positive 
band was cut out of the agarose gel, purified by the Promega Wizard
®
 SV Gel and PCR Clean-up 
system, and sequence by Eurofins MWG Operon.  
 
4.2.3 Production of site-directed mutants 
 The site-directed AANATL7 mutants were generated using the overlap extension 
method.
28
 The AANATL7 mutants were amplified using PfuUltra High-Fidelity DNA polymerase 
with the following set of PCR conditions: initial denaturing step of 95°C for 2 min, then 30 
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cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), then a final extension step of 72°C for 10 
min.  Primers were designed by using Agilent QuickChange Primer Design tool (Table 4.1) and 
synthesized by Eurofins MWG Operon.  Using NdeI and XhoI restriction enzymes, the resulting 
AANATL7 mutant PCR products were then inserted into a pet28a(+) vector.  The AANATL7 
mutant proteins were expressed and purified using the same protocol as the wild-type enzyme.  
 
Table 4.1. AANATL7 site-directed mutagenesis primers 
Mutant 
Forward or 
Reverse Primer 
Primer Sequence 
E26A 
Forward CTT CTT CGC CGA CGC GCC GCT AAA CAA GG 
Reverse CCT TGT TTA GCG GCG CGT CGG CGA AGA AG 
P27A 
Forward CTT CGC CGA CGA GGC GCT AAA CAA GGC 
Reverse GCC TTG TTT AGC GCC TCG TCG GCG AAG 
R138A 
Forward TGG ACT CGT GCT ACG CTG GCC AGG GGA TTG 
Reverse CAA TCC CCT GGC CAG CGT AGC ACG AGT CCA 
T167A 
Forward GAA GGC CGA TGC CGC CGG CAT CTT CTC 
Reverse GAG AAG ATG CCG GCG GCA TCG GCC TTC 
S171A 
Forward GAA AGA TCT TCT GCG CGA AGA TGC CGG TG 
Reverse CAC CGG CAT CTT CGC GCA GAA GAT CTT TC 
T167A/S171A 
Forward GAA GGC CGA TGC CGC CGG CAT CTT CGC 
Reverse GCG AAG ATG CCG GCG GCA TCG GCC TTC 
H206A 
Forward CCG TGG AGG CGC CCG CCA TCA AAT TGC AGC A 
Reverse TGC TGC AAT TTG ATG GCG GGC GCC TCC ACG G 
 
4.2.4 Enzyme assay  
 Ellman’s reagent29 was used to assay the AANATL7 activity by measuring the release of 
coenzyme A at 412 nm with a molar extinction coefficient of 13,600 M
-1
 cm
-1
.  Initial velocities 
were measured by a Cary 300 Bio UV-Visible spectrophotometer at 22°C in 300 mM Tris pH 
8.0, 150 µM DTNB.  The apparent kinetic constants were generated for each amine substrate by 
holding acetyl-CoA at a fixed saturating concentration.  Apparent kinetic constants for each 
acyl-CoA substrate were determined by holding histamine at a fixed saturating concentration.  
The resulting data were fit to equation 4.1 using Sigma Plot 12.0 to generate the steady-state 
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kinetic constants, where vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app 
is the apparent Michaelis constant, and [S] is the substrate concentration.  Each assay was 
performed in triplicate.  Uncertainty calculations for kcat,app, (kcat/Km)app, and relative (kcat/Km)app 
were calculated using equation 4.2, where σ is the standard error.30 
   
Equation 4.1 
   
           
          
 
 
Equation 4.2 
  
 
 
  
 
 
  
  
 
 
 
  
  
 
 
 
 
 
 4.2.5 Kinetic mechanism 
Initial velocity patterns for acetyl-CoA and histamine were assessed by varying the 
concentration of one substrate while holding the concentration of the other substrate at a fixed 
concentration.  The resulting data was then fitted to equation 4.3 for an ordered Bi-Bi mechanism 
and plotted as a double reciprocal plot using IGOR Pro 6.34A., where Kia (Michaelis constant) is 
the dissociation constants, Kb (Michaelis constant) is the Km of substrate B (histamine), and Ka is 
the Km of substrate A (acetyl-CoA).  The two plots were generated by holding the histamine 
concentration constant (250 µM, 500 µM, 750 µM, and 2500 µM) and varying the concentration 
of acetyl-CoA.  The second plot held the concentration of acetyl-CoA constant (10 µM, 25 µM, 
50 µM, and 100 µM) and varied the concentration of histamine. 
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Equation 4.3 
  
          
                        
 
 
In combination with the initial velocity analysis, we used dead-end inhibition to solve the 
kinetic mechanism.  Oleoyl-CoA and tyrosol were evaluated as dead-end inhibitors for 
AANATL7.  The initial velocities were generated by holding one substrate (acetyl-CoA or 
histamine) at a fixed concentration, varying the concentration of the other substrate, with each 
data set evaluated at different fixed concentrations of the inhibitor.  Using SigmaPlot 12.0, the 
resulting data were fit to equation 4.4 – 4.6 for competitive, noncompetitive, and uncompetitive 
inhibition respectively; where vo is the initial velocity, Vmax,app is the apparent maximal velocity, 
Km,app is the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor 
concentration, and Ki is the inhibition constant.  Each assay was performed in triplicate. 
 
Equation 4.4 
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Equation 4.6 
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4.2.6 Rate versus pH dependence 
 The pH dependence on the apparent kinetic constants was determined for both 
acetyl-CoA and histamine.  The kinetic constants for each substrate were evaluated at intervals 
of 0.5 pH units ranging from pH 6.0 – 9.5.  The following buffers were used for the pH 
dependence experiments: MES (pH 6.0 – 7.0), Tris (pH 7.0 – 9.0), and AMeP (pH 9.0 – 9.5).  
Using Igor Pro 6.34A, the resulting data were fit to equation 4.7 (log kcat/Km – acetyl-CoAand log 
kcat/Km – histamine) and equation 4.8 (log kcat), where c is the pH-independent plateau, to determine 
the apparent pKa of measured ionizable groups.  The wild-type enzyme is reported from triplicate 
experiments, whereas the E47A mutant profile was performed in duplicate. 
 
Equation 4.7 
                       
         
 
Equation 4.8 
                    
                  
 
4.2.7 Intrinsic fluorescence measurements for the determination of the coenzyme A 
dissociation constant 
A JASCO FP-8300 spectrofluorometer was used to generate fluorescent spectra for the 
AANATL7 wild-type and R138A mutant enzymes.  Fluorescent emission spectra (excitation 280 
nm, emission 290 – 300 nm) were generated for both the AANATL7 wild-type and R138A 
mutant in a 0.4 cm pathlength cell containing 400 µL of 300 mM Tris pH 8.0, a fixed enzyme 
concentration of 0.1 mg/mL of either protein, and varying concentrations of coenzyme A at 
22°C.  Emission spectra were collected with a 50 nm/min scan speed, excitation bandwith – 5 
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nm, and emission bandwith – 2.5 nm in triplicate.  The coenzyme A dissociation constant for 
AANATL7 wild-type and R138A mutant were determined by fitting the data to equation 4.9 
using SigmaPlot 12.0, where ΔFmax is the maximum change of fluorescence at infinite ligand 
concentration, ΔF is the change in intrinsic fluorescence, L is the ligand concentration, and Kd is 
the ligand dissociation constant. 
 
Equation 4.9 
   
        
      
 
 
4.3 Results and discussion 
4.3.1 Transcript localization of AANATL7 
The localization of the D. melanogaster AANATL7 transcript was evaluated using reverse 
transcription polymerase chain reaction (RT-PCR).  The agarose gel for the amplification of the 
AANATL7 transcript (Figure 4.1) showed a similar trend in both the fly head and 
thorax-abdomen when compared to the GAPDH control.  These data suggest that the AANATL7 
transcript is found at similar levels in both anatomical regions, indicating this enzyme will 
catalyze the acyl-CoA dependent N-acylation of biogenic amines in both the head and 
thorax-abdomen of the fly.  Further evaluation of the respective substrates and final products of 
the AANATL7-catalyzed reaction will be discussed in subsequent sections.     
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Figure 4.1. AANATL7 RT-PCR.  (A) AANATL7 – 268 bp product. Lane 1 – 4 RT-PCR product 
from D. melanogaster cDNA library generated from the heads with different PCR annealing 
temperatures. Lane 1. 45°C, Lane 2. 50°C, Lane 3. 55°C, Lane 4. 60°C.  Lane 5. New England 
Biolabs Quick-Load
®
 100 bp DNA Ladder.  Lane 6 – 9 RT-PCR product from D. melanogaster 
cDNA library generated from the thorax-abdomen with different PCR annealing temperatures. 
Lane 6. 45°C, Lane 7. 50°C, Lane 8. 55°C, Lane 9. 60°C.  (B) GAPDH control 
(NM_001038847.1) – 449 bp product. Lane 1 – 4 RT-PCR product from D. melanogaster cDNA 
library generated from the heads with different PCR annealing temperatures. Lane 1. 45°C, Lane 
2. 50°C, Lane 3. 55°C, Lane 4. 60°C.  Lane 5. New England Biolabs Quick-Load
®
 100 bp DNA 
Ladder.  Lane 6 – 9 RT-PCR product from D. melanogaster cDNA library generated from the 
thorax-abdomen with different PCR annealing temperatures. Lane 6. 45°C, Lane 7. 50°C, Lane 
8. 55°C, Lane 9. 60°C.             
 
4.3.2 Steady-state kinetic characterization of AANATL7 acyl-CoA substrates 
 Activity was assayed using Ellmans reagent
29
 by monitoring the rate of coenzyme A 
release at 412 nm.  Different acyl-CoA substrates with increasing acyl chain length were 
evaluated with AANATL7 to determine their respective substrate specificity at saturating 
concentrations of histamine.  The relative (kcat/Km)app for the acyl-CoA substrates decreased as 
the acyl chain length was increased (Table 4.2).  Butyryl-CoA and hexanoyl-CoA was only 
found to have 10% and 0.082% the activity of acetyl-CoA, respectively.  The significant 
decrease in the (kcat/Km)app resulted mainly from the kcat,app value, while the Km,app value was 
similar for each acyl-CoA substrate.  Octanoyl-CoA and oleoyl-CoA were also evaluated as 
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substrates with histamine as the corresponding amine substrate and activity was not observed at 
500 µM of each substrate.  These data suggest that AANATL7 will predominantly catalyze the 
N-acetylation of histamine.  Another enzyme recently characterized in D. melongaster was 
arylalkylamine N-acetyltransferase variant A (AANATA),
6
 which was shown to catalyze the 
formation of N-acetylarylalkylamides, similar to AANATL7.  The AANATL7 data are in 
significant contrast to D. melanogaster AANATA, where AANATA was shown to have more 
promiscuity for acyl-CoA substrates.
6
  At saturating concentration of tyramine, the AANATA 
(kcat/Km)app value for butyryl-CoA and hexanoyl-CoA did not observed as dramatic of a decrease 
as observed with these same substrates for AANATL7 at saturating concentrations of histamine.  
The first question that arose from these data was if these differences between AANATA and 
AANATL7 observed for the (kcat/Km)app - acetyl-CoA/(kcat/Km)app – butyryl-CoA or hexanoyl-CoA is (a) a 
function of the amine substrate used in the evaluation of the acyl-CoA steady-state kinetic 
constants or (b) is it related to general structural differences in the enzyme active site yielding 
AANATL7 less accommodating for longer chain (> C6) acyl-CoA substrates.  To assess if the 
significant decrease in the (kcat/Km)app - acetyl-CoA/(kcat/Km)app – acyl-CoA observed for AANATL7 is 
derived from the amine substrate, we reevaluated the kinetic constants for acetyl-CoA and 
butyryl-CoA at saturating concentrations of tyramine.  A similar trend was observed for the 
acyl-CoA kinetic constants when tyramine (Table 4.2) and histamine were used as the 
corresponding saturating amine substrate, where the (kcat/Km)app for acetyl-CoA and butyryl-CoA 
is (1.1 ± 0.1) × 10
6
 and (2.9 ± 0.2) × 10
5
, respectively (kcat,app – acetyl-CoA = 21 ± 1 s
-1
, Km,app – 
acetyl-CoA = 20 ± 1; kcat,app – butyryl-CoA = 1.87 ± 0.04 s
-1
, Km,app – butyryl-CoA = 7 ± 1).  A structural 
rational for these data when compared to D. melanogaster AANATA is difficult without a 
crystal structure; however, AANATA was found to have a deep funnel leading to its active site.
6
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This suggests that as the acyl chain length is increased for the acyl-CoA substrate, it can perturb 
the amine substrate binding by occupying its respective binding site.  This could result in a 
decrease rate of catalysis, which we observed for both AANATA and AANATL7.  Our data 
suggest that the AANATL7 binding pocket does not have the available space to accommodate a 
larger than C-6 acyl-CoA substrate (hexanoyl-CoA), independent of the amine substrate.   
 
Table 4.2. AANATL7 steady-state kinetic constants for different acyl-CoAs
a,b
 
Substrate 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
Relative 
(kcat/Km)app
c 
Acetyl-CoA 29 ± 2  32 ± 1  (1.1 ± 0.1) × 10
6
 1200 ± 400 
Butyryl-CoA 6 ± 1  0.66 ± 0.02  (1.1 ± 0.2) × 10
5
 130 ± 50 
Hexanoyl-CoA 64 ± 21 0.06 ± 0.01 (9 ± 3) × 10
2
 1.0 ± 0.5 
a 
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 7.5 mM histamine, and varying 
concentration of acyl-CoA. 
b 
Kinetic constants are reported as ± standard error (n=3). 
c 
The relative (kcatt/Km)app – acyl-CoA is indexed with hexanoyl-CoA. 
 
 
4.3.3 Steady-state kinetic characterization of AANATL7 amine substrates 
 Different amine substrates were characterized to determine the substrate specificity for 
AANATL7.  A panel of various arylalkylamines, polyamines, histamine, and ethanolamine were 
evaluated for their respective steady-state kinetic constants (Table 4.3) at saturating 
concentrations of acetyl-CoA.  Herein, we define structure-activity relationships for amine 
substrates that posses different “structural features” and evaluated their respective effect on 
binding and/or catalysis.  These structural features are divided into five general classes consisting 
of (a) indole ring and phenyl ring modifications, (b) length of the spacer group dividing the 
phenyl ring and the nucleophilic primary amine, (c) modification of the α-position of the 
ethylamine spacer group, (d) modification of the β-position of the ethylamine spacer group, and 
finally (e) evaluation of other non-arylalkylamine substrates.    
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 The first arylalkylamines to be evaluated were a set of substrates with different functional 
groups (-H, -OH, -OMe, and –OCH2C6H5) substituted at the 5-position of the indole ring, which 
yielded (kcat/Km)app values that decreased in the following order: 5-benzyloxytryptamine 
(-OCH2C6H5) > tryptamine (-H) > 5-methoxytryptamine (-OMe) > serotonin (-OH).  The 
(kcat/Km)app order predominantly resulted from the measured Km,app value, suggesting that amine 
substrate binding is important for its specificity.  Serotonin is hydroxylated at the 5-position of 
the indole ring, which produced the highest Km,app value (160 ± 20 µM).  5-Benzyloxytryptamine 
is generated by the modification of tryptamine with a benzyloxy group at the 5-position of the 
indole ring, which yielded the lowest Km,app value (9 ± 1 µM).  These data suggest that amine 
substrate binding affinity is driven by the hydrophobicity of the modified group at the 5-position 
of the indole ring, where the more hydrophobic the substitution, the lower Km,app value.  There 
was not a significant difference in the observed kcat,app values for each substrate evaluated that 
possessed an indole ring, except for 5-benzyloxytryptamine, which yielded a 2.3 – 3.0-fold lower 
turnover number compared to tryptamine, serotonin, and 5-methoxytryptamine.  These data 
coincides with the observation that 5-benzyloxytryptamine had the lowest observed Km,app value, 
which suggest that the large hydrophobic modification at the 5’ position of the indole ring could 
have an effect on a rate-limiting step, possibly product release by decreasing the koff rate for the 
enzyme-catalyzed products.  These data also suggest that AANATL7 can catalyze the direct 
formation of melatonin from acetyl-CoA and 5-methoxytryptamine.  Melatonin is biosynthesized 
from the cognate amino acid, L-tryptophan, in four sequential reactions:  initial hydroxylyation 
of L-tryptophan to generate 5-hydroxytryptophan, then decarboxylation to serotonin, followed by 
acetylation to N-acetylserotonin, and finally methylation to generate melatonin.
31-32
  Our data 
shows that 5-methoxytryptamine has a 2.8-fold increase in the (kcat/Km)app value when compared 
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to serotonin, which is consistent with what was found in D. melanogaster AANATA,
6
 yeast 
AANAT,
33
 human AANAT,
33
 ovine AANAT,
33
 and other vertebrate and nonvertebrate AANAT 
enzymes.
34
  These data suggest that AANATL7 could catalyze the direct formation of melatonin 
in D. melanogaster; however, further work is necessary to evaluate if this is physiologically 
relevant.   
 
Table 4.3. AANATL7 steady-state kinetic constants for different amine substrates
a,b 
Substrate Structure 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
5-Benzyloxytryptamine 
 
9 ± 1  5.7 ± 0.1  (6.3 ± 0.4) × 10
5
 
Tryptamine 
 
26 ± 2  15.8 ± 0.3  (6.0 ± 0.4) × 10
5
 
Tyramine 
 
42 ± 2  22.8 ± 0.4  (5.5 ± 0.3) × 10
5
 
3-Methoxyphenethylamine 
 
61 ± 4 26 ± 1  (4.3 ± 0.3) × 10
5
 
5-Methoxytyrptamine 
 
42 ± 2  13.1 ± 0.2  (3.1 ± 0.2) × 10
5
 
3-
(Trifluoromethyl)phenethylamine  
180 ± 10  40 ± 1  (2.2 ± 0.1) × 10
5
 
Phenethylamine 
 
320 ± 40  42 ± 2  (1.3 ± 0.2) × 10
5
 
Octopamine 
 
120 ± 10 15.6 ± 0.3  (1.3 ± 0.1) × 10
5
 
Dopamine 
 
170 ± 20  21 ± 1  (1.2 ± 0.1) × 10
5
 
β-Methylphenethylamine 
 
260 ± 30  29 ± 1  (1.1 ± 0.1) × 10
5
 
Serotonin 
 
160 ± 20  17 ± 1  (1.1 ± 0.1) × 10
5
 
4-Methoxyphenethylamine 
 
190 ± 20  15.2 ± 0.4  (8.0 ± 0.7) × 10
4
 
 
 
85 
 
Table 4.3. (Continued) 
 
3,4-
Methylenedioxyphenethylamine  
320 ± 30  23 ± 1  (7.4 ± 0.7) × 10
4
 
Histamine 
 
520 ± 50  30 ± 1  (5.8 ± 0.6) × 10
4
 
Norepinephrine 
 
230 ± 50  13 ± 1  (6 ± 1) × 10
4
 
4-Phenylbutylamine 
 
610 ± 30  8.5 ± 0.2  (1.4 ± 0.1) × 10
4
 
Putrescine 
 
81 ± 11 0.25 ± 0.01 (3.0 ± 0.4) × 10
3
 
Benzylamine 
 
890 ± 80 0.87 ± 0.02 980 ± 100 
Agmatine 
 
790 ± 100 0.68 ± 0.03 850 ± 110 
Ethanolamine  
(1.00 ± 
0.01) × 10
5 2.3 ± 0.1  23 ± 1.0 
a 
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying 
concentration of the amine substrate. 
b 
Kinetic constants are reported as ± standard error (n=3). 
 
Next, we evaluated different arylalkylamine substrates that possess a phenyl ring that are 
analogs of phenylalanine or tyrosine.  These data showed that tyramine has the highest 
(kcat/Km)app value and norephinephrine the lowest (kcat/Km)app value for all the substrates 
possessing a two methylene spacer group.  Each arylalkylamine substrate in this category ranged 
from a 1.3 – 9.2-fold difference (3-methoxyphenethylamine → norepinephrine) in the (kcat/Km)app 
value when compared to tyramine.  The comparison of the phenyl ring analogs yielded substrates 
with minimal differences in specificity; however, within these data the largest differences 
resulted from the modification of the phenyl ring when compared to substrates that are 
unmodified (phenethylamine and β-methylphenethylamine).  Within this respective data set, the 
(kcat/Km)app values differ predominantly from the Km,app with small differences resulting from the 
kcat,app.  For the phenyl ring analogs, the Km,app values ranged from 42 ± 2 µM → 320 ± 40 µM 
(tyramine → phenethylamine) yielding a 7.6-fold difference while the kcat,app values ranged from 
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42 ± 2 → 13 ± 1 (phenethylamine → norepinephrine) constituting a 3.2-fold difference.  A 
general trend observed in the data is that an increased kcat,app value, albeit a small difference, was 
observed for substrates without a modified phenyl ring.  One exception to this general trend is 
(trifluoromethyl)phenethylamine, which is modified at the 3-position on the ring with a small 
trifluoromethyl- group produced a similar kcat,app value (40 ± 1 s
-1
) as phenethylamine (42 ± 2 s
-1
).  
An opposite trend was generally observed for the Km,app values where an increase was observed 
for substrates without a modified phenyl ring, except for 3,4-methylenedioxyphenethylamine.  
This trend presumably results from a partial rate limiting step of product release, where the 
products of weakly bound substrates (unmodified phenyl ring) can dissociate faster yielding a 
higher turnover rate.  
 Another structural feature that has an effect on enzyme activity is the length of spacer 
group between the amino group and the phenyl ring.  Increasing the spacer length from two 
methylene groups to four methylene groups (4-phenylbutylamine) has a 9-fold decrease in the 
(kcat/Km)app value when compared to phenethylamine.  The decrease in the (kcat/Km)app resulted 
from an 2-fold increase in the Km,app and a 5-fold decrease in the kcat,app values.  Decreasing the 
spacer length by one methylene group is benzylamine, which observed a 133-fold decrease in the 
(kcat/Km)app value when compared to phenethylamine.   The decrease in the (kcat/Km)app resulted 
from an 3-fold increase in the Km,app and a 48-fold decrease in the kcat,app values.  These 
differences observed for benzylamine and 4-phenylbutylamine can be explained by the optimal 
length necessary for the primary amine to bind and function in catalysis.  These data suggest that 
the positioning of the primary amine in an optimal region for nucleophilic attack is critical; 
therefore, changes to the length will impact substrate binding and enzyme catalysis.  Our data 
indicates the optimal length of the spacer would be two methylene groups (phenethylamine).  
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 We next evaluated other non-arylalkyamine substrates consisting of histamine, 
ethanolamine, putrescine, agmatine, histidine, N
ω
-acetylhistamine, and isoniazid.  The decreasing 
order for the observed (kcat/Km)app values for these non-arylalkylamine substrates is histamine > 
putrescine > agmatine >> ethanolamine.  AANATL7 utilizing non-arylalkylamines substrates 
highlights a greater promiscuity for amine substrates than that observed for D. melanogaster 
AANATA.  From the non-arylalkylamine substrates evaluated in this study, histamine was the 
“best” substrate, with a (kcat/Km)app that is 9% of the “best” arylalkylamine substrate, 
5-benzyloxytryptamine.  The difference in second order rate constant between histamine and 
5-benzyloxytryptamine results from the 58-fold difference in the Km,app value.  The kcat,app value 
for histamine is 5.3-fold greater than 5-benzyloxytryptamine, in addition to possessing the third 
highest kcat,app value for all the amine substrates evaluated in this study.  Only phenethylamine 
and 3-(trifluoromethyl)phenethylamine observed a greater kcat,app than histamine.  The in vivo 
role of AANATL7 in catalyzing the formation of N-acetylhistamine is unknown; however, there 
is a preponderance of evidence suggesting in could function in this chemistry.  First, the total 
amount of histamine found in D. melanogaster head
10-11
 is 1.98 ± 0.15 ng, contributing to a total 
concentration of 540 µM and 574 µM in the heads and eyes, respectively.
11
  This is consistent 
with the detection of N-acetylhistamine
12
 and our identification of the AANATL7 transcript 
colocalized in the fly head.  Additionally, the Km,app value determined for histamine (520 ± 50 
µM) correlates well with the published concentrations of histamine in the fly head and eyes.
 11
  
All these data combined indicates a likely in vivo role for AANATL7 in the N-acetylation of 
histamine.  There are some reports in the literature of N-acetyltransferase enzymes that catalyze 
the formation of N-acetylhistamine,
35-37
 whereas two reports, (a) of a polyamine N-
acetyltransferase identified in the parasitic flatworm Fasciola hepatica
35
  and (b) two 
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arylalkylamine N-acetyltransferase (aaNAT2 and aaNAT5b) in Aedes aegypti
37
 have a similar 
apparent Km (760 µM, 740 µM, and 660 µM, respectively) as AANATL7.  This suggests that 
N-acetylation of histamine, albeit understudied, could occur in a broad range of different species.  
Putrescine, agmatine, and ethanolamine were shown to be poor substrates for AANATL7, where 
the (kcat/Km)app value is 0.48%, 0.13%, and 0.0037% of the (kcat/Km)app value for 
5-benzyloxytryptamine, respectively.  This is the second report to our knowledge of an enzyme 
that will catalyze the formation of N-acetylagmatine,
38
 albeit with low specificity when 
compared to the other arylalkylamine substrates.  We then evaluated N
ω
-acetylhistamine to help 
delineated if the acetylation occurs with the primary amine or the imidazole amine.  Activity was 
not observed at 1 mM N
ω
-acetylhistamine, which suggests, along with all the other data 
generated in this study that the acetylation occurs at the primary amine on the spacer group.  
Then we showed that isoniazid, which is a first line drug in the treatment of tuberculosis,
39-41
 will 
not serve as a substrate for AANATL7. 
Finally, we evaluated the cognate amino acids as substrates for AANATL7.  A rate of 
coenzyme A release was not observed at 1 mM of each amino acid, which suggests that this 
enzyme will not catalyze the formation of N-acetyl amino acids. The amino acids evaluated in 
this study were tyrosine, tryptophan, phenylalanine, and histidine, which differ from tyramine, 
tryptamine, phenethylamine, and histamine by modification of the spacer group α-position with a 
carboxylate.  Our data suggest that inserting a carboxylate at the α-position of the spacer group 
will prevent the corresponding amino acid from serving as a substrate because of either an 
electrostatic effect or a steric effect that perturbs substrate binding to the AANATL7 active site.  
To evaluate these possibilities, we used tyrosine methyl ester, which would remove the possible 
electrostatic effect induced by the negatively charged carboxylate.  We determined that tyrosine 
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methyl ester was not a substrate at a concentration of 1 mM, which suggests that modification of 
the α-position induces a steric effect that interferes with binding to the active site of AANATL7.  
Further evidence to support this theory was generated by assaying each amino acid and tyrosine 
methyl ester as inhibitors to the AANATL7-catalyzed formation of N-acetylhistamine.  Each 
amino acid (tyrosine, tryptophan, phenylalanine, and histidine) and tyrosine methyl ester was 
evaluated at a concentration of 1 mM, while holding acetyl-CoA and histamine at a constant 
concentration equal to their respective Km,app value.  We did not observed any inhibition at 1 mM 
of each inhibitor evaluated, suggesting that tyrosine, tryptophan, phenylalanine, histidine, and 
tyrosine methyl ester will either not bind to AANATL7 or bind with low affinity (Kd > 10 mM).  
These data suggest that the modification with a α-carboxylate or α-carboxylate ester will 
decrease the binding affinity to AANATL7 because of steric effect that perturbs binding in the 
active site.  Interesting, these data are in direct contrast to what was observed for modification of 
the β-position of the spacer group (β-methylphenethylamine, octopamine, and norepinephrine), 
where we did not observed a significant difference in the kinetic constants when compared to 
unmodified amine substrates (phenethylamine, tyramine, and dopamine; respectively). 
A summary of the structure-activity relationships of amine substrates from Table 4.3 are 
as follows: (a) arylalkylamine substrates exhibited differences in binding dependent on the 
hydrophopicity of the group at the 5-position of the indole ring, whereas the kcat,app value is 
relatively unchanged except for 5-benzyloxtryptamine; (b) the length of the spacer group effects 
both binding and catalysis, with the optimal length being two methylene groups; (c) the Km,app 
value for phenyl ring substituted analogs were generally lower than phenethylamine; (d) 
substitution at the α-position of the spacer group induces steric interference for binding to the 
active site of AANATL7, while substitution at the β-position had minimal impact on the kinetic 
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constants; (e) and AANATL7 catalyzes the formation of some non-arylalkylamine substrates 
consisting of histamine, putrescine, agmatine, and ethanolamine showing greater promiscuity for 
amine substrates when compared to D. melanogaster AANATA. 
 
4.3.4 Kinetic mechanism 
 Initial velocities for AANATL7 were measured for acetyl-CoA and histamine, while 
holding the other substrate at a fixed concentration.  The resulting double reciprocal plots (Figure 
4.2) show a pattern of intersecting lines for both acetyl-CoA and histamine.  The intersecting 
lines indicate that AANATL7 catalyzes the formation of N-acetylhistamine by a sequential 
mechanism, in which both substrates must be bound to generate the ternary complex before 
catalysis can occur.  The next question is whether the kinetic mechanism is an ordered or random 
sequential mechanism.   
Dead-end inhibition studies were used to distinguish between these respective sequential 
mechanisms, using oleoyl-CoA and tyrosol as the inhibitors in this study.  Oleoyl-CoA is an 
analog of acetyl-CoA that did not show a rate of reaction above the baseline rate of hydrolysis.  
Tyrosol was used as a structural analog of the amine substrate, in which the primary amine is 
replaced with a hydroxyl group.  Tyrosol did not show a rate of coenzyme A release above the 
background rate of hydrolysis at a concentration of 25 mM, which also suggests that AANATL7 
will not catalyze the O-acetylation of at least this substrate.  These two inhibitors were 
previously used as dead-end inhibitors for the determination of the kinetic mechanism for D. 
melanogaster AANATA
6
 while oleoyl-CoA was also shown to be an inhibitor of mammalian 
serotonin N-acetyltransferase.
42-43
   Oleoyl-CoA was found to be a competitive inhibitor versus 
acetyl-CoA and a pure noncompetitive inhibitor versus histamine with inhibition constants of 
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200 ± 10 nM and 410 ± 10 nM, respectively (Figure 4.3).  Tyrosol was found to be an 
uncompetitive inhibitor versus acetyl-CoA and a competitive inhibitor versus histamine, with 
inhibition constants of 620 ± 20 µM and 430 ± 20 µM, respectively.  These inhibition patterns 
demonstrate that AANATL7 will catalyze the formation of N-acetylhistamine as an ordered 
sequential mechanism, with acetyl-CoA binding first followed by histamine to generate a ternary 
complex of AANATL7•acetyl-CoA•histamine before catalysis occurs.  This type of kinetic 
mechanism is consistent with what was found for both D. melanogaster AANATA
6
 and sheep 
serotonin N-acetyltransferase.
44
           
Figure 4.2. Double reciprocal plots of initial velocities for acetyl-CoA and histamine.  (A) 
Velocities measured at a fixed concentration of histamine: 2.5 mM (●), 750 µM (o), 500 µM 
(▼), 250 µM (Δ).  (B) Velocities measured at a fixed concentration of acetyl-CoA: 100 µM (●), 
50 µM (o), 25 µM (▼), 10 µM (Δ). 
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Figure 4.3. Dead-end inhibtion analysis of AANATL7. (A) Velocities measured at a fixed 
concentration of histamine (520 µM), varying the concentration of acetyl-CoA, and varying the 
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 600 nM (▼); Ki = 200 ± 10 
nM.  (B) Velocities measured at a fixed concentration of acetyl-CoA (29 µM), varying the 
concentration of histamine, and varying the concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 
200 nM (o), 600 nM (▼);Ki = 410 ± 10 nM. (C) Velocities measured at a fixed concentration of 
histamine (520 µM), varying the concentration of acetyl-CoA, and varying the concentration of 
the inhibitor, tyrosol: 0 µM (●), 650 µM (o), 1.3 mM (▼); Ki = 620 ± 20 µM.  (D) Velocities 
measured at a fixed concentration of acetyl-CoA (29 µM), varying the concentration of 
histamine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 650 µM (o), 1.3 mM 
(▼); Ki = 430 ± 20 µM.   
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4.3.5 Evaluation of the pH dependence on the kinetic constants and the use of site-directed 
mutagenesis to define catalytic amino acids  
 We used a combination of pH activity studies and site-directed mutagenesis to aid in the 
identification of the AANATL7 catalytic residues and subsequently use these data to propose a 
chemical mechanism for AANATL7.  In the absence of a crystal structure, we indexed all the 
data generated herein, to D. melanogaster AANATA,
6, 45
 sheep serotonin N-acetyltransferase,
46-
51
 and other GNAT enzymes to define a function for the amino acid residues evaluated in this 
study.  The first method to help delineate the residues involved in catalysis was to generate a pH 
rate profile to ascertain the apparent pKa of the catalytic amino acid residues.  A rising 
(kcat/Km)app pH rate profile was observed for both acetyl-CoA (Figure 4.4C) and histamine 
(Figure 4.4D), with pKa,app values of 6.8 ± 0.1 and 7.6 ± 0.1, respectively.  The (kcat/Km)app pH 
rate profile represents the ionizable groups important for binding and catalysis for the free 
enzyme and substrate, up until the first irreversible step (E + S  ⇋ ES) in catalysis; therefore, it is 
likely that these two apparent pKa values both represent the general base in catalysis.  The kcat,app 
pH profile for both acetyl-CoA and histamine observed a bell-shaped profile (Figures 4.4A and 
4.4B) with two pKa,app values (pKa,app – acetyl-CoA = 7.1 ± 0.1 and 9.5 ± 0.1; pKa,app – histamine = 7.2 ± 
0.1 and 9.6 ± 0.1).  The apparent pKa value of 7.2 (7.1) is attributed to the general base identified 
in both (kcat/Km)app profiles, while the apparent pKa value of 9.5 (9.6) can represent either a 
general acid in catalysis or the thiol group of coenzyme A.  A pKa,app value of 9.5 (9.6) was not 
observed in either (kcat/Km)app pH rate profiles, suggesting this ionizable group contributes to 
catalysis after the first irreversible step (ES → E + P).  A lack of a pKa,app value ≥ 9.5 in the 
(kcat/Km)app profiles can also result from inability to evaluate AANATL7 at higher pH values, 
because the instability of Ellman’s reagent and hydrolysis of the acetyl-CoA substrate.  We must 
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note that the pKa,app value identified in the kcat,app profiles is 9.5 (9.6), which is ≥ to the highest 
pH evaluated in this study, and this apparent value is a product of the best fit from our data to 
equation 4.8.  Therefore, the lack of pKa,app value ≥ 9.5 in the (kcat/Km)app profiles may just be a 
result from our inability to evaluated AANATL7 at pH(s) > 9.5.  The observed difference from 
the (kcat/Km)app and kcat,app pH rate profiles for the general base likely results from the kinetic 
stickiness of the substrates evaluated in this study.       
 
Figure 4.4. AANATL7 pH rate profiles. (A) kcat for acetyl-CoA.  pKa1 - slope = 1, pKa2 - slope = -0.6.  
(B) kcat for histamine. pKa1 - slope = 0.9, pKa2 - slope = -0.5.  (C) kcat/Km for acetyl-CoA.  pKa1 - slope = 
0.8.  (D) kcat/Km for histamine.  pKa1 - slope = 0.9. 
 
   The pH-activity profiles do not provide definitive information on the specific residues 
involved in catalysis.  Therefore, we further evaluated amino acid residues that can function as 
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either a general base or acid by site-directed mutagenesis.  With the lack of a crystal structure, 
we utilized a primary sequence alignment of AANATL7 with D. melanogaster AANATA
6
 to 
identify possible amino acid residues that can function in substrate binding and/or catalysis.  
AANATA has been previously characterized with the function of specific residues clearly 
defined, including a general base in catalysis and other residues critical in substrate binding 
and/or regulation of catalysis.
6
  From the primary sequence alignment, the proposed general base 
of AANATA (Glu-47)
6
 is conserved, corresponding to Glu-26 in AANATL7.  Two serines in D. 
melanogaster (Ser-182 and Ser-186)
45
 have been proposed to function in catalysis, which 
corresponds to Thr-167 and Ser-171 in AANATL7.
6
  Other amino acid residues with defined 
functions from AANATA (Pro-48, Arg-153, and His-220) that are also conserved in 
AANATL7,
6
 consists of Pro-27, Arg-138, and His-206.  We mutated each one of these residues 
to an alanine to define their respective function in AANATL7.  The resulting data was indexed to 
the data from corresponding residue in AANATA
6, 45
 to finally propose its respective function in 
AANATL7.   
Glu-26 is the AANATL7 residue that could function as a general base in catalysis.  The 
mutation to an alanine resulted in 22- to 32-fold decrease in the kcat,app relative to the wild-type 
(Table 4.4).  The (kcat/Km)app – acetyl-CoA (kcat/Km)app – histamine was only 7.0% and 0.15% of the 
wild-type, respectively.  In addition, the E26A mutant has a similar Km,app – acetyl-CoA when 
compared to the wild-type; however, the Km,app – histamine was increased 31-fold.  E26A was the 
most catalytically deficient residue evaluated in our study (Table 4.4) and most likely represents 
the pKa,app value of ~ 7.2 observed in the pH rate profiles (Figure 4.4).  
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Table 4.4. Steady-state kinetic constants for AANATL7 site-directed mutants
a 
Mutant
 b
 
Acetyl-CoA 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
 
          
 
    
  
 
             
     
% 
Wild-type 29 ± 2   32 ± 1 (1.1 ± 0.1) × 10
6
 100 
E26A 13 ± 1  1.01 ± 0.02 (7.7 ± 0.5) × 10
4
 7.0 
R138A 550 ± 60 88 ± 3 (1.6 ± 0.2) × 10
5
 15 
T167A 140 ± 4 1.84 ± 0.02 (1.36 ± 0.05) × 10
4
 1.2 
S171A 19 ± 1 8.6 ± 0.1 (4.6 ± 0.1) × 10
5
 42 
T167A/S171A 29 ± 2 1.61 ± 0.03 (5.6 ± 0.3) × 10
4 
5.1 
H206A 210 ± 5 9.6 ± 0.1 (4.6 ± 0.1) × 10
4
 4.2 
Mutant
 c
 
Histamine 
Km, app 
(mM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
 
          
 
    
  
 
             
     
% 
Wild-type 
0.52 ± 
0.05  
30 ± 1 (5.8 ± 0.6) × 10
4
 100 
E26A 16 ± 1  1.39 ± 0.04 86 ± 32 0.15 
R138A 4.9 ± 0.4  71 ± 2 (1.5 ± 0.1) × 10
4
 26 
T167A 6.7 ± 0.7 1.9 ± 0.1 280 ± 30 0.48 
S171A 3.4 ± 0.2  10.4 ± 0.2 (3.0 ± 0.2) × 10
3
 5.2 
T167A/S171A 13 ± 1 2.2 ± 0.1 160 ± 20 0.28 
H206A 2.3 ± 0.1 7.7 ± 0.1 (3.3 ± 0.2) × 10
3
 5.7 
a 
Kinetic constants are reported as ± standard error (n=3). 
b
 The kinetic constants were measured at a fixed saturating concentration of histamine while varying the 
concentration of acetyl-CoA. 
c
 The kinetic constants were measured at a fixed saturating concentration of acetyl-CoA while varying the 
concentration of histamine. 
 
To further evaluate if Glu-26 functions as the general base in catalysis, we generated a 
pH rate profile for the E26A mutant.  The kcat,app – acetyl-CoA and (kcat/Km)app – acetyl-CoA pH rate 
profiles for the E26A mutant resulted in a linear increase as the pH was increased from 7.5 – 9.5, 
with a slope of 0.6 and 0.2, respectively (Figure 4.5).  We were not able to resolve a velocity for 
E26A above the background hydrolysis rate at pH = 7.0, suggesting the mutant enzyme is close 
to being catalytically dead at pH conditions < 7.5.  The linear pH rate profile likely results from 
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hydroxide chemically rescuing the function of Glu-26 in deprotonation of the positively charged 
primary amino group of histamine.  These data for the E26A mutant are consistent with what has 
been published for D. melanogaster AANATA.
6
  Furthermore, the proposal of a Glu residue to 
function as a general base has been reported for other GNAT enzymes, including human 
spermidine/spermine N
1
-acetyltransferase
52-53
 and the Gcn5/PCAF family of histone 
N-acetyltransferases.
54-55
   
Figure 4.5. AANATL7 E26A pH rate profiles. (A) kcat. (B) kcat/Km for acetyl-CoA.  
 
Next, we evaluated the role Thr-167 and Ser-171 has in binding and/or catalysis.  The 
corresponding residues in AANATA (Ser-182 and Ser-186, respectively) were previously 
proposed to function in catalysis.
45
  Therefore, we mutated Thr-167 and Ser-171 each to an 
alanine to define a specific function in AANATL7 catalysis.  The T167A mutant produced a 
kcat,app decrease of 16- to 17-fold relative to the wild-type enzyme.  The (kcat/Km)app – acetyl-CoA and 
(kcat/Km)app – histamine for T167A was only 1.2% and 0.49% of the wild-type enzyme, respectively.  
In addition, the T167A mutant yielded a Km,app – acetyl-CoA that increases 5-fold when compared to 
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wild-type and a Km,app – histamine that was increased 13-fold.  The S171A mutant produced a kcat,app 
decrease of 3- to 4-fold relative to the wild-type enzyme.  The (kcat/Km)app – acetyl-CoA and 
(kcat/Km)app – histamine for S171A was 42% and 5.2% of the wild-type enzyme, respectively.  In 
addition, the S171A mutant has a similar Km,app – acetyl-CoA when compared to wild-type; however, 
the Km,app – histamine was increased 7-fold.  These data suggest that Thr-167 and Ser-171 could 
function in catalysis and/or substrate binding; however, a direct role as a general acid is unlikely.  
Since threonine and serine are chemically similar (both possess a hydroxyl group), we evaluated 
a T167A/S171A double mutant to delineate if these residues function in a redundant role.  The 
T167A/S171A double mutant produced a kcat,app decrease of 14- to 20-fold relative to the 
wild-type enzyme, similar to what was observed for the T167A mutant.  The (kcat/Km)app – 
acetyl-CoA and (kcat/Km)app – histamine for T167A/S171A was 5.1% and 0.28% of the wild-type 
enzyme, respectively.  In addition, the T167A/S171A mutant has the same Km,app – acetyl-CoA as the 
wild-type; however, the Km,app – histamine was increased 25-fold.  These data, as well as data 
generated for the corresponding residues from D. melaongaster AANATA,
6, 45
 allows us to 
define a function for both of these residues.  The corresponding residue for Ser-171 from 
AANATA was proposed to function as the general acid in catalysis.
45
  Specifically, AANATA 
Ser-186 was proposed to protonate the thiolate of CoA-S
-
 in the breakdown of the tetrahedral 
intermediate.
45
  If the corresponding residue in AANATL7, Ser-171, has a similar function, then 
the pKa = 9.5 would represent this amino acid residue.  We do not favor a serine or threonine to 
function as a general acid in catalysis.  This would require a significant depression in the pKa 
(3-5 pH units), as well as it is thermodynamically unfavorable for a serine to protonate a thiolate.  
A redundant role in catalysis for these residues is unlikely since the T167A/S171A double 
mutant was not anymore catalytically impaired than the T167A mutant.  Instead, we propose that 
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Thr-167 and Ser-171 is functioning to change the active site architecture, most likely through a 
network of hydrogen bonds, similar to what was observed for the corresponding amino acids in 
AANATA.
6
   
This proposal still does not obviate the need to define the ionizable group responsible for 
the pKa,app of 9.5 (9.6) identified in the kcat,app pH rate profiles.  We propose that the thiol group 
from the CoA-SH product is responsible for this pKa,app, which has been reported to range from 
9.6-10.4,
56-57
 similar to the pKa,app value observed in our study.  Protonation of CoA-SH is a 
chemical step that occurs during the collapse of the tetrahedral intermediate and is likely 
necessary for catalysis.  The decrease in the kcat,app at pH ≥ 9.0, results from the deprotonation of 
CoA-SH to yield CoA-S
-
, inhibiting its release from the active site.  This proposal alleviates the 
need for an amino acid residue to function as a general acid in catalysis.        
 
4.3.6 Use of site-directed mutagenesis to define the function of AANATL7 amino acids in 
binding and/or regulation of catalysis 
 From the primary sequence alignment, AANATL7 Pro-27, Arg-138, and His-206 was 
found to be conserved with AANATA (Pro-48, Arg-153, and His-220);
6
 therefore, we mutated 
each of these residues to an alanine and evaluated the kinetic constants (Tables 4.4 and 4.5) in an 
effort to define their function. The P27A mutant produced a 38- to 42-fold decrease in the kcat,app 
value when histamine was used as the amine substrate. Additionally, the Km,app – acetyl-CoA and 
Km,app – histamine increased 3-fold for both substrates, yielding (kcat/Km)app – acetyl-CoA and (kcat/Km)app 
– histamine values that were only 0.67% and 0.76% relative to the wild-type enzyme.  The 
significant decrease in the kcat,app and an increase in the Km,app for the P27A mutant, suggest that 
Pro-27 functions to organize the active site and regulate catalysis.  The corresponding residues 
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from sheep serotonin N-acetyltransferase (Pro-64)
47, 58-59
 and D. melanogaster AANATA 
(Pro-48)
6
 were located on a flexible loop that undergoes a major conformational change resulting 
in the formation the amine binding pocket.  This conformational change converts the substrate 
binding pocket from a low affinity state to a high affinity state.
59
  For sheep serotonin 
N-acetyltransferase, there are two crystal structures solved, one showing the apo enzyme (PDB 
code: 1B6B)
58
 and the other was co-crystallized with the bisubstate inhibitor, 
tryptamine-acetyl-CoA (PDB code: 1CJW).
47
  These crystal structures identify that Pro-68 is 
located in the acetyl-CoA binding pocket in the low affinity state (apo form), whereas the 
conformational change yields a high affinity state where the proline residue migrates ~8 Å to 
form a direct base-stacking interaction with the tryptamine moiety of the bisubstrate inhibitor.
6, 
47, 59
  The promiscuity of AANTL7 for amine substrates allows us to test the possibility of direct 
binding interactions from Pro-27.  We further evaluated the AANATL7 P27A mutant with 
agmatine as the amine substrate at saturating concentrations of acetyl-CoA as shown in Table 
4.5.  If Pro-27 has a direct binding interaction with histamine, then we would expect a smaller 
Km,app-P27A/Km,app-wildtype ratio for agmatine, when the amine substrate is modified from an neutral 
imidazole group to a positively charged guanidinium group.  If Pro-27 is only important for the 
formation of the amine binding site and does not have a direct binding interaction with 
histamine, then we would expect the Km,app-P27A/Km,app-wildtype ratio for agmatine to be the same as 
histamine.  The Pro-27 mutant produced a kcat,app - agmatine that decreased 57-fold and Km,app – 
agmatine that increased only 1.6-fold relative to the wild-type enzyme.  The P27A data for 
histamine and agmatine yielded a (Km,app-P27A/Km,app-wild-type)histamine/(Km,app–P27A/Km,app–
wild-type)agmatine ratio of 2.2, suggesting that Pro-27 functions in both the general organization of the 
active site and in a direct interaction with the amine substrate, possibly by a base-stacking 
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interaction.  These data suggest that a disruption of a direct binding interaction between the 
amine substrate and Pro-27 occurs when the amine substrate is modified from an imidazole 
group to a positively charged guanidinium group.   
 
Table 4.5. Steady-state kinetic constants for Pro-27 site-directed mutant
a
  
Mutant
a
 
Varied 
Substrate 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
 
          
 
    
  
 
             
     
% 
Wildtype
b
 
Acetyl-CoA 
29 ± 2 32 ± 1 (1.1 ± 0.1) × 10
6
 100 
P27A
b
 105 ± 4 0.77 ± 0.02 (7.4 ± 0.3) × 10
3
 0.67 
Wildtype
c
 
Histamine 
520 ± 50 30 ± 1 (5.8 ± 0.6) × 10
4
 100 
P27A
c
 1800 ± 100 0.80 ± 0.02 440 ± 30 0.76 
Wildtype
c
 
Agmatine 
790 ± 100 0.68 ± 0.03 850 ± 110 100 
P27A
c
 1300 ± 100 
0.012 ± 
0.001 
9.7 ± 0.7 1.1 
a 
Kinetic constants are reported as ± standard error (n=3). 
b
 The kinetic constants were measured at a fixed saturating concentration of histamine. 
c
 The kinetic constants were measured at a fixed saturating concentration of acetyl-CoA. 
 
 Next, we mutated Arg-138 to an alanine to delineate its respective function. The R138A 
mutant resulted in increases for the kcat,app (2.4- to 2.8-fold) and both Km,app – acetyl-CoA (19-fold) 
and Km,app – acetyl-CoA values (9-fold).  The increases in the kcat,app value for R138A is counteracted 
by the increase in the Km,app values to yield a mutant enzyme with (kcat/Km)app – acetyl-CoA and 
values (kcat/Km)app – histamine that is only 15% and 26% of the wild-type, respectively (Table 3).  
These data suggest that Arg-138 functions to regulate catalysis and in substrate binding.  
Arg-138 likely does not have a direct role in catalysis as a general acid or base; however, the 
increase in the kcat,app data is more consistent with regulating a conformational change that 
induces domain mobility yielding product release partially rate-limiting.  The corresponding 
residue in D. melanogaster AANATA (Arg-153)
6
 produced a similar increase in the kcat,app value, 
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which is attributed to the elimination of a salt bridge that is critical for a conformation change 
that regulates the rate of CoA-SH release.  The AANATL7 R138A mutant likely eliminates a salt 
bridge, which increase the rate of CoA-SH release, similar to what was observed for AANATA.  
We would expect that if the R138A mutant is increasing the koff rate for the CoA-SH product, 
then its dissociation constant should increase since the Kd = the ration of koff – CoA-SH/kon – CoA-SH.  
We determined the Kd for CoA-SH binding for the wild-type enzyme and R138A mutant by 
measuring its quenching of intrinsic AANATL7 fluorescence as the [CoA-SH] is increased.  This 
resulted in a Kd – wild-type = 530 ± 110 µM and Kd – R138A = 1.1 ± 0.2 mM (Figure 4.6), showing a 
2.1-fold decrease in the binding affinity for the R153A mutant relative to the wild-type enzyme.  
The ratio of Kd –R153/Kd –wild-type (2.1-fold) is in reasonable agreement with the kcat –R153A/kcat – 
wild-type (2.4- to 2.8-fold) ratio (Table 4.4).  These data suggest that a salt bridge consisting of 
Arg-138 is important to regulate the protein dynamics of AANATL7, contributing to a partial 
rate-limiting release of CoA-SH.  These data are consistent with what is observed with D. 
melanogaster AANATA
6
 and other GNAT enzymes that have product release as a partial 
rate-limiting step.
26, 46, 60-61
 
Similar to Pro-27 and Arg-138, His-206 is conserved with D. melanogaster AANATA 
(His-220).
6
  The H206A mutant produced a 3- to 4-fold decrease in the kcat,app value (Table 4.4) 
and an increase in the Km,app for both acetyl-CoA (7-fold) and histamine (4-fold).  This suggests 
that His-206 functions to organize the binding pocket for both substrates, similar to what is 
proposed for the corresponding residue in AANATA (His-220).
6
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Figure 4.6. Determination of the coenzyme A dissociation constant by measuring the intrinsic 
fluorescence quenching of AANATL7 for the wild-type enzyme and R138A mutant.  (A) 
Wild-type. (B) R153A. 
 
4.3.7 Proposed chemical mechanism for AANATL7 
 A chemical mechanism consistent with our data is shown in Scheme 4.2.  The mechanism 
details (a) ordered substrate binding, with acetyl-CoA binding first followed by histamine to 
generate a AANATL7•acetyl-CoA•histamine ternary complex prior to catalysis, (b) followed by 
Glu-26 serving as the general base in catalysis by deprotonating of the positively charged 
primary amino group of histamine through ordered water molecules, similar to AANATA, (c) 
nucleophilic attack of histamine to the carbonyl of the acetyl-CoA thioester to generate the 
zwitterionic tetrahedral intermediate, (d) collapse of the zwitterionic tetrahedral intermediate 
followed by the protonation the coenzyme A thiolate, (e) and finally, ordered product release, 
with N-acetylhistamine leaving first, followed by CoA-SH.  Evidence supporting ordered 
product release results for the ability to measure the direct binding affinity for CoA-SH in the 
absence of the N-acetylated product, which is also consistent with a synergistic effect from 
ordered substrate binding.  This chemical mechanism is consistent with the data generated 
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herein, with the mechanism proposed for D. melanogaster AANATA,
6
 and for other GNAT 
enzymes.
62-63
   
Scheme 4.2. Proposed chemical mechanism for D. melanogaster AANATL7.  The dashed arrow 
represents the possible positions of the irreversible step based on data generated herein and for 
other D. melanogaster AANATL enzymes.
6, 45
  
 
4.3.8 Conclusions 
We showed that AANATL7 will catalyze the formation of N-acylamides from the 
corresponding acyl-CoA and amine substrates.  AANATL7 is relatively discriminative for the 
acyl-CoA substrates, showing that the (kcat/Km)app for acetyl-CoA is ≥ 10-fold higher than any 
other acyl-CoA substrate analyzed in this study.  The amine substrates have more promiscuous 
selectively, where arylalkylamines, histamine, putrescine, agmatine, and ethanolamine will all 
serve as AANATL7 substrates.  We proposed a chemical mechanism for the 
AANATL7-catalyzed formation of N-acetylhistamine as illustrated in Scheme 4.2.  First, 
substrate binding is ordered sequential with acetyl-CoA binding first, followed by histamine to 
generate the ternary complex (AANATL7•acetyl-CoA•histamine) prior to catalysis.  Next, we 
invoked Glu-26 as the general base in catalysis with a pKa,app of ~7.2, that will deprotonate the 
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positively charged primary amino group of histamine through ordered water molecules that make 
up an active site “proton wire”.  Finally, we suggest that protein dynamics has a significant 
regulatory effect on AANATL7 catalysis, where non-catalytic amino acid residues (Arg-138 and 
Pro-27) have a significant impact on the rate of catalysis. 
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Chapter Five  
Probing the Chemical Mechanism and Critical Regulatory Amino Acid Residues of Drosophila 
melanogaster Arylalkylamine N-acyltransferase Like 2 
 
5.1. Introduction 
 The N-acylation of biogenic amines are important for neurotransmitter inactivation, 
cuticle sclerotization, melatonin biosynthesis, and biosynthesis of potent cell signaling lipids.  
The biogenic amines identified in Drosophila melanogaster consist of serotonin, dopamine, 
octopamine, tyramine, and histamine.
1
  Biosynthesis of these amines and the subsequent 
N-acylamide products are all derived from their cognate amino acid precursors.  Tyramine, 
octopamine, and dopamine are all derived from tyrosine metabolism, whereas serotonin is 
generated from tryptophan.  Histamine and N-acetylhistamine is a product of histidine 
metabolism.  The biosynthesis of tyramine (Scheme 5.1) initially occurs from decarboxylation of 
tyrosine by tyrosine decarboxylase
2-3
 and then is either acylated by an arylalkylamine 
N-acetyltransferese (AANAT)
4-6
 to generate N-acyltyramine or is hydroxylated to form 
octopamine, which is catalyzed by tyramine β-hydroxylase.7-9  Subsequently, octopamine can be 
acetylated by AANAT to generate N-acetyloctopamine.
6, 10-12
  In addition, tyrosine can be 
hydroxylated by tyrosine hydroxylase
2, 13-15
 to generate L-dopa followed by decarboxylation by 
an aromatic amino acid decarboxylase (AADC) to generate dopamine.
16-18
  Dopamine can then 
be N-acylated by an AANAT to generate the N-acyldopamine product.
4
  Serotonin biosynthesis 
occurs initially by the hydroxylation of tryptophan by tryptophan hydroxylase
19
 to generate 
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5-hydroxyl-L-tryptophan followed by decarboxylation by AADC.
18-19
  In addition to tyramine, 
octopamine, dopamine; serotonin is also N-acylated by an AANAT
4, 6
 to generate the 
N-acylserotonin product.  Herein, we report the characterization of arylalylamine 
N-acyltransferase like 2 (AANATL2), which is responsible for the chemical formation of 
N-acetylarylalkylamides, long-chain N-acylserotonins, and long-chain N-acyldopamines. 
Scheme 5.1. Biosynthetic pathway for biologically relevant arylalkylamine biogenic amines and 
their N-acylated products in D. melanogaster. (A) Tyrosine biosynthesis. Rxn 1,tyrosine 
decarboxylase (TDC); 2, tyrosine hydroxylase (TYH); 3, aromatic amino acid decarboxylase 
(AADC); 4, tyramine β-hydroxylase (TβH); 5, arylalkylamine N-acetyltransferase (AANAT). 
(B) Tryptophan biosynthesis. Rxn 6, tryptophan decarboxlyase (TPH); 7, aromatic amino acid 
decarboxylase (AADC); arylalkylamine N-acetyltransferase (AANAT). 
 
 AANATL2 is a member of the GCN5-related N-acetyltransferase (GNAT) family
20-21
 of 
enzymes and has been identified to catalyze the formation of N-acylarylalkylamides
11, 22
 from the 
corresponding acyl-CoA and arylalkylamine.  The N-acetylation of biogenic amines were first 
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identified in D. melanogaster by measuring N-acetyltransferase activity in fly crude extracts, by 
Dewhurst et al. in 1972.
4
  We previously showed that this enzyme is likely involved in the 
biosynthesis of long-chain N-acyldopamines and N-acylserotonins (Appendix B), while also 
showing that this enzyme will catalyze the formation of N-acetylserotonin, N-acetyldopamine, 
N-acetyltyramine, and N-acetyloctopamine.
11
  Endogenous levels of N-acetylated products of 
these biogenic amines have been identified in D. melanogaster,
23
 along with long-chain 
N-acylserotonins
11
 and N-acyldopamines.
24
  Therefore, it is likely that this enzyme or another 
AANATL enzyme could function the biosynthesis of these biologically revelvant 
N-acylarylalkyamides.   
Herein, we define the substrate specificity of different amine substrates for the 
AANATL2-catalyzed formation of N-acetylamides.  Subsequently, we solved the kinetic 
mechanism by using double reciprocal analysis and dead-end inhibition, followed by using 
pH-rate profiles and site-directed mutagenesis in order to generate data that led to a proposed 
chemical mechanism for AANATL2.  Finally, we discuss some structure-activity relationships 
for different amine substrates and define functions of AANATL2 amino acid residues involved 
in binding and regulation of catalysis. 
 
5.2. Material and methods 
5.2.1 Materials 
 PCR primers were purchased from Eurofins MWG Operon.  PfuUltra High-Fidelity DNA 
polymerase was purchased from Agilent.  pET-28a(+) vector, XL10 E.coli cells, and BL21 
(DE3) E.coli cells were purchased from Novagen.  NdeI, XhoI, Antarctic Phosphatase and T4 
DNA ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG 
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were purchased from Gold Biotechnology.  ProBond™ nickel-chelating resin was purchased 
from Invitrogen.  Acetyl-CoA and oleoyl-CoA were purchased from Sigma-Aldrich.  Wild-type 
AANATL2 was expressed and purified with the same procedures as published by Dempsey et al 
or also found in Appendix B.
11
  All other reagents were of the highest quality available from 
either Sigma-Aldrich or Fisher Scientific. 
 
5.2.2 Cloning, expression, and purification of AANATL2 site-directed mutants 
 All the AANATL2 mutants were generated by using the overlap extension method.
25
  
PCR primers (Table 5.1) were generated for each mutant by using the Agilent QuickChange 
Primer Design tool.  The following PCR conditions were used with PfuUltra High-Fidelity DNA 
polymerase: initial denaturing step of 95°C for 2 min, then 30 cycles of (95°C for 30 s; 60
o
C for 
30 s; 72°C for 1 min), then a final extension step of 72°C for 10 min.  The AANATL2 mutant 
PCR product was then inserted into a pET-28a(+) vector using NdeI and XhoI restriction sites.  
The AANATL2-mutant-pET-28a product was then transformed into E. coli XL10 competent 
cells, plated on Luria Broth (LB) agar plates supplemented with 40 µg/mL kanamycin, and 
incubated overnight at 37°C.  The following day, a single colony from the LB agar plate 
containing E. coli XL10 cells with the AANATL2-mutant-pET-28a vector was used to inoculate 
an overnight culture in LB media, supplemented with 40 µg/mL kanamycin at 37°C.  The next 
day, the AANATL2-mutant-pET-28a plasmid was purified using Promega Wizard® Plus SV 
Minipreps DNA purification kit and sequenced by Eurofins MWG operon.  Following 
confirmation of the AANATL2 mutant sequence, the AANATL2-mutant-pET-28a plasmid was 
then transformed into BL21 (DE3) E.coli cells.  Each AANATL2 mutant protein was expressed 
and purified using the same procedures that were defined for the wild-type enzyme (Appendix 
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B).
11
  After the purification of each enzyme, the AANATL2 mutants and wild-type enzyme were 
dialyzed out of the elution buffer and into 20 mM Tris pH 7.4, 200 mM NaCl for 16 hr at 4°C.       
 
Table 5.1. Site-directed mutagenesis primers 
Mutant Primer Primer Sequence 
E29A 
Forward CCA TTT CTT TAA GCA GGC ACC GCT GAT GCT GAT TC 
Reverse GAA TCA GCA TCA GCG GTG CCT GCT TAA AGA AAT GG 
P30A 
Forward TCA GCA TCA GCG CTT CCT GCT TAA AGA AAT GGA CTG 
Reverse CAG TCC ATT TCT TTA AGC AGG AAG CGC TGA TGC TGA 
R138A 
Forward CGT CGA TGT GTC CAT TGC TCG CCA ACG T 
Reverse ACG TTG GCG AGC AAT GGA CAC ATC GAC G 
S167A 
Forward CGT TTA CTA TTT TGG TTC GCG CAC GTT GAG GTC ACG AC 
Reverse GTC GTG ACC TCA ACG TGC GCG AAC CAA AAT AGT AAA CG 
S171A 
Forward GTC ATC AGG CGT TTA GCA TTT TGG TTC GAG CAC GTT GAG G 
Reverse CCT CAA CGT GCT CGA ACC AAA ATG CTA AAC GCC TGA TGA C 
H206A 
Forward GTG CCT CAG AAC CGG CCA CGA GTG CAT CCG 
Reverse CGG ATG CAC TCG TGG CCG GTT CTG AGG C 
 
   
5.2.3 Enzyme assay  
 Ellman’s reagent (DTNB) was used to determine the kinetic constants for different amino 
donor substrates and acetyl-CoA with AANATL2 by measuring the rate of coenzyme A release 
at 412 nm (molar extinction coefficient = 13,600 M
-1
 cm
-1
).  The assay consisted of: 300 mM 
Tris pH 8.0, 150 µM DTNB, varying concentration of one substrate, and holding the other 
substrate at a fixed saturating concentration at 22°C and measuring the initial velocities with a 
Cary 300 Bio UV-Visible spectrophotometer.  The resulting data was fit to equation 5.1, in 
which vo is the initial velocity, Vmax is the maximal velocity, [S] is the substrate concentration, 
and Km is the Michaelis constant.  Each assay was performed in triplicate and the uncertainty for 
the kcat,app and (kcat/Km)app values were calculated by using equation 5.2,
26
 which σ is the standard 
error.      
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Equation 5.1 
   
        
      
 
 
Equation 5.2 
  
 
 
  
 
 
  
  
 
 
 
  
  
 
 
 
 
 
5.2.4 Kinetic mechanism 
Initial velocity patterns for acetyl-CoA and tyramine were used to delinate between a 
sequential or ping-pong kinetic mechanism.  The initial velocities were measured for acetyl-CoA 
by holding the tyramine concentration constant (1 µM, 2 µM, 10 µM, and 25 µM) and varying 
the concentration of acetyl-CoA.  The initial velocities for tyramine were measured by holding 
the acetyl-CoA concentration constant (1 µM, 2 µM, 10 µM, and 25 µM) and varying the 
concentration of tyramine.  The resulting data were fit to equation 5.3 for a Bi Bi sequential 
kinetic mechanism and plotted as a double reciprocal plot using IGOR Pro 6.34A.  In equation 
5.3, Kia is the dissociation constant for substrate A (acetyl-CoA), Ka is the Km (Michaelis 
constant) for substrate A (acetyl-CoA), and Kb is the Km (Michaelis constant) for substrate B 
(tyramine).      
 
 Equation 5.3 
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Following the double reciprocal analysis, dead-end inhibitor analysis was used to 
differentiate between an ordered or random sequential kinetic mechanism.  Oleoyl-CoA and 
tyrosol were used as dead-end inhibitors that are analogs for acetyl-CoA and tyramine, 
respectively.  Initial velocities for the inhibition experiments were measured for acetyl-CoA and 
tyramine by varying the concentration of one substrate, holding the other substrate at a fixed 
concentration equal to the respective Km,app (acetyl-CoA = 7.2 µM; tyramine = 3.9 µM),
11
 at 
different concentrations of the inhibitor.  Inhibition patterns were determined by fitting the 
resulting data, using SigmaPlot 12.0, to equations 5.4 – 5.6; for competitive, noncompetitive, and 
uncompetitive inhibition, respectively.  The terms in equations 5.4 – 5.6 represent the following: 
vo is the initial velocity, Vmax is the maximal velocity, [S] is the substrate concentration, Km is the 
Michaelis constant, [I] is the inhibitor concentration, and Ki is the inhibition constant.  Each 
assay was performed in triplicate. 
 
Equation 5.4 
    
        
     
   
  
     
 
Equation 5.5 
    
        
     
   
  
        
   
  
 
 
 
Equation 5.6 
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5.2.5 Rate versus pH dependence 
 The pH dependence on the kinetic constants for the wild-type and E29A mutant enzymes 
were determined for acetyl-CoA.  The kinetic constants were determined at pH values ranging 
from 6.5 – 9.5 at intervals of every 0.5 pH units.  The following buffers were used for the pH 
dependence study: MES (pH 6.5 – 7.0), Tris (pH 7.0 – 9.0), and AMeP (pH 9.0 – 9.5).  The 
kinetic constants from the pH dependence experiments were fit using IGOR Pro 6.34A, to 
equation 5.6 [log (kcat/Km – tyramine)] and equation 5.7 [log (kcat)], where c is the pH-independent 
plateau.  Each assay was performed in duplicate. 
 
Equation 5.6 
    
    
  
                                
Equation 5.7 
                      
                  
 
5. 3. Results and discussion 
5.3.1 Structure-activity relationship of AANATL7 substrates 
 Previously, we showed that short- and long-chain acyl-CoAs will serve as substrates for 
AANATL2.
11
  This same study also determined that only serotonin or dopamine are utilized as 
the corresponding biogenic arylalkylamine substrate when a long-chain acyl-CoA (oleoyl-CoA) 
is the other substrate in the conjugation reaction.
11
  However, when acetyl-CoA is used as the 
corresponding acyl-CoA substrate, then all the D. melanogaster biogenic arylalkylamines will 
serve as amino donor substrates to generate N-acetylarylalkylamides.
11
  Herein, we further 
evaluate the structure-activity relationships for other amino donor substrates with acetyl-CoA 
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serving as the corresponding acyl-CoA substrate (Table 5.2).  This study focused on five major 
structure features of potential amino donor substrates consisting of: (a) modification of the 5’ 
position of substrates containing an indole ring, (b) modification of the phenyl ring for substrates 
containing a two methyl spacer group that links the phenyl ring and primary amine, (c) the length 
of the spacer group that links the phenyl ring and primary amine, (d) modification of the a two 
methyl spacer group, and (e) other non-arylalkylamine amino donors.   
 The first set of substrates that were evaluated is decarboxylated analogs of tryptophan, in 
which each substrate contained an indole ring.  The (kcat/Km)app value for these panel of 
substrates are found in decreasing order: 5-benzyloxytryptamine ≥ serotonin ≥ tryptamine > 
5-methoxytryptamine.  The only indole ring substrate evaluated in this study that was outside the 
standard error range for the other substrates was 5-methoxytryptamine, resulting mainly from a 
1.8 - 3.5-fold (tryptamine – serotonin) increase in the Km,app value.  The kcat,app value was 
generally the same for each indole ring substrate evaluated, except for a ~2-fold higher value for 
tryptamine.  In all, the kinetic constants for this panel of substrates had minimal difference when 
compared to the other substrates that contain an indole ring. 
 
Table 5.2. Steady-state kinetic constants for different amino donors
a,b 
 
Substrate Structure 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
3-(Trifluoromethyl)phenethylamine 
 
10 ± 2  4.5 ± 0.2  (4.4 ± 0.7) × 10
5
 
4-Methoxyphenethylamine 
 
10 ± 2  3.7 ± 0.1 (3.7 ± 0.6) × 10
5
 
3-Methoxyphenethylamine 
 
13 ± 2  4.4 ± 0.2  (3.5 ± 0.6) × 10
5
 
5-Benzyloxytryptamine 
 
8 ± 1 2.8 ± 0.1  (3.3 ± 0.4) × 10
5
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Table 5.2. (Continued) 
 
β-Methylphenethylamine 
 
9 ± 1  2.9 ± 0.1 (3.2 ± 0.4) × 10
5
 
Tryptamine 
 
14 ± 3 4.3 ± 0.3  (3.1 ± 0.6) × 10
5
 
Tyramine 
 
5 ± 1 1.47 ± 0.03 (2.9 ± 0.3) × 10
5 
3,4-Methylenedioxyphenethylamine 
 
27 ± 5 6.3 ± 0.4 (2.3 ± 0.4) × 10
5
 
Phenethylamine 
 
35 ± 10  7.3 ± 1  (2.1 ± 0.7) × 10
5
 
Norepinephrine 
 
27 ± 3  5.6 ± 0.3  (2.1 ± 0.3) × 10
5
 
4-Phenylbutylamine 
 
9.5 ± 0.4  1.03 ± 0.02 
(1.09 ± 0.05) × 
10
5
 
5-Methoxytyrptamine 
 
25 ± 2   2.6 ± 0.1 (1.0 ± 0.1) × 10
5
 
Benzylamine 
 
210 ± 4 
0.092 ± 
0.002 
430 ± 10 
Histamine 
 
3500 ± 
200  
0.90 ± 0.02  260 ± 5 
Ethanolamine  
(1.1 ± 0.1) 
× 10
5
 
0.82 ± 0.03 7 ± 1 
 
a 
Reaction condition – 300 mM Tris pH 8.0, 150 µM DTNB, 50 µM acetyl-CoA, and varying 
concentration of amine substrate. 
b 
Kinetic constants are reported as ± standard error (n=3). 
 
 The second set of substrates evaluated were arylalkylamines that contained a phenyl ring 
+ two methyl spacer group + primary amine.  3-(Trifluoromethyl)phenethylamine, 
4-methoxyphenethylamine, and 3-methoxylphenethylamine were shown to be the amino donor 
substrates that had the highest (kcat/Km)app value for this group of substrates.  We could not 
distinguish between these amino donor substrates which had the largest (kcat/Km)app value, 
because each one is within the uncertainty of 3-(trifluoromethyl)phenethylamine.  The other 
amino donor substrates in this group that are outside the uncertainty of 
3-(trifluoromethyl)phenethylamine are β-methylphenethylamine, tyramine, 
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3,4-methylenedioxyphenethylamine, phenethylamine, norepinephrine, dopamine, and 
octopamine.  The largest difference in the (kcat/Km)app value results from octopamine, which is 
7% of that reported for 3-(trifluoromethyl)phenethylamine, resulting mainly from the 8-fold 
increase in the Km,app value.  All the other amino donors in this group are found to have a 
(kcat/Km)app that is ≥ 35% (dopamine) of that reported for 3-(trifluoromethyl)phenethylamine.  
The Km,app values for this group of amino donors ranged from 5 – 78 µM (tyramine – 
octopamine), whereas the kcat,app values ranged from 1.47 – 6.5 s
-1
 (tyramine – dopamine).  
Overall, very little difference was observed for the kinetic constants in this group of amino donor 
substrates, pointing to an enzyme with significant substrate promiscuity.  
 The third set of substrates evaluated were those that have a different length of the spacer 
group that links the phenyl group to the primary amine.  The (kcat/Km)app value in this group of 
amino donor substrates ranks from highest to lowest as: phenethylamine > 4-phenylbutylamine 
>> benzylamine.  The (kcat/Km)app value for phenethylamine was only 2-fold higher than 
4-phenylbutlyamine; however, phenethylamine was ~500-fold > benzylamine.  These data 
suggest that a two methyl spacer group is optimal for substrate specificity; however, AANATL2 
will use substrates with a spacer group of four methyl groups (4-phenylbutylamine) with similar 
specificity.  Decreasing the spacer group by one CH2 group to generate benzylamine; 
significantly increases the Km,app and decreases the kcat,app, resulting in a large decrease in the 
(kcat/Km)app value.  
 The fourth set of substrates we evaluated were amino donors that contain a phenyl group 
+ two methyl spacer + primary amine, where the two methyl linker group is modified at either 
the α- or β-position.  We first evaluated the modification of the α-position with a carboxylate, 
resulting in the amino acids: tyrosine, phenylalanine, tryptophan, and histamine.  Activity was 
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not observed for these amino acids above the baseline hydrolysis rate at a concentration of 1 
mM, suggesting that the modification of the α-position on the spacer group induces either a steric 
or electrostatic effect.  To evaluate these possibilities, we used tyrosine methyl ester at a 
concentration of 1 mM, in which we did not observe a rate above the baseline rate suggesting 
that the arylalkylamines with a modification at the α-position of the spacer group will not serve 
as substrates prominently due to a steric effect.  We further evaluated tyrosine, phenylalanine, 
tryptophan, histamine, and tyrosine methyl ester as inhibitors for the AANATL2-catalyzed 
formation of N-acetyltyramine.  No inhibition was observed at a concentration of 1 mM of each 
inhibitor, confirming that these α-position modified arylalkylamines do not bind or binds weakly 
(Kd ≥ 10 mM) to AANATL2, predominantly due to steric interference in the active site.  Next, 
we evaluated how modifications at the β-position will affect the kinetic constants.  These data 
resulted in minimal difference in the (kcat/Km)app value except for octopmaine, in which we rank 
these amino donor substrates in decreasing order: β-methylphenethylamine ≥ phenethylamine ≥ 
norephinephrine > octopamine.  The (kcat/Km)app value for octopamine was 10% of that reported 
for phenethylamine, due to both an increase in the Km,app (1.4-fold) and decrease in the kcat,app 
(3.2-fold). 
 Next, we evaluated if other non-arylalkylamines will serve as substrates for AANATL2.  
We identified that AANATL2 will catalyzed the N-acetylation of histamine and ethanolamine, 
albeit with low specificity when compared to arylalkylamine substrates.  Both histamine and 
ethanolamine have a large increase in the Km,app (350- and 1.1 × 10
4
-fold, respectively) and 
decrease in the kcat,app values (5-fold for both substrates) when compared to the “best” substrate, 
3-(trifluoromethyl)phenethylamine.  These data resulted in histamine and ethanolamine having 
(kcat/Km)app values that are only 0.06% and 0.002% of 3-(trifluoromethyl)phenethylamine, 
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respectively.  We also determined that AANATL2 does not catalyze the N-acetylation of 
isoniazid, which is a first line drug for the treatment of tuberculosis.
27-29
  These data suggest that 
AANATL2 predominantly catalyzes the N-acylation of biologically relevant arylalkyamines.         
Previous data suggests that the promiscuity of AANATL2 for certain arylalkylamines is 
decreased as the acyl-chain length is increased from acetyl-CoA (C2) to oleoyl-CoA (C18).
11
  
These data resulted in tyramine and octopamine serving as substrates for AANATL2 when 
acetyl-CoA is the corresponding acyl-CoA substrate; however, tyramine and octopmaine does 
not function in the conjugation chemistry with oleoyl-CoA.  There are two possible explanations 
to these data: (a) longer chain acyl-CoAs will serve as substrates in a different enzyme form (or 
different active site) which is only specific for serotonin or dopamine, or (b) the acyl group of the 
long-chain acyl-CoAs will occupy the amine binding pocket, resulting in the perturbed binding 
of amino donor substrates.  The Km,app value increased > 25-fold for both serotonin and 
dopamine when a longer chain acyl-CoA (C16 – C20) is used instead of acetyl-CoA.  Coupling 
these data to the dead-end inhibition data (section 3.2), it is more likely that the longer acyl 
group is perturbing amino donor binding, resulting in only certain amino donors (serotonin and 
dopamine) that will function as substrates.
11 
Overall, a preponderance of the data from the structure-activity studies and other data 
published for AANATL2 identifies that this enzyme has significant substrate promiscuity for 
both acyl-CoA
11
 and amino donor substrates.  The three major structural features that affected 
binding and/or catalysis for AANATL2 substrates were amino donors that were modified at the 
α-position, the length of the acyl group for the acyl-CoA substrate, and the length of the spacer 
group linking the phenyl and primary amino groups of the amine substrates.  Amino donors that 
were modified at the α-position will not bind to AANATL2 because of steric inference within the 
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active site, resulting in the inability to function in catalysis.  The length of the spacer group for 
the amine substrate linking the phenyl group and primary amine was shown to be critical, where 
decreasing the length by one CH2 group resulted in a significant decrease in the kcat,app and 
increase in the Km,app values.  This is likely a result from the primary amino group needing to be 
properaly positioned for nucleophilic attack of acetyl-CoA.  Shortening the length of the spacer 
group likely results in improper positioning of the amine group, whereas the active site of 
AANATL2 is more accommodating for an increase in the length of the spacer group as observed 
for 4-phenylbutlamine.  Earlier work highlighted that AANATL2 functions to catalyze the 
formation of long-chain N-acylserotonins and N-acyldopamines; however, will not utilize 
octopamine and tyramine as substrates when a long-chain acyl-CoA (oleoyl-CoA) serves as the 
other substrate.
11
  Selectively for the amino donor seems to increase when long-chain acyl-CoAs 
are used in the conjugation reaction by AANATL2, whereas when acetyl-CoA is used as the 
corresponding acyl-CoA substrate, then the enzyme has significant promiscuity for amino donor 
substrates.  Further work, consisting of solving the kinetic mechanism (discussed section 5.3.2) 
and crystal structure could give additional insight into the structural makeup of the AANATL2 
active site and how it affects amino donor selectivity that is dependent on the length of the 
acyl-CoA substrate. 
 
5.3.2 Kinetic mechanism 
 Solving the kinetic mechanism for AANATL2 could give insight on the reason for broad 
acyl-CoA substrate specificity.  In addition, understanding ordered substrate binding can assist in 
the understanding for the promiscuity differences with the amino donor substrates when 
acetyl-CoA or oleoyl-CoA is the corresponding acyl-CoA substrate.  We used a double 
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reciprocal analysis for acetyl-CoA and tyramine to delineate between a ping-pong or sequential 
mechanism.  The intersecting double reciprocal plots (Figure 5.1) for both substrates strongly 
suggest that this enzyme will catalyze the formation of N-acylarylalkylamides by a sequential 
mechanism.  This suggests that AANATL2 generates a ternary complex prior to catalysis.    
Figure 5.1. Double reciprocal plots of initial velocities for acetyl-CoA and tyramine.  (A) 
Velocities measured at a fixed concentration of tyramine: 25 µM (●), 10 µM (o), 2 µM (▼), 1 
µM (Δ).  (B) Velocities measured at a fixed concentration of acetyl-CoA: 25 µM (●), 10 µM (o), 
2 µM (▼), 1 µM (Δ). 
 
Following these data, we sought to delineate between random or ordered substrate 
binding for acetyl-CoA and tyramine.  To accomplish this, we used dead-end inhibition with 
structural analogs for each substrate that serves as inhibitors.  Previous data showed that 
oleoyl-CoA will not serve as a substrate for AANATL2 when tyramine is the corresponding 
amino donor substrate;
11
 therefore, we decided to use it as a dead-end inhibitor that is an analog 
for acetyl-CoA.  Long-chain acyl-CoAs have been previously used as inhibitors
30-32
 for GNAT 
enzymes and as dead-end inhibitors to evaluate the kinetic mechanism for other D. melanogaster 
AANATL enzymes.
6
  We employed tyrosol as the other dead-end inhibitor in determining the 
kinetic mechanism for AANATL2.  Tyrosol is a structural analog of tyramine, in which the 
amino group of tyramine is replaced with a hydroxyl group.  Tyrosol has been used to study the 
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kinetic mechanism of other GNAT enzymes.  We evaluated the possibility that AANATL2 will 
catalyze the formation of the O-acetylation of tyrosol by measuring the rate of reaction at a 
concentration of 10 mM.  We did not observed any rate above the baseline hydrolysis rate, 
suggesting that AANATL2 will not catalyzed the formation of O-acetyltyrosol; therefore, we 
could use tyrosol as a dead-end inhibitor in solving the kinetic mechanism.  Following these 
analyses, we evaluated the inhibition profile for oleoyl-CoA and tyrosol (Figure 5.2).  
Oleoyl-CoA is a competitive inhibitor with respect to acetyl-CoA (Ki = 180 ± 30 nM) and 
noncompetitive for tyramine (Ki = 540 ± 40 nM).  Tyrosol is an uncompetitive inhibitor with 
respect to acetyl-CoA (Ki = 104 ± 6 µM) and a competitive inhibitor for tyramine (Ki = 52 ± 9 
µM).  In addition to the double reciprocal analysis, these dead-end inhibition data identifies that 
AANATL2 will catalyze the formation of N-acetyltyramine with an ordered sequential 
mechanism, in which acetyl-CoA binds first followed by tyramine to generate the 
AANATL2*acetyl-CoA*tyramine ternary complex prior to any product formation.  These data 
also provide more insight into the amino donor substrate promiscuity differences observed 
between the use of acetyl-CoA or oleoyl-CoA as the correspdoning acyl-CoA substrate.  The 
promiscuity differences likely result from active site tolerance of the acyl group versus the ability 
to position the amino donor substrate properly for nucleophilic attack.  Since an 
AANATL2•acetyl-CoA complex is required prior to tyramine binding, it is likely that the 
AANATL2 enzyme becomes more discriminatory to amino donors as the length of the acyl-CoA 
substrate is increased, because the acyl group begins to occupy the amino donor binding site, 
perturbing the ability for certain amines to bind and function in catalysis.  An ordered sequential 
mechanism identified for AANATL2 is consistent with other D. melanogaster AANATL 
enzymes and with the mammalian ortholog, sheep serotonin N-acetyltransferase.
33
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Figure 5.2. Dead-end inhibtion analysis of AANATL2. (A) Velocities measured at a fixed 
concentration of tyramine (3.9 µM), varying the concentration of acetyl-CoA, and varying the 
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 125 nM (o), 250 nM (▼); Ki = 180 ± 30 
nM.  (B) Velocities measured at a fixed concentration of acetyl-CoA (7.2 µM), varying the 
concentration of tyramine, and varying the concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 
125 nM (o), 250 nM (▼); Ki = 540 ± 40 nM. (C) Velocities measured at a fixed concentration of 
tyramine (3.9 µM), varying the concentration of acetyl-CoA, and varying the concentration of 
the inhibitor, tyrosol: 0 µM (●), 50 µM (o), 100 µM (▼); Ki = 104 ± 6 µM.  (D) Velocities 
measured at a fixed concentration of acetyl-CoA (7.2 µM), varying the concentration of 
tyramine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 50 µM (o), 100 µM 
(▼); Ki = 52 ± 9 µM.   
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5.3.3 Evaluation of the AANATL2 acid/base chemistry and the corresponding catalytic 
residue(s) 
 We used a series of pH-rate profiles, primary sequence alignment with other D. 
melanogaster AANATL enzymes, and site-directed mutagenesis to generate data that can be 
used to propose a chemical mechanism for AANATL2.  First, we determined the pH-dependence 
on the acetyl-CoA kinetic constants (Figure 5.3).  Both, the kcat,app – acetyl-CoA and (kcat/Km)app – 
acetyl-CoA profiles produced a bell-shaped curve with two apparent pKa values.  The pKa,app values 
for the kcat,app – acetyl-CoA profile were 7.4 ± 0.2 and 8.9 ± 0.2, whereas the pKa,app values for the 
(kcat/Km)app – acetyl-CoA profile were 6.8 ± 0.2 and 9.0 ± 0.1.  The pKa,app values of 7.4 and 6.8 from 
both profiles, likely represents the same ionizable group, the general base in catalysis.  The 
differences in these two pKa,app values most likely results from either the kinetic stickiness of 
acetyl-CoA or from the difficulty in measuring the acetyl-CoA kinetic constants with varying 
concentrations that range at the low end of the linear response for the DTNB assay.  The second 
pKa,app values of 8.9 and 9.0 represents the same ionizable group, either a general acid in 
catalysis or the thiol group of coenzyme A.  The pKa for the thiol group of coenzyme A has been 
reported to range from 9.6 to 10.4.
34-35
   
 Studying the pH-dependence for kinetic constants of the AANATL2 wild-type 
enzyme can only give information on the general acid/base chemistry that this enzyme catalyzes, 
but cannot delineate the respective amino acid residues (or substrate/product) responsible for 
these ionizable groups.  Therefore, we used a combination of primary sequence alignment with 
other D. melanogaster AANATL enzymes
6
 and site-directed mutagenesis of conserved residues 
to identify the respective amino acids that function in catalysis.  A primary sequence alignment 
of the eight D. melanogaster AANATL enzymes generated five conserved amino acid residues 
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that may have important functions in catalysis and/or substrate binding: Glu-29, Pro-30, 
Arg-138, Ser-171, and His-206.
11
  For each of these amino acids in AANATL2, the 
corresponding residues in D. melanogaster AANATA
6
 and AANATL7 were evaluated and have 
a defined function.  Therefore, we can index the data from the site-directed alanine mutants 
(Table 5.3) to the corresponding residues from the previously studied D. melanogaster AANATL 
enzymes, in order to delineate a respective function in AANATL2.
6
   
Figure 5.3. AANATL2 pH rate profiles. (A) kcat,app for acetyl-CoA.  pKa1 - slope = 0.8, pKa2 - slope = 
-0.6.  (B) (kcat/Km)app for acetyl-CoA.  pKa1 - slope = 0.6, pKa2 - slope = -0.7. 
 
In both AANATA and AANATL7, a glutamate has been proposed to be the general base 
in catalysis.  The corresponding glutamate found in AANATL2 is Glu-29; therefore, based of the 
primary sequence alignment, this amino acid residue likely has a similar function as the general 
base in catalysis.  The kcat,app value of the E29A mutant was 23% - 25% of the wild-type enzyme, 
whereas the (kcat/Km)app for acetyl-CoA and tyramine decreased 4.3- and 66-fold, respectively.  
The E29A mutant did not produced a change in the Km,app value for acetyl-CoA when compared 
to the wild-type enzyme, indicating that this residue does not function in acetyl-CoA binding.  
Interestingly, the small decrease in the kcat,app value suggests that Glu-29 is not the general base 
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in catalysis; however, the large increase in the tyramine Km,app (17-fold) indicates that this 
residue is important to amino donor binding.  Since the corresponding glutamates found in D. 
melanogaster AANATA (Glu-47)
6
 and AANATL7 (Glu-26), were identified as the general base 
in catalysis, we wanted to confirm that Glu-29 in AANATL2 does not have the same function in 
catalysis.  This was accomplished by evaluating the pH-dependence on the acetyl-CoA kinetic 
constants for the E29A mutant (Figure 5.4).  Both, the kcat,app – acetyl-CoA and (kcat/Km)app – acetyl-CoA 
profiles for E29A produced a bell-shaped curve with two apparent pKa values, similar to the 
wild-type.  The pKa,app values for  this mutant were: kcat,app – acetyl-CoA = 7.0 ± 0.1 and 8.8 ± 0.1, 
whereas the pKa,app values for the (kcat/Km)app – acetyl-CoA profile = 7.1 ± 0.2 and 9.1 ± 0.2.  The 
pKa,app value of ~7.0 for the E29A mutant corresponds to the general base in catalysis, whereas 
the pKa,app value of ~9.0 is either the general acid in catalysis or the thiol group of the coenzyme 
A product.  Since the pKa,app value of ~7.0 was not abolished in the E29A pH-rate profile when 
compared to the wild-type enzyme, it suggests that Glu-29 is not the general base in catalysis.  
This is a striking difference from the two other D. melanogaster AANATL enzymes, where the 
corresponding glutamate functions as the general base.
6
  When the glutamate is mutated to an 
alanine in these enzymes, the pH-rate profile for the alanine mutant has a linear profile (instead 
of a bell-shaped profile), where the general base pKa,app disappears, confirming that the 
corresponding glutamates function as catalytic amino acids in D. melanogaster AANATA and 
AANATL7.
6, 36
  This is likely not observed for AANATL2, because either Glu-29 is not the 
general base or it functions in a redundant role with another amino acid residue that is not 
identified to date.  There is literature precedent for two residues functioning in a redundant role 
as the general base in catalysis, as observed for sheep serotonin N-acetyltransferase (His-120 and 
His-122).
37-42
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Table 5.3. Steady-state kinetic constants for AANATL2 site-directed mutants
a 
Mutant
 b
 
Acetyl-CoA 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
 
          
 
    
  
 
             
     
% 
Wild-type 5 ± 1 1.6 ± 0.1 (3.1 ± 0.4) × 10
5 
100 
E29A 5.1 ± 0.2 0.37 ± 0.01 (7.2 ± 0.3) × 10
4
 23 
P30A 3.3 ± 0.4 0.032 ± 0.001 (10 ± 1) × 10
3
 3.2 
R138A 1.6 ± 0.1  0.313 ± 0.004 (1.9 ± 0.1) × 10
5
 61 
S167A 40 ± 2 0.75 ± 0.01 (1.9 ± 0.1) × 10
4
 6.1 
S171A nd
c 
nd
c 
nd
c 
nd
c 
H206A nd
c 
nd
c 
nd
c 
nd
c 
Mutant
 d
 
Tyramine 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
 
          
 
    
  
 
             
     
% 
Wild-type
 
5 ± 1 1.47 ± 0.03 (2.9 ± 0.3) × 10
5 
100 
E29A 85 ± 5 0.37 ± 0.01 (4.4 ± 0.3) × 10
3
 1.5 
P30A 52 ± 7 0.043 ± 0.001 820 ± 110 0.28 
R138A 6 ± 1 0.26 ± 0.01 (4.5 ± 0.7) × 10
4
 16 
S167A 19 ± 2 1.03 ± 0.04 (5.3 ± 0.7) × 10
4
 18 
S171A nd
c 
nd
c 
nd
c 
nd
c 
H206A nd
c 
nd
c 
nd
c 
nd
c 
a 
Kinetic constants are reported as ± standard error (n=3). 
b
 The reaction rate was measured at a fixed saturating concentration of tyramine while varying the 
concentration of acetyl-CoA. 
c
 The notation of “nd” is used for a mutant that did not display a rate of coenzyme A release at 412 nm. 
d
 The reaction rate was measured at a fixed saturating concentration of acetyl-CoA while varying the 
concentration of tyramine. 
 
The second pKa,app observed in the wild-type pH-rate profiles (pKa,app ~9.0) is either the 
general base in catalysis or the thiol group of the CoA-SH product.  The decrease in the kinetic 
constants likely results from CoA-S
-
 having greater affinity to AANATL2 than the CoA-SH 
form (Kd, CoA-SH > CoA-S
-
).  Two AANATL2 residues, Ser-167 and Ser-171, could function 
as the general acid in catalysis.  It has been previously proposed that the corresponding residue 
of AANATL2 Ser-171 found in AANATA (Ser-186) is the general acid in catalysis.
36
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Therefore, we mutated both serines to an alanine and determined the kinetic constants in order to 
delineate if these residues could function in catalysis.  The S167A mutant produced a kcat,app 
value that is 47% of the wild-type and a Km,app-acetyl-CoA and Km,app-tyramine that increased 8- and 
4-fold, respectively.  The minimal decrease in the S167A kcat,app value suggests that this residue 
does not function directly in catalysis as the general acid.  However, the increase in both 
substrates Km,app values indicates that this residue has an effect in substrate binding, possibly by 
functioning in the organization of the active site.  The second serine mutant, S171A, was 
completely deficient of catalysis, in which there was not a rate observed above the baseline 
hydrolysis rate.  This could indicate that Ser-171 is the general acid in catalysis or that this 
residue has a critical function in one (or more) of the following: (a) structural component in the 
formation of the active site, (b) participates in a “proton wire” by shuttling protons out of the 
active site,
6, 21, 38, 43
 or (c) required for the proper positioning of the catalytic residues.   Since 
S171A is catalytically deficient, we could not evaluate the mutant pH-rate profile to determine if 
this residue corresponds to the second pKa,app value observed in the wild-type enzyme.  It seems 
unlikely that Ser-171 functions as a general acid, since it is thermodynamically unfavorable for a 
serine residue to transfer a proton to a thiolate anion.  The serine residue requires a substantial 
depression in the pKa value (3-5 pH units) to function in the protonation of a thiolate.  It is more 
likely that this residue has a critical structural function, when disrupted, completely abolishes 
catalysis. 
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Figure 5.4. AANATL2 E29A pH rate profiles. pKa1 - slope = 0.7, pKa2 - slope = -0.8.  (A) kcat,app for 
acetyl-CoA. (B) (kcat/Km)app for acetyl-CoA.  pKa1 - slope = 0.8, pKa2 - slope = -0.7. 
 
 
5.3.4 Evaluation of AANATL2 amino acid residues that function in substrate binding and 
regulation of catalysis 
 We further evaluated the other conserved residues to understand their respective function 
in AANATL2.  The amino acid residues, Pro-30, Arg-138, and His-220, were each mutated to an 
alanine and their respective kinetic constants evaluated.  To further understand the function of 
these residues in the absence of a crystal structure, we indexed the data to that generated for the 
corresponding residue from D. melanogaster AANATA and AANATL7.
6
  This will help 
delineate a possible function for these conserved residues.  The P30A mutant produced a kcat,app 
value that is 2% - 3% of the wild-type enzyme, whereas the Km,app for tyramine increased 
10-fold.  In contrast to the data generated for tyramine, the Km,app for acetyl-CoA was similar to 
the wild-type enzyme.  These data suggest that Pro-30 has an important function in regulating 
catalysis and amino donor substrate binding; however, has minimal impact on acetyl-CoA 
binding.  The corresponding residue in D. melanogaster AANATA and AANATL7 was 
proposed to function in regulating catalysis by being positioned on a "floppy loop" that occupies 
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the binding site of acetyl-CoA.
6
  After acyl-CoA binding, the proline residue migrates ~ 8 Å to 
open up the amine substrate binding pocket, in addition to having a direct stacking interaction 
with the arylalkylamine substrate.  The dynamics of the “floppy loop” that the proline residue 
resides, functions in converting the enzyme from a low to high affinity state.
6, 44
  The significant 
decrease in the kcat,app value and increase in the Km,app – tyramine could be indicative of a similar 
function for AANATL2 Pro-30.  A conformation change resulting in the movement of 
AANATL2 Pro-30 residue likely functions in converting AANATL2 from a low to high affinity 
state.  This movement of Pro-30, results in the formation of the amino donor binding pocket, 
which gives a structural rational to the ordered sequential mechanism (discussed in section 3.2), 
where acetyl-CoA binds first, followed by tyramine.  This proposed function for Pro30 as a 
catalytic switch and in direct binding of the arylalkylamine substrates is consistent with our data 
and for other GNAT enzymes characterized to date.
6, 44
  It is unclear why there is not a change in 
the Km,app – acetyl-CoA for the AANATL2 P30A mutant, as was observed for both corresponding 
prolines from D. melanogaster AANATA and AANATL7.  It could be from the relative position 
of Pro-30 in the low affinity state, which does not have as dramtic effect on acetyl-CoA binding.  
What can be delineated from these data is that AANATL2 Pro-30 functions in regulating 
catalysis and amine substrate binding.    
 The next amino acid residue we evaluated was Arg-138.  The R138A mutant produced a 
kcat,app value that is 18% – 20% of the wild-type enzyme.  This mutant also has a Km,app value for 
acetyl-CoA and tyramine that was similar to that observed for the wild-type enzyme.  Previously, 
the corresponding arginine to alanine mutant in D. melanogaster AANATA and AANATL7 
generated kinetic constants where the kcat,app and the Km,app for both substrates increased.
6
  The 
arginine residue was proposed to function in the regulation of catalysis and the formation of the 
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AANATL2 active site.  This amino acid residue regulates catalysis by the formation of an 
arginine:aspartate salt bridge, which regulates a conformation change responsible for product 
(CoA-SH) release being rate-limiting.
6
  Based off the kinetic constants generated for the 
AANATL2 R138A mutant, this residues does not have the same function as the corresponding 
arginines in D. melanogaster AANATA and AANATL7.  It is not clear why Arg-138 does not 
have a similar function in AANATL2, but some possibilities include: (a) product release might 
not be rate-limiting for AANATL2, (b) Arg-138 does not function in the formation of the 
acyl-CoA binding pocket or the AANATL2 active site, and/or (c) Arg-138 is not found in a salt 
bridge with any residue in AANATL2.  It is possible that Arg-138 has more structural flexibility 
in AANATL2, assisting in the observed promiscuity for acyl-CoA substrates.  Further work to 
define a crystal structure for AANATL2 is necessary to define the complete function this residue 
contributes to enzyme structure and function. 
 The final AANATL2 amino acid residue evaluated in our study was His-206.  The 
H206A mutant did not yield a rate of catalysis above the background acetyl-CoA hydrolysis.  
This mutation renders AANATL2 catalytically dead, suggesting an important function.  The 
corresponding residues in D. melanogaster AANATA and AANATL7 functions in general 
active site organization and formation.
6
  It is possible a similar function can be attributed to 
His-206 in AANATL2; however, then this residue must be more critical in the active site 
organization.  His-206 could function to organize the active site by positioning the catalytic 
amino acid residues in their respective position for catalysis.  It is also possible that this residue 
functions as the general base in catalysis, since Glu-29 was identified to not catalyze this 
chemistry.  A crystal structure will be necessary to delineate the corresponding function for 
His-206 in AANATL2.  
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 Interestly, all the amino acid residues evaluated for AANATL2 have variable differences 
when compared to their corresponding residues in D. melanogaster AANATA and AANATL7, 
even though AANATL2 catalyzes similar chemistry with similar substrates.
6
  So, one major 
question is: why do we see these differences?  Do these residues have a similar function in 
AANATL2 as seen in AANATA and AANATL7; however, will have a different net effect on 
binding and/or catalysis or do these residues have a completely different function in this 
enzyme.
6
  One possible explanation for the variable differences is that AANATL2 evolved to 
have a greater promiscusity for amine or acyl-CoA substrates, especially functioning in the 
formation of long-chain N-acyldopamines and N-acylserotonins.
11
  We were the first group to 
report an enzyme that could catalyze the formation of these fatty acid amides.
11
  One major 
question yet to be solved is: what is the major structural/chemical differences between 
AANATL2 and AANATA (or AANATL7) that allows for the conjugation of these long-chain 
cell signaling lipids?  Further work is nessessary to define these differences in order to fully 
understand how these important lipids are biosynthesized. 
Scheme 5.2. Proposed chemical mechanisms for D. melanogaster AANATL2.  R = different 
acyl chain length for acyl-CoA. 
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5.3.5 Proposed chemical mechanism for AANATL2 
Two possible chemical mechanisms consistent with the data generated herein are 
illustrated in Scheme 5.2.  Currently, our data does not delineate between these two possible 
mechanisms.  The first possible mechanism (Scheme 5.2A) features: (a) ordered substrate 
binding to generate the AANATL2•acetyl-CoA•tyramine ternary complex prior to catalysis, (b) 
deprotonation of the positively charged amine of tyramine by a catalytic base, possibly through 
ordered water molecules (“proton wire”), (c) nucleophilic attack of the carbonyl of the 
acetyl-CoA thioester by the deprotonated tyramine to generate the zwitterionic tetrahedral 
intermediate, (d) finally the breakdown of the zwitterionic tetrahedral intermediate with the 
concomitant protonation of coenzyme A.  The pKa,app values of ~7.0 and 9.0 in this possible 
mechanism corresponds to a undefined general base and the thiolate of CoA-SH.  The second 
possible mechanism (Scheme 5.2B) consists of: (a) a sequential ordered mechanism with 
acetyl-CoA binding first followed by tyramine to generate the AANATL2•acetyl-CoA•tyramine 
ternary complex prior to catalysis, (b) nucleophilic attack of the carbonyl of the acetyl-CoA 
thioester by tyramine to generate the zwitterionic tetrahedral intermediate, (c) followed by the 
collapse of the zwitterionic tetrahedral intermediate by base catalyzed deprotonation of the 
positively charge amine intermediate, in addition to acid catalyzed protonation of coenzyme A.  
The pKa,app values of ~7.0 and 9.0 in this possible mechanism corresponds to a undefined general 
base and general acid in catalysis.  Both mechanisms in Scheme 5.2 have been proposed for 
other GNAT enzymes,
21, 44, 46-49
 where the mechanism found in Scheme 5.2A being proposed for 
D. melanogaster AANATA and AANATL7.
6
  In addition to this chemical mechanism, we 
highlight that Pro-30, Ser-171, and His-206 are critical in regulating the AANATL2-catalyzed 
reaction.  Further work in solving a crystal structure is necessary to completely define the 
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function of the amino acid residues evaluated herein, and to ultimately define the chemical 
mechanism of AANATL2. 
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Abstract 
 Arylalkylamine N-acetyltransferase (AANAT) catalyzes the penultimate step in the 
biosynthesis of melatonin and other N-acetylarylalkylamides from the corresponding 
arylalkylamine and acetyl-CoA.  The N-acetylation of arylalkylamines is a critical step in 
Drosophila melanogaster for the inactivation of the bioactive amines and the sclerotization of 
the cuticle.  Two AANAT variants (AANATA and AANATB) have been identified in D. 
melanogaster, in which AANATA differs from AANATB by the truncation of 35 amino acids 
from the N-terminus.  We have expressed and purified both D. melanogaster AANAT variants 
(AANATA and AANATB) in Escherichia coli and used the purified enzymes to demonstrate 
that this N-terminal truncation does not affect the activity of the enzyme.  Subsequent 
characterization of the kinetic and chemical mechanism of AANATA identified an ordered 
sequential mechanism, with acetyl-CoA binding first, followed by tyramine.  We used a 
combination of pH-activity profiling and site-directed mutagenesis to study perspective residues 
believed to function in AANATA catalysis.  These data led to an assignment of Glu-47 as the 
general base in catalysis with an apparent pKa of 7.0.  Using the data generated for the kinetic 
mechanism, structure/function relationships, pH rate profiles, and site-directed mutagenesis, we 
propose a chemical mechanism for AANATA.    
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Biogenic amines are important neuroactive amines found in both vertebrates and 
invertebrates functioning as neurotransmitters, neuromodulators, or neurohormones via their 
binding to specific receptors.  In insects, the biogenic arylalkylamines are dopamine, tyramine, 
serotonin, and octopamine, which function primarily as neurotransmitters.
1
  The pathways for 
biosynthesis and degradation have important roles in the function of the arylalkylamines as a 
balance between production and clearance is necessary to maintain the appropriate cellular 
concentrations of the amines.  Dysfunction in either of these opposing pathways would lead to 
improper cellular levels of the arylalkylamines, leading to errors in the processes regulated by 
them.
2
   
The biogenic arylalkylamines are all derived in vivo from the cognate aromatic amino 
acid (tyrosine or tryptophan) precursor.  The precursor amino acid is initially hydroxylated by an 
aromatic amino acid hydroxylase (tyrosine hydroxylase or tryptophan hydroxylase)
3-4
 and then 
decarboxylated by aromatic L-amino acid decarboxylase (3,4-dihydroxylphenylalanine 
decarboxylase)
5
 to generate either dopamine or serotonin, respectively.  Tyramine is derived 
from the decarboxylation of tyrosine by tyrosine decarboxylase,
6-7
 which can then be 
β-hydroxylated to generate octopamine, a reaction that is catalyzed by tyramine -hydroxylase.8-
10
  One proposed inactivation reaction for the arylalkylamines is N-acetylation as catalyzed by 
arylalkylamine N-acetyltransferase (AANAT):  acetyl-CoA +  arylalkylamine → 
N-acetylarylalkylamine + CoA-SH.
11-12
   In addition to arylalkylamine inactivation, acetyl-CoA 
dependent N-acetylation is involved in cuticle sclerotization
13-16 
and melatonin  
biosynthesis.
17-18
   
 AANAT (EC 2.3.1.87), also known as serotonin N-acetyltransferase and dopamine 
N-acetyltransferase, has been identified in D. melanogaster
11
 and is a member of the GCN5-
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related N-acetyltransferase (GNAT) superfamily.
19-20
  The identification of N-acetyltransferase 
activity for arylalkylamines in D. melanogaster was first shown in 1972 by Dewhurst et al.,
11
 
followed by the initial characterization of AANAT in 1977 by Maranda and Hodgetts.
21
  In 1998, 
Brodbeck et al.
22
 identified two biologically relevant variants, variant A (AANATA) and variant 
B (AANATB), which differ by 35 amino acids found only at the N-terminus of the larger 
AANATB.  Differential transcription of a single AANAT gene leads to the two different 
AANAT variants.
22
  These variants are expressed in different tissues and at different life stages, 
with AANATA being found in the brain, ventral nerve cord, and midgut during late stage 
embryogenesis and in adults.  AANATB is less abundant and is found in the brain only during 
late pupal stages and in adults as well.
22
  AANAT enzymes have been characterized from many 
organisms and are known to catalyze the rate-limiting penultimate step in the formation of 
melatonin.
20, 23-25
  Melatonin is a hormone that is produced in a diurnal cycle
24
 (higher levels are 
found at night) and is suggested to regulate the life-span of D. melanogaster.
18
   
 Eight putative AANAT-like enzymes (AANATL) have been identified in D. 
melanogaster
26
 and are proposed to play a role in the biosynthesis of fatty acid amides.
27-28
  
 Herein, we report on the cloning, expression, purification, and characterization of D. 
melanogaster AANATA and AANATB from recombinant E. coli.  Our data shows that 
AANATA and AANATB are catalytically similar with respect to substrate specificities and 
measured kinetic constants (Km,app, and kcat,app).  More detailed studies of AANATA were 
performed to define the kinetic mechanism and to elaborate a chemical mechanism that is 
consistent with both the pH rate profiles and data from a set of site-directed mutant enzymes. 
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Experimental Procedures 
Materials 
 Ambion RETROscript® Kit, ProBond™ nickel-chelating resin and MicroPoly(A) 
Purist
TM
 were purchased from Invitrogen.  NdeI, XhoI, Antarctic Phosphatase, and T4 DNA 
ligase were purchased from New England Biolabs.  BL 21 (DE3) E. coli cells, XL10 E. coli 
cells, and the pET-28a(+) vector were purchased from Novagen.   Kanamycin monosulfate and 
IPTG were purchased from Gold Biotechnology.  Oligonucleotides were purchased from 
Eurofins MWG Operon and PfuUltra High-Fidelity DNA polymerase was purchased from 
Agilent.  Benzoyl-CoA, acetyl-CoA, butyryl-CoA, hexanoyl-CoA, octanoyl-CoA, 
decanoyl-CoA, oleoyl-CoA, and N-acetylserotonin were purchased from Sigma-Aldrich.  All 
other reagents were of the highest quality available from either Sigma-Aldrich or Fisher 
Scientific. 
 
Cloning of D. melanogaster AANATA and AANATB 
 A cDNA library was generated from D. melanogaster heads, using Ambion 
RETROscript® Kit and MicroPoly(A) Purist
TM
 kits.  AANATA (NCBI reference sequence 
NM_079115.2) and AANATB (NCBI reference sequence NM_206212.1) were amplified from 
the D. melanogaster head cDNA library using the following primers: forward 5’ GAC TCA TAT 
GAT GGA GGA CGC ATT GAC C 3’ and reverse 5’ ATC CCT CGA GCT ACA GCT TGG 
TCT GCG C 3’; forward 5’ GCT ACA TAT GAT GGA AGT GCA GAA GCT and reverse 3’ 
ATC CCT CGA GCT ACA GCT TGG TCT GCG C respectively.  PCR was performed using 
PfuUltra High-Fidelity DNA polymerase, using the following set of conditions: initial denaturing 
step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), then a final 
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extension step of 72°C for 10 min.  The AANATA product or the AANATB PCR product was 
inserted into a pET-28a(+) vector using the NdeI and XhoI restriction enzymes, yielding 
expression vectors for each enzyme, AANATA pET-28a and AANATB pET-28a.  The AANATA 
pET-28a or AANATB pET-28a vectors were then transformed into E. coli XL10 competent cells 
and cultured in Luria Broth (LB) media supplemented with 40 µg/mL kanamycin at 37°C.  The 
plasmids were purified using the Promega Wizard
®
 Plus SV Minipreps DNA purification kit and 
sequenced by Eurofins MWG operon.  In separate experiments, the AANATA pET-28a or 
AANATB pET-28a vector was then transformed into E. coli BL21 (DE3) cells for expression of 
AANATA or AANATB. 
 
Expression and purification of AANATA and AANATB 
 The E. coli BL21(DE3) cells harboring either the AANATA pET-28a or AANATB 
pET-28a expression vector was cultured in LB media supplemented with 40 µg/mL kanamycin 
at 37°C.  The cell cultures were induced at an OD600 of 0.6 with 1 mM isopropyl β-D-1-
thiogalactopyranoside for 4 h at 37°C.  The final cultures were then harvested by centrifugation 
at 5,000 g for 10 min at 4°C and the pellet was collected. 
 The pellet was then resuspended in 20 mM Tris pH 7.9, 500 mM NaCl, and 5 mM 
imidazole; the cells were lysed by sonication; and the cellular debris was removed by 
centrifugation (10,000 × g for 15 min at 4°C).  The supernatant was loaded onto a column 
packed with 6 mL of ProBond™ nickel-chelating resin.  The column was first washed with 10 
column volumes of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, and 5 mM imidazole, then with 10 
column volumes of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, 60 mM imidazole, and AANATA 
or AANATB eluted in 1 mL fractions of 20 mM Tris-HCl pH 7.9, 500 mM NaCl, and 500 mM 
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imidazole.   Purity was assessed by a 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and visualized using Coomassie stain.  Protein concentration was 
determined using the Bradford dye binding assay. 
 
Production of site-directed mutants 
 Each site-directed AANATA mutant was generated by the overlap extension method
29
 
using PfuUltra High-Fidelity DNA polymerase under the following PCR conditions: initial 
denaturing step of 95°C for 2 min, then 30 cycles (95°C for 30 s; 60°C for 30 s; 72°C for 1 min), 
then a final extension step of 72°C for 10 min.  Primers for each mutant (Table S1) were 
designed with the Agilent QuickChange Primer Design tool.  The AANATA mutant PCR products 
were then inserted into a pET-28a(+) vector using the NdeI and XhoI restriction enzymes.  The 
AANATA mutant pET-28a vectors were transformed into E. coli XL10 competent cells and 
cultured in LB media supplemented with 40 µg/mL kanamycin at 37°C.  The plasmids were then 
purified using the Promega Wizard
®
 Plus SV Minipreps DNA purification kit and sequenced by 
Eurofins MWG operon.  Individual mutant AANATA proteins were expressed and purified as 
described previously for the wild-type enzyme.   
 
Measurement of enzyme assay  
 AANATA and AANATB activity was analyzed using Ellman’s reagent30 by measuring 
the release of coenzyme A at 412 nm in 300 mM Tris-HCl pH 8.0, 150 µM DTNB, and the 
desired concentrations of the amino donor substrate and  acyl-CoA substrate.  Initial velocities of 
CoA-SH release were measured using a Cary 300 Bio UV-Visible spectrophotometer and the 
resulting initial velocity kinetic data were fit to the desired equation using SigmaPlot 12.0.  
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Steady-state kinetic constants were obtained by a fit to equation 1, where vo is the initial velocity, 
[S] is the substrate concentration, Vmax is the maximal velocity, and Km is the Michaelis constant. 
 
Equation 1 
   
        
      
 
Apparent kinetic constants for each arylalklyamine substrate were determined by holding 
acetyl-CoA at a fixed saturating concentration, whereas those for each acyl-CoA substrate were 
determined by holding tyramine at a fixed saturating concentration at 22°C.  Assays were 
performed in triplicate and the uncertainty for the (kcat/Km)app and the relative (kcat/Km)app values 
were defined by using equation 2, where σ is the standard error.31 
 
Equation 2 
  
 
 
  
 
 
  
  
 
 
 
  
  
 
 
 
 
 
Kinetic mechanism and inhibitor analysis 
Initial velocity patterns for acetyl-CoA and tyramine were produced by varying the 
concentration of one substrate while holding the concentration of the other substrate at a fixed 
concentration and fitting the data to equation 3 for an ordered Bi-Bi mechanism using Igor Pro 
6.34A, where Kia is the dissociation constant for substrate A (acetyl-CoA), Kb is the Km for 
substrate B (tyramine), and Ka is the Km for substrate A (acetyl-CoA).  The two experimental 
sets were generated by holding the tyramine concentration constant (5 µM, 10 µM, 25 µM, and 
50 µM) and varying the concentration of acetyl-CoA, whereas the second set involved holding 
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the concentration of acetyl-CoA constant (20 µM, 40 µM, 60 µM, and 100 µM) and varying the 
concentration of tyramine. 
 
Equation 3 
  
          
                        
 
 
 
The IC50 values for long-chain acyl-CoAs and tyrosol were determined at the Km 
concentration for the appropriate substrate, tyramine at 12 µM or acetyl-CoA at 39 µM, while 
varying the concentration of the respective inhibitor.   The IC50 value was determined by a fit of 
the resulting data to equation 4 using SigmaPlot 12.0, where vo is the initial velocity without 
inhibitor, vi is the initial velocity at different concentration of inhibitor, and [I] is the inhibitor 
concentration.  The assays were performed in triplicate. 
 
Equation 4 
  
  
 
 
   
   
    
 
 
Dead-end inhibitor analysis was determined for both oleoyl-CoA and tyrosol.   The 
inhibition patterns were determined by holding one substrate (acetyl-CoA or tyramine) at a fixed 
concentration and varying the concentration of the other substrate, with each set carried out at a 
different fixed concentration of the inhibitor.  The initial velocities from these inhibitor 
experiments were fit to equations 5 – 7 for competitive, noncompetitive, and uncompetitive 
inhibition, respectively, where vo is the initial velocity, Vmax is the maximal velocity, [S] is the 
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substrate concentration, Km is the Michaelis constant, [I] is the inhibitor concentration, and Ki is 
the inhibition constant.  The assays were performed in triplicate. 
 
Equation 5 
    
        
     
   
  
     
 
Equation 6 
    
        
     
   
  
        
   
  
 
 
 
Equation 7 
    
        
         
   
  
 
 
 
Rate versus pH dependence 
 The pH dependence of the steady-state kinetic constants was determined for both 
acetyl-CoA and tyramine as varied substrates while holding the other substrate at a fixed 
concentration.  Kinetic constants were determined at 0.5 pH intervals from pH 6.0 – 9.5, using 
the following buffers: MES (pH 6.0 – 7.0), Tris (pH 7.0 – 9.0), and 
2-amino-2-methyl-1-propanol (AMeP) (pH 9.0 – 9.5).  The resulting data were fit to equation 8 
[log (kcat/Km – acetyl-CoA) or log (kcat/Km – tyramine)] and equation 9 (log kcat), where c is the 
pH-independent plateau using Igor Pro 6.34A. 
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Equation 8 
                         
         
 
Equation 9 
                      
                  
 
Intrinsic fluorescence measurements for the determination of the coenzyme A dissociation 
constant 
Fluorescent spectra were generated with a JASCO FP-8300 spectrofluorometer equipped 
with a circulating water bath maintained at 22°C.  Emission spectra (excitation 280 nm, emission 
290 – 300 nm) were measured in a 0.4 cm path length cell containing 400 µL of 300 mM Tris-
HCl, pH 8.0, varying concentrations of coenzyme A, and a fixed AANATA enzyme 
concentration (wild-type – 0.08 mg/mL, R153A – 0.1 mg/mL).  Fluorescent emission spectra 
were acquired in triplicate, with a 50 nm/min scan speed, excitation bandwith – 5 nm, and 
emission bandwith – 2.5 nm.  The Kd for coenzyme A was determined by fitting the data to 
equation 10 with SigmaPlot 12.0, where ΔF is the change in intrinsic fluorescence, ΔFmax is the 
maximum change of fluorescence at infinite ligand concentration, Kd is the ligand dissociation 
constant, and L is the ligand concentration. 
 
Equation 10 
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Product characterization 
 Product characterization was performed using a Phenomenex Kinetex™ 2.6 µm C18 100 
Å  
(50 × 2.1 mm) reverse phase column coupled with an Agilent 6540 liquid 
chromatography/quadrupole time-of-flight mass spectrometer (LC/QTOF-MS) in positive ion 
mode.  An enzyme reaction comprised of 300 mM Tris-HCl pH 8.0, 500 µM acetyl-CoA, 1 mM 
serotonin, and 5 µg AANATA to a final volume of 750 µL was incubated for 30 min at room 
temperature.  Then AANATA was removed from the reaction by centrifugation using a Millipore 
10 kDa filter.  The resulting sample was injected on the LC/QTOF-MS and the retention time 
and high resolution mass were compared with a  
commercial standard of N-acetylserotonin.  Conditions for the LC/QTOF-MS analysis are 
described in Dempsey et al.
27
    
 
Results  
 
Overexpression and purification of AANATA and AANATB 
 AANATA and AANATB were cloned from a cDNA library generated from the D. 
melanogaster head (Figure S1).  Both genes were inserted into a pET28a(+) vector that encodes 
for a N-terminal His6-tag.  Both AANATA and AANATB were purified using ProBond™ 
nickel-chelating resin to homogeneity, yielding 21 mg of AANATA or 3 mg of AANATB per 
liter culture.  Purity was assayed by SDS-PAGE (Figure S2) and determined to be >95% pure.     
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Characterization of the amino acceptor substrates  
 Amino acceptors are defined herein as any acyl-CoA or aryl-CoA substrate.  Our data for 
AANATA and AANATB (Table 1) show that the amino acceptor specificities are approximately 
the same for both enzymes. Both catalyze the formation of N-acyltyramines, utilizing a set of 
straight-chain saturated acyl-CoAs with little variation in the Km,app values from acetyl-CoA to 
hexanoyl-CoA for the two enzymes.  A two-carbon increase in the acyl chain length to decanoyl-
CoA has a dramatic and negative effect on catalysis.  The Km,app is ~10-fold higher and the kcat,app 
is ~10-fold lower than the values for octanoyl-CoA, such that the (kcat/Km)app,decanoyl-CoA is ~1% of 
the (kcat/Km)app,octanoyl-CoA and only ~0.04% of the(kcat/Km)app,acetyl-CoA (Table 1).  Acyl-CoA 
thioesters possessing an acyl-chain of ≥12 carbon atoms were not substrates for AANATA.  
Although lauroyl-CoA and the longer-chain acyl-CoA thioesters were not AANATA substrates, 
all were inhibitors of the enzyme with IC50 values  1.1 M.  We find a slight increase in the 
apparent binding affinity as the acyl-chain length increases, with the IC50 values decreasing from 
1.1 M for lauroyl-CoA to 0.4 M for oleoyl-CoA (Table 2).    
Benzoyl-CoA was also included in our analysis of amino acceptor substrates to facilitate 
the comparison of our substrate specificity data with those published for other N-
acyltransferases.
32, 33
   The (Km,app)benzoyl-CoA is similar to the values we measured for short-chain 
acyl-CoA thioesters, but the kcat,app is significantly lower, such the (kcat/Km)app,benzoyl-CoA is ~1.5% 
of the (kcat/Km)app,acetyl-CoA. 
 
Characterization of the amino donor substrates 
 Amino donors are defined herein as compounds that contain a free amino moiety.  The 
substrate specificity of AANATA was evaluated using a set of arylalkylamine amino donors; 
162 
 
these data show that tyramine is the amino donor with the highest (kcat/Km)app value at saturating 
acetyl-CoA (Table 3).  The kinetic constants for tyramine, with both AANATA and AANATB, 
were very similar at saturating acetyl-CoA (AANATB, (Km,app)tyramine = 20 ± 3 M and 
(kcat,app)tyramine = 16 ± 1 s
-1
 compared with the AANATA data in Table 3).  
A group of other arylalkylamines was evaluated as AANATA amino donor substrates to 
better understand the general structural features that affect binding and catalysis (Table 3).  The 
(kcat/Km)app values ranged over 2 – 3 orders of magnitude for the amino donors we included in 
our study, with tyramine as the best amino donor with the highest (kcat/Km)app value and 3,4-
dimethoxyphenethylamine as the worst amino donor substrate with the lowest (kcat/Km)app value.  
Tyramine and tryptamine exhibit relatively high (kcat/Km)app values (Table 3); therefore, 
modification at the -position was explored to determine if their cognate amino acids could 
serve as substrates.  No activity was observed above the baseline rate of acetyl-CoA hydrolysis 
for tyrosine, tyrosine methyl ester, or tryptophan.  Next, we assessed tyrosine, tyrosine methyl 
ester, and tryptophan as AANATA inhibitors at a 1.0 mM concentration, with the acetyl-CoA 
(39 µM) and tyramine (12 µM) fixed at their respective Km,app values.  No inhibition was 
observed for these three compounds. 
The amino donor substrate specificity for AANATA was further evaluated to determine if 
non-arylalkylamines could serve as substrates.  The decarboxylated amino acids, histamine 
(histidine) and ethanolamine (serine), were not AANATA substrates.   Isoniazid, a first line drug 
for the treatment of tuberculosis,
34-36
 was evaluated for AANATA binding.  There was no 
observed decrease in the rate of reaction in the presence of 1.0 mM isoniazid.   
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Product characterization 
 The product formed from the AANATA reaction using acetyl-CoA and serotonin as 
substrates was analyzed by LC/QTOF-MS in the positive ion mode.  Identification of the product 
formed from this reaction was compared with the commercial standard, N-acetylserotonin.  The 
AANATA product, N-acetylserotonin, was successfully identified by comparing by both 
retention time on a Kinetex™ 2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column and the [M 
+ H] (m/z) high resolution mass spectroscopy peak with the commercial standard (Table S2).   
 
Kinetic mechanism and inhibitor analysis 
 Initial velocity plots were generated using tyramine and acetyl-CoA, by varying the 
concentration of one substrate while holding the other substrate at a fixed saturated 
concentration.  The resulting double reciprocal plots (Figure 1) reveal a pattern of intersecting 
lines, suggesting a sequential kinetic mechanism in which both substrates must be bound before 
catalysis can occur.  Inhibition studies were used to differentiate between a random and an 
ordered sequential mechanism for AANATA, using oleoyl-CoA and tyrosol as the dead-end 
inhibitors.  Oleoyl-CoA is an analog of acetyl-CoA, whereas tyrosol is an analog of tyramine, 
neither is a substrate for AANATA.  Oleoyl-CoA is competitive inhibitor (Figure 2) vs. 
acetyl-CoA and a pure noncompetitive inhibitor vs. tyramine, with inhibition constants of 78 ± 8 
nM and 150 ± 9 nM respectively.  Tyrosol is uncompetitive vs. acetyl-CoA and competitive vs. 
tyramine, with inhibition constants of 260 ± 10 µM and 302 ± 34 µM, respectively.   
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pH dependence of the initial rates 
 We studied the pH dependence on the kcat,app and (kcat/Km)app for both acetyl-CoA and 
tyramine.  A rising pH profile was observed for both the (kcat/Km)app - acetyl-CoA (Figure 3C) and 
(kcat/Km)app - tyramine  (Figure 3D).   The data for both are best fit using a single pKa,app value, 
yielding a pKa,app value of 7.1 ± 0.2  for the (kcat/Km)app - acetyl-CoA and a pKa,app value  of  7.0 ± 0.3 
for the (kcat/Km)app - tyramine profile.  The kcat,app profile is bell-shaped (Figures 3A and 3B) for 
acetyl-CoA and tyramine, yielding two ionizable groups with the same apparent pKa values, 
consisting of an apparent pKaof 7.0 ± 0.1 and an apparent pKa of 9.8 ± 0.2.   
 
Site-direct mutagenesis of amino acids proposed to function in acid-base catalysis  
 
Our pH rate data indicate that AANATA catalysis involves one species with a pKa,app of 
7.0 and a second species with a pKa,app of 9.8.  The pH rate profile data provide the apparent pKa 
values for the entities involved in catalysis but do not provide definitive information concerning 
the identity of these chemical species.  Identification of these species is critical for a more 
complete understanding of the catalytic mechanism.  One method we used to pinpoint residues 
important for catalysis was the alignment of the primary sequences of known AANAT-like 
(AANATL) enzymes from D. melanogaster (Figure S3).
26
   
The general base in the AANATA catalytic cycle is likely Glu-47, Asp-142, or His-178, 
based on our pH rate data, sequence alignment, and crystal structure (Figure 5).   We mutated 
each of these residues to Ala to further define their respective role in catalysis.  Mutation of Glu-
47 has the greatest effect on catalysis, in that the kcat,app value decreases ~15-fold and the 
(kcat/Km)app decreases 10- to 200-fold relative to wild-type (Table 4).     In addition, the E47A 
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mutant exhibited the same Km,app – acetyl-CoA  value as the wild-type (within experimental error), but 
did show a 10- to 15-fold increase in the Km,app – tyramine.  The D142A and H178A mutants were 
catalytically competent, exhibiting kcat,app values that were 80-170% of the wild-type.  The small 
decreases observed in the (kcat/Km)app values for the D142A and H178A mutants relative to wild-
type resulted largely from increases in the Km,app values for both acetyl-CoA and tyramine (Table 
4).     
The AANATA crystal structure also point towards Tyr-64, Cys-181, Ser-182, or Ser-186 
serving as the general acid (Figure 6) with a pKa,app of 9.8, visible in our pH rate studies.   Each 
of these residues was mutated to an Ala and the kinetic parameters for each mutant were 
determined.  The steady-state kinetic parameters for the C181A mutant are similar to the wild-
type values.   In contrast with the C181A mutant, the Y64A and S186A mutants were 
catalytically deficient, yielding (kcat/Km)app values that were 5-40% of wild-type, the decrease 
mostly came from increases in the Km,app values (Table 4).  Also, we constructed and evaluated 
the S182A/S186A double mutant.  The kinetic parameters for the S182A/S186A were similar to 
those of the single S186A mutant, with the exception of an even higher Km,app - tyramine, such that 
the value increased from 12 M for the wild-type, to 73 M for the S186A mutant, and to 190 
M for the S182A/S186A double mutant (Table 4).   
 
Site-direct mutagenesis of other amino acids conserved between AANATA and other AANAT-like 
enzymes found in Drosophila 
 
Three residues, Pro-48, Arg-153, and His-220, were conserved amongst AANATA and 
the other Drosophila AANATL enzymes (Figure S3) and seem necessary in maintaining the 
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AANATA structure.
37
  Each of these residues was mutated to an Ala in an attempt to 
characterize their function (Figures S4 and S5).   The results are similar for both the P48A and 
H220A mutant enzymes,  including (kcat/Km)app values that are 16- to 830-fold lower than wild-
type resulting from decreases in the kcat,app values (16- to 870-fold lower) and increases in the 
Km,app values for the substrates (4- to 40-fold higher) (Table 4).   Notably, the (kcat /Km)app - tyramine 
for the P48A mutant is 830-fold lower than that of wild-type.  The pattern of results for the 
R153A mutant is different as the (kcat/Km)app value is decreased only 2-5-fold relative to wild-
type.  The outcome for the R153 mutant results from a 5- to 7-fold increase in kcat,app values that 
is balanced against 10- to 24-fold increases in the Km,app values for the acetyl-CoA and tyramine 
substrates, respectively (Table 4). 
 
Salt dependence of the initial rates 
Arg-153 forms a salt bridge with Asp-46 and our evaluation of the R153A mutant 
indicates that the Arg-153/Asp-46 is important in substrate binding and catalysis.  The salt 
dependence of kinetic parameters, if any, could provide additional support for this suggestion.  
We found an increase in the kcat,app and Km,app – acetyl-CoA as the concentration of NaCl added to the 
reaction buffer increased from 0 to 500 mM (0 mM NaCl – Table 1; 100 mM NaCl – 
(kcat,app)acetyl-CoA = 49 ± 1, (Km,app)acetyl-CoA = 89 ± 10; 500 mM NaCl – (kcat,app)acetyl-CoA = 60 ± 1, 
(Km,app)acetyl-CoA = 150 ± 10). 
 
Coenzyme A (CoA-SH) binding to wild-type AANATA and the R153A mutant 
 The increase in kcat,app values for the R153A mutant was unexpected and may be related 
to a decrease in the binding affinity of the AANATA for CoA-SH, one product of the reaction.  
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The equilibrium constant for the dissociation of CoA from the enzymeCoA complex was 
obtained by measuring the quenching of intrinsic protein fluorescence at different CoA-SH 
concentrations for both wild-type AANATA and the R153A mutant.   From these studies, we 
determined that the Kd, wild-type = 400 ± 50 µM and the Kd, R153A = 950 ± 110 µM (Figure 4).   
 
Discussion 
 
Comparison of AANATA and AANATB 
AANATA differs from AANATB by an N-terminal truncation of 35 amino acids.  Both 
variants are physiologically relevant in D. melanogaster, but differences are known in the 
expression patterns for each enzyme with respect to tissue distribution and stages of 
development.
22
   Although the differences in the expression patterns for the two enzymes suggest 
that AANATA and AANATB do not serve the same metabolic role in D. melanogaster, it is not 
known if truncation of AANATA to AANATB has any effect on the catalytic efficiency of the 
enzyme.  A comparison of the kinetic constants for AANATA and AANATB show that the two 
enzymes are catalytically equivalent, at least for the substrates included in our study.  Thus, our 
data provide no clear insight regarding the differential expression of two AANAT variants in 
Drosophila.  Most likely, the presence of AANATA and AANATB is important for differences 
in (a) subcellular localization for the two enzymes, (b) substrate specificities between the two 
enzymes that were not revealed by our work, (c) the modes regulation for the two enzymes, 
and/or (d) the post-translational modification of the two enzymes.  Potential differences in post-
translational modification patterns between AANATA and AANATB could be important 
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because the activity of sheep serotonin N-acetyltransferase is regulated by the phosphorylation of 
Thr/Ser residues located at N-terminal or C-terminal regions of the protein.
38-46
    
 
Substrate specificity and the potential role of AANATA in fatty acid amide biosynthesis  
We have had a longstanding interest in the biosynthesis of the fatty acid amides, a broad 
family of cell signaling lipids.  One straightforward route to the fatty acid amides would be the 
reaction of a biogenic amine with an acyl-CoA, a possibility that has received relatively little 
attention.  The identification of N-acyltransferases that catalyze the acyl-CoA-dependent 
formation of N-fatty acylglycines,
47
 N-fatty acylserotonins,
27
 and N-fatty acyldopamines
27
 means 
that this chemistry should be examined in greater detail.  Fatty acid amides are produced in D. 
melanogaster,
48
 but the enzyme(s) responsible for their production in the fly are largely 
unknown.   There is a single report of an enzyme, arylalkylamine N-acyltransferase like 2 
(AANATL2), that catalyzes the formation of long-chain N-acylserotonins and 
N-acyldopamines.
27
 We undertook a detailed investigation of the substrate specificity of 
AANATA to address this question.   
We first evaluated the substrate specificity for the acyl-CoA thioester substrates.  The 
Km,app –acyl-CoA values were similar for acetyl-CoA through octanoyl-CoA indicating that the 
AANATA active site can effectively bind the straight-chain acyl chain with lengths of 8 carbon 
atoms.  However, the kcat,app decreased ~30-fold as the acyl change length increased from acetyl-
CoA to octanoyl-CoA, with acetyl-CoA being the substrate with the highest (kcat/Km)app value.   
Lengthening the acyl chain to >8 carbon atoms resulted in a dramatic effect on the kinetic 
parameters.  Decanoyl-CoA is a poor substrate relative to the shorter-chain acyl-CoA substrates, 
with a Km,app value of 220 M, >10-fold higher than octanoyl-CoA, and a kcat,app value of 0.04 s
-1
, 
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7-fold lower than octanoyl-CoA.  Lauroyl-CoA and longer-chain acyl-CoA thioesters are not 
AANATA substrates, but are inhibitors of the enzyme, with IC50 values of 0.4 – 1. 0 M.  These 
data show that acetyl-CoA is best positioned for nucleophilic attack by the amino group of 
tyramine within the AANATA active site and that an increase in the length alters the 
arrangement of the two substrates into suboptimal positions, resulting in a decrease in the kcat,app.  
The AANATA active site must have sufficient flexibility to accommodate the lengthening acyl 
chain, up to 8-carbon atoms, and still position the two substrates for chemistry with reasonable 
effectiveness as the (kcat/Km)app for octanoyl-CoA is 3% of the acetyl-CoA value.  The limit of 
active site “tolerance” is an acyl chain of 10 carbon atoms because decanoyl-CoA is a poor 
substrate with a (kcat/Km)app value that is 0.04% of the acetyl-CoA value.  Acyl-CoA thioesters 
with acyl chains longer than 10 carbon atoms bind to AANATA and are not substrates; the long-
chain acyl-CoA thioesters either prevent tyramine binding in a position that allows chemistry to 
occur or actually prevent tyramine from binding.  Thus, the long-chain acyl-CoA thioesters are 
inhibitors of AANATA. 
Amino donors are defined herein as compounds that contain a free amino moiety.  The 
substrate specificity of AANATA was evaluated using a variety of arylalkylamine amino donors 
and these data show that tyramine is the amino donor with the highest (kcat/Km)app value.  The 
kinetic constants for tyramine, with both AANATA and AANATB, were very similar 
(AANATB, Km,app- tyramine = 20 ± 3 M and kcat,app -tyramine = 16 ± 1 s
-1
 compared to the data for 
AANATA in Table 3).  
We evaluated a number of biologically important arylalkylamines as AANATA 
substrates, including tyramine, octopamine, dopamine, tryptamine, norepinephrine, and 
serotonin.  These arylalkylamines are found in vivo and potentially could be found as the amine 
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partner in the fatty acid amide family.  All are respectable AANATA substrates with tyramine 
exhibiting the highest (kcat/Km)app value (at saturating acetyl-CoA) and serotonin the worst, with 
a ratio of (kcat/Km)app,tyramine/(kcat/Km)app,serotonin = 6 (Table 3).  The differences in the kinetic 
parameters amongst this set of biologically relevant arylalkylamines is reflected in the Km,app 
values, whereas the kcat,app values are similar for these amino donor substrates.  Our results for 
the substrate specificity of AANATA with respect to both the acyl-CoA and biologically relevant 
arylalkylamines provide evidence that the fatty acid amides can be produced by the conjugation 
of biogenic amines to an acyl-CoA.  However, AANATA is probably not involved in the in vivo 
biosynthesis of long-chain fatty acid amides because the long-chain fatty acyl-CoA thioesters are 
not substrates.  The major function of AANATA in the cell is likely amine acetylation, a reaction 
important in neurotransmitter inactivation, melatonin biosynthesis, and cuticle sclerotization. 
Our discovery of the AANATA-catalyzed acetylation of 5-methoxytryptamine opens up 
an alternative route for melatonin biosynthesis.  Melatonin is produced from L-tryptophan in a 
series of four steps:  hydroxylation to 5-hydroxytryptophan, decarboxylation to serotonin, 
acetylation to N-acetylserotonin, and methylation to N-acetyl-5-methoxytryptamine 
(melatonin).
49-50
  Our data on the AANATA-catalyzed acetylation of serotonin and 5-
methoxytryptamine, (kcat/Km)app,5-methoxytryptamine/(kcat/Km)app,serotonin ~ 2, show that both of these 
amines are effective AANATA substrates, similar to that reported by Falcon et al.
51
  It seems 
plausible that melatonin biosynthesis could involve either serotonin acetylation followed by 
methylation or serotonin methylation followed by acetylation.  One question is whether 
5-methoxytryptamine is biosynthesized in vivo to allow direct acetylation to melatonin.  
5-Methoxytryptamine was shown to have a time-dependent increase in hamster skin cells upon 
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incubation with serotonin.
52
   Further studies are required to address this possible route to 
melatonin in D. melanogaster. 
 In addition to the biologically relevant amines, a larger group of arylalkylamine 
substrates were analyzed to understand the general structural features of the amino donor 
substrates that affect AANATA binding and/or catalysis.  These include indole and phenyl ring 
modifications, the length of the spacer group between the amino group and the phenyl ring, 
modification of the α- and β-position on the ethylamine spacer group, and other 
non-arylalkylamines that may function as amine substrates.  
The ring-substituted analogs of tyramine included herein are dopamine, phenethylamine,  
3-(trifluoromethyl)phenethylamine, 3-methoxyphenethylamine, 4-methoxyphenethylamine, 
3,4-methylenedioxyphenethylamine, 3,4-methoxyphenethylamine, and 7-methyltrypamine.  All 
are respectable AANATA substrates with kcat,app values that are approximately the same as that 
for tyramine (19 sec
-1
) or higher.  The tyramine analog with the highest kcat,app value of 71 s
-1
 is 
3-(trifluoromethyl)phenethylamine.  However, there is considerable variation in the Km,app values 
amongst the tyramine series, ranging from 12 M for tyramine to 3200 M for 3,4-
dimethoxyphenethylamine (Table 3).   Similar trends were observed in comparing the kinetic 
parameters between tryptamine and the ring-substituted tryptamine analog:  little variation in the 
kcat,app values with greater differences being found for the Km,app values.   
Tyramine and tryptamine exhibit relatively high (kcat/Km)app values allowing us to also 
examine how changes in the spacer group between the amine moiety and the phenyl or indole 
ring affects AANAT catalysis.  First, we determined that the cognate amino acids, tyrosine and 
tryptophan, were neither substrates nor inhibitors of AANATA, as were the results for tyrosine 
methyl ester.  These data demonstrate that the presence of an -carboxylate or -carboxylate 
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ester dramatically decrease AANATA binding affinity, mainly due to steric interference in the 
active site.    In contrast with our data on the effect of -substitution of tyramine, we find that 
modification at the β-position has only a small effect on binding and catalysis as octopamine, 
norepinephrine, and β-methylphenethylamine are all AANATA substrates with (kcat/Km)app 
values that are 20-80% of the value for tyramine.  The relatively minimal effect of β-substitution 
is on binding affinity as all of the β-substituted tyramines have approximately the same kcat,app 
values.  This pattern holds true for the comparison of dopamine to norepinephrine  
(β-hydroxyldopamine), which both have approximately the same Km,app, kcat,app, and (kcat/Km)app 
values.  Also, we interrogated the importance of the spacer length between the amino group and 
the phenyl ring using another set of tyramine analogs.  Decreasing the spacer length from two 
methylene groups to one methylene group yields benzylamine, C6H5-CH2-NH2.  Benzylamine is 
not a substrate.  Increasing the spacer length from two methylene groups to four methylenes 
yields 4-phenylbutylamine, C6H5-(CH2)4-NH2.  4-Phenylbutylamine is a poor AANATA 
substrate, exhibiting a (kcat/Km)app that is 120-fold decreased relative to tyramine, with the largest 
extent of the decrease reflected in a ~20-fold increase in the Km,app (12 M for tyramine vs. 270 
M for 4-phenylbutylamine, Table 3).   Our specificity studies on the amino donor substrates 
again demonstrate that the AANATA active site is flexible, being able to accommodate a variety 
of structures particularly analogs of tyramine or tryptamine, with either a  
β-substitution of the ethylamine moiety or the addition of hydrophobic bulk to the phenyl or 
indole rings.  AANATA is less tolerant of substitution at the -substitution of the ethylamine 
moiety or changing the length of the methylene spacer between the amino group and the ring.  
Substitution at the α-position seems to eliminate binding to AANATA while alternation in the 
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length of space hinders the optimal positioning of amino donor for nucleophilic attack of acetyl-
CoA.  
The availability of recombinant AANATA has afforded us the opportunity to explore the 
specificity of this enzyme for both its acyl-CoA and amine substrates.  The structure-activity 
information obtained from this work will be valuable for the future development of inhibitors 
targeted against the N-acyltransferases, particularly those involved in fatty acid amide 
biosynthesis.  Errors in fatty acid amide metabolism are correlated to human disease
53-56
 and 
considerable effort has been devoted to development of inhibitors for the major enzyme 
responsible for fatty acid amide degradation, fatty acid amide hydrolase (FAAH).
57 
   
 
Kinetic mechanism and inhibitor analysis 
 
An intersecting initial velocity double reciprocal plot indicates that a ternary complex is 
formed prior to catalysis for AANATA.  The dead-end inhibitor patterns for oleoyl-CoA and 
tyrosol point towards an ordered sequential mechanism, with acetyl-CoA binding first, followed 
by tyramine binding to generate the AANATA•acetyl-CoA•tyramine ternary complex before 
catalysis occurs.  An ordered sequential mechanism with acetyl-CoA binding first suggests that 
acetyl-CoA binding drives a conformational change to convert the amine binding pocket from a 
low affinity state to a high affinity state.  Oleoyl-CoA is a known inhibitor of human and sheep 
serotonin N-acetyltransferase and the inhibition is not a detergent-effect of the C18-tail because 
the IC50 for oleic acid is 500-fold higher than that for oleoyl-CoA.
58, 59
  Tyrosol is an analog of 
tyramine, with the amine being replaced with a hydroxyl group.  A rate was not observed for 
tyrosol acetylation at 100 mM, which shows that AANATA will not catalyze the O-acylation of 
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at least this substrate.  Tryptophol, a similar analog of tryptamine, is an inhibitor of sheep 
serotonin N-acetyltransferase and was useful in studies to define the kinetic mechanism of this 
enzyme.
60
   An ordered sequential mechanism for D. melanogaster AANATA is consistent with 
isothermal calorimetry data demonstrating little binding of dopamine to AANATA in the 
absence of acetyl-CoA,
37
 as well as with the kinetic mechanism proposed for sheep serotonin 
N-acetyltransferase.
60
   
 
Site-directed mutagenesis to match catalytic amino acids to the measured pKa,app values  
 
 We employed protein sequence alignments, pH rate studies, site-directed mutagenesis of 
targeted amino acids, and information from the AANATA crystal structure
37
 to propose a 
chemical mechanism for the AANATA-catalyzed formation of N-acylarylalkylamides.  Primary 
sequence alignment of AANATA with other D. melanogaster AANATL enzymes identified a 
number of conserved residues that might function in catalysis.  A primary sequence alignment of 
D. melanogaster AANATA with sheep serotonin N-acetyltransferase, identified a low sequence 
alignment score (< 12%) and the catalytic core of the mammalian ortholog
61-66
 is not conserved 
in the fly enzyme.   Therefore, AANATA could catalyze the formation of the same 
N-acetylarylalkylamide products as the mammalian ortholog with either a completely different 
chemical mechanism, or at minimum, different catalytic amino acid residues. 
Our pH rate studies implicate two chemical species with pKa,app values of 7.0 and 9.8 in 
AANATA catalysis (Figure 3).  The pKa,app value of 7.0 was observed in both the kcat,app and the 
(kcat/Km)app profiles and, most likely, reflects deprotonation by Glu-47.  Evidence consistent with 
the proposal that Glu-47 serves as a general base in the AANAT catalytic cycle includes the 
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conservation of Glu-47 amongst the D. melanogaster family of AANATL enzymes, the catalytic 
deficiency of the E47A mutant, and the disappearance of the pKa,app = 7.0 in the pH rate profile 
of the E47A mutant.  Cheng et al.
36
 report that the log(kcat/Km)app vs. pH profile for the E47A 
mutant is linear, with a slope of 0.3, probably resulting from hydroxide chemically rescuing Glu-
47 as the base in AANATA catalysis.   Furthermore, a Glu residue has been proposed as the 
general base in other GNAT enzymes such as members of the Gcn5/PCAF family of histone 
N-acetyltransferases
67-68
 and human spermidine/spermine N
1
-acetyltransferase.
69-70
   
A pKa,app = 9.8 was only observed in the pH rate profiles for kcat,app indicating that this 
chemical species only contributes to catalysis after the first irreversible step (Figures 3A and 
3B).  We must point out that Ellman’s reagent is unstable and the acyl-CoA substrates are 
subject to rapid base-catalyzed hydrolysis at pH > 9.5.  Since we measure AANAT activity by 
assaying for CoA release using Ellman’s reagent, our pH rate studies are confined to pH values  
9.5.  Thus, the lack of a pKa,app  9.8  in our (kcat/Km)app profiles may reflect our inability to 
conduct measurements at pH > 9.5 and the presence of pKa,app = 9.8 for in the kcat,app profiles is 
based on a fit of our data, all generated at pH  9.5, to equation 9.   Cheng et al.37 extended their 
studies to pH 10 and found a clearly defined pKa,app of 9.0  0.2 in their pH rate profiles for 
(kcat/Km)app.  Experimental differences between our work and that of Cheng et al.
37
 render direct 
comparisons of the respective data sets difficult, but it seems likely that a chemical species with 
a pKa = 9-10 does participate in AANATA catalysis. 
With this in mind, we sought to identify the chemical species that would serve as a 
general acid in AANATA; possibilities include Tyr-64, Cys-181, Ser-182, Tyr-185, or Ser-186 
(Figure 6).  Cys-181 and Tyr-185 were eliminated because the corresponding alanine substitution 
mutants (C181A and Y185A) showed little to no effect on the kcat,app relative to wild-type (Table 
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4 and ref. 36).  Tyr-64 is located within a non-polar binding pocket for the amino donor 
substrate
37
 and comparison of the Y64A mutant to wild-type reveals increases in the Km,app 
values for both substrates (2-fold for acetyl-CoA and 6-fold for tyramine) and only a ~2-fold 
decrease in the kcat,app values (Table 4).   Most likely, Tyr-64 is involved in substrate binding and 
is not the general acid in AANATA catalysis.  Ser-182 and Ser-186 remain as potential general 
acids.  The mutation of both to Ala decreases kcat,app relative to wild-type, 12-fold for the S182A 
mutant and 3- to 5-fold for the S186A mutant (Table 4 and ref. 36).  The pH rate profiles for the 
S182A and S186A mutants are pH independent
37
 at pH  7.0, meaning that the pKa,app of 9.0 is 
not observed for these two mutant enzymes.  Based on these data and the close proximity of both 
Ser-182 and Ser-186 to the acetyl-CoA thiol group, 4.0 Å and 4.1 Å respectively (Figure 7), it is 
conceivable that either Ser-182 or Ser-186 is the general acid in AANATA catalysis.  In fact, 
Cheng et al.
37
 argue that Ser-186 is the general acid, functioning to protonate the departing 
thiolate anion of CoA to complete the catalytic cycle.  An argument could be made that Ser-182 
and Ser-186 serve redundant roles in catalysis where one of these serines is the general acid, 
whereas the other serine serves to depress the pKa of the catalytic serine.  In the absence of the 
catalytic serine, the other serine could chemically “rescue” the function of the other serine.   
We do not favor either Ser-182 or Ser-186 as the general acid in AANATA catalysis.  
This would require a significant depression of 3-5 pH units in the pKa for Ser-182 or Ser-186 
plus we would expect the S182A/S186A double mutant to be dramatically impaired as a catalyst 
relative to either the S182A or S186A single mutant.   Instead, we find that the S182A/S186A 
double mutant exhibits a kcat,app similar to the S186A mutant; the largest difference in the 
S182A/S186A is an increased Km,app for tyramine.  A tyrosine serves as the general acid for other 
GNAT enzymes, but the mutation studies eliminate the two active tyrosine residues, Tyr-64 and 
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Tyr-185, as possibilities.  There are no other obvious candidate amino acids to serve as a general 
acid within the acetyl-CoA binding pocket.
37
   
We propose that the pKa,app of 9.8 in our pH rate profiles (and the pKa,app of 9.0 from 
Cheng et al.
37
) represents the pKa of the thiol group of CoA, which has been reported to range 
from 9.6-10.4.
71-72
   Formation of the protonated CoA-SH product results from the collapse of the 
tetrahedral intermediate (Scheme 1), as proposed for other N-acyltransferases.
73-75
  The 
deprotonation of CoA-SH to CoA-S
-
, in the AANATA active site, inhibits product release, 
accounting for the decrease of kcat,app at pH > 9.  This was likely not observed in the (kcat/Km)app 
profiles because of either the difficulty in measuring the kinetic constants at high pH (instability 
of DTNB and/or the rapid hydrolysis of acetyl-CoA) or the protonation of CoA-S
-
 occurs after 
the first irreversible step in catalysis.  Our suggestion obviates the need for an active site residue 
that serves as the general acid and is consistent with the data available for AANATA.   
 
Site-directed mutagenesis of amino acids important in substrate binding and AANAT structure 
As detailed previously, we mutated a number of amino acids in AANATA in an attempt 
to match an active site amino acid to the pKa,app values identified in the pH rate profiles.   The set 
of AANATA mutants that we produced also provide information regarding the amino acids 
involved in substrate binding and, point towards structural changes in the protein.   In silico 
docking of dopamine into the AANATA structure with acetyl-CoA bound suggests that the 
amino donor substrate binds into a hydrophobic binding pocket containing Phe-43, Leu-61, Tyr-
64, Ile-116, and Ile-145.
37
  Our results are consistent with the docking results as the Km,app – 
tyramine values for the E47A, P48A, and Y64A mutants are >6-fold higher than the wild-type 
(Table 4).   The Km,app – tyramine values for H220A and S186A single mutants also are 6-fold 
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higher than wild-type, indicating that these amino acids contribute to the binding of the amino 
donor substrate.  Of the mutants with a 6-fold increase in the Km,app – tyramine value relative to the 
wild-type value, only the E47A and S186A mutants shown no difference in the Km,app – acetyl-CoA, 
indicating that Glu-47 and Ser-186 contribute little to acetyl-CoA binding.   The Km,app – tyramine 
value for the S182A/S186A double mutant is significantly higher than wild-type (190 M vs. 12 
M), suggesting that Ser-182 and Ser-186 function synergistically in maintaining the proper 
active site architecture for optimal binding to the amino donor substrate.  The binding pocket for 
acetyl-CoA is more extensive than the pocket for the amino donor substrate and includes the 
amino acids involved in catalysis.   
There are amino acids uniquely involved in acetyl-CoA binding, which there is a change 
of only the value for the Km,app – acetyl-CoA upon mutation.  This was observed for the D142A and 
H178A mutants:  Km,app – tyramine values that are approximately the same as wild-type and Km,app – 
acetyl-CoA values that are 2- to 3-fold higher than wild-type.  Both the Km,app – tyramine and Km,app – 
acetyl-CoA values for the P48A, Y64A, R153A, and H220A mutants are all different from and 
greater than the wild-type values (Table 4).  These amino acids are either involved in domains 
within AANATA that overlap between the acetyl-CoA and amino donor binding pockets or are 
key to maintaining the AANATA structure in a conformation that is optimal for substrate 
binding.  Overlap between the binding sites for the two substrates is expected because the 
binding pocket for acetyl-CoA is more extensive than the pocket for the amino donor substrate
36
 
and should include the amino acids that are required to position the amino group of the amino 
donor for nucleophilic attack at the carbonyl of the acetyl-CoA thioester moiety.  In addition, the 
synergistic effect of acetyl-CoA binding to convert the amine binding pocket from a low affinity 
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state to a high affinity state means that specific amino acids important for acetyl-CoA binding 
can also have a dramatic effect on amine binding. 
In comparing the kinetic constants of our mutants to wild-type AANATA (Table 4), we 
find that three of our mutants stand out:  E47A, P48A, and R153A.  We argue that Glu-47 is the 
catalytic base and find, as anticipated, that E47A is catalytically deficient with relatively low 
kcat,app values.  The AANATA structure containing bound acetyl-CoA
37
 reveals a set of ordered 
water molecules between the carboxylate of Glu-47 and the carbonyl of the acetyl-CoA thioester.  
The distance from the carboxyl of Glu-47 to the carbonyl of the acetyl-CoA thioester is 6.8 Å.   
We suggest that Glu-47 functions as a general base to enable the water-assisted deprotonation of 
the positively charged amino group of the donor substrate (a “proton wire”) and to properly 
position the neutral amine for attack at the carbonyl of the acetyl-CoA thioester (Scheme 1).  
Elimination of the anionic carboxylate of Glu-47 by mutation to Ala would alter the positions of 
the ordered water molecules (perhaps, even resulting in their loss) and would decrease the 
affinity for only the amino donor substrate, as found for the E47A mutant.   
Pro-48 is found at the beginning of a flexible loop and is positioned within the predicted 
binding pocket for the amine donor substrate (Figure S6).   We superimposed the AANATA 
crystal structure (PDB code: 3TE4)
37
 with sheep serotonin N-acetyltransferase (PDB code: 
1CJW)
61
 using Protein Binding Site Tools (ProBiS Tools) and found that Pro-48 from D. 
melanogaster AANATA is equivalent to Pro-64 from sheep serotonin N-acetyltransferase.  In 
sheep serotonin N-acetyltransferase,  Pro-64 is also positioned on a flexible loop that undergoes a 
major structural change to alter the amino donor substrate binding pocket from a low to high 
affinity state.
76-77
  In the low affinity state, Pro-64 occupies the acetyl-CoA binding pocket, 
whereas in the high affinity state, Pro-64 moves ~8 Å to form a base-staking interaction with the 
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tryptamine moiety of the tryptamine-acetyl-CoA bisubstrate inhibitor co-crystallized with the 
sheep enzyme.   Our data for the P48A mutant, low kcat,app and high Km,app – tyramine and Km,app – 
acetyl-CoA values, suggest that Pro-48 in AANATA functions similarly to Pro-64 in sheep serotonin 
N-acetyltransferase and further hints that protein dynamics could regulate catalysis for 
AANATA.   His-220 is in van der Waals contact with Pro-48 in AANATA (Figure 8).  
Replacement of His-220 with Ala will alter this interaction and, similar to the data for the P48A 
mutant, would lead to the observed increases in the Km,app – tyramine and Km,app – acetyl-CoA values for 
the H220A mutant.  
The R153A mutant is intriguing, with higher values than wild-type values for kcat,app, 
Km,app – tyramine, and Km,app – acetyl-CoA.  The ~6-fold increase in kcat,app is balanced against 10- to 20-
fold increases in the Km,app values, such that the (kcat/Km)app value for the R153A mutant is lower 
than wild-type by 40-80%.  As revealed from the AANATA structure with acetyl-CoA bound,
37
 
Arg-153 participates in a water-mediated hydrogen bond with the carbonyl amide of the 
pantothenate moiety (Atom: O9P) of acetyl-CoA and in a salt-bridge to Asp-46 (Figure 9).  The 
increase in the Km,app values for both substrates suggests that Arg-153 is not only critical in 
acetyl-CoA binding pocket, but also in forming the binding pocket for the amine substrate.  The 
increase in the kcat,app value suggest that Arg-153 contributes to a rate-determining step in 
catalysis, related to the salt-bridge between Arg-153 and Asp-46.  We suspect that the Arg-
153/Asp-46 salt bridge is critical to an AANATA conformation that decreases the rate of CoA-
SH release, such that product release is, at least, partially rate limiting.  Partially rate-determining 
CoA-SH release has been identified in many other N-acetyltransferases.
20, 66, 78-79
  Elimination of 
the Arg-153/Asp-46 salt bridge in the R153A increases the rate of CoA-SH release, reflected in 
the increase in kcat,app, but decreases the affinity of AANATA for both substrates, reflected in the 
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increases in the Km,app values.  Another approach to decrease the influence of the Arg-153/Asp-
46 salt bridge on the rate of CoA-SH release would be to increase the salt concentration in the 
reaction buffer.  Our prediction being that that a greater salt concentration would mimic the 
pattern of results we obtained for the R153A mutant, which is exactly what we found.  The 
values for the kcat,app and Km,app - acetyl-CoA increased as the concentration of added NaCl increased 
from 0 to 500 mM.  Similar data were obtained for sheep serotonin N-acetyltransferase,
25
 which 
was argued to increase the rate of CoA-SH release by shielding charge-charge interactions of the 
enzyme with the anionic phosphates of acetyl-CoA. Also, we determined the Kd for CoA-SH 
binding to both wild-type AANATA and the R153A mutant by measuring the quenching of 
intrinsic protein fluorescence as a function of [CoA-SH], the Kd, wild-type = 400 ± 50 µM and Kd, 
R153A = 950 ± 110 µM (Figure 4).  The 2.4-fold decrease in affinity for the binding of CoA-SH to 
the R153A mutant is in reasonable agreement with the (kcat,app)wild-type/(kcat,app)R153A ratio of 5-6 
(Table 4).  The salt dependent increase in both the kcat,app and Km,app – acetyl-CoA and the increase in 
Kd for CoA-SH for the R153A mutant provide evidence that the salt bridge between Arg-
153/Asp-46  is important in decreasing the rate of CoA-SH release from wild-type AANATA.   
Similar to our data for the P48A mutant, our data for the R153A mutant point towards protein 
dynamics regulating catalysis for AANATA. 
 
Chemical mechanism for AANATA catalysis 
A chemical mechanism for the catalytic cycle for AANATA, consistent with our new 
data and previously published data,
21, 37
 is illustrated in Scheme 1.  The mechanism features (a) 
chemistry occurring after the formation of the AANATA•acetyl-CoA•tyramine complex, (b) 
Glu-47 serving as a general base to facilitate water-assisted deprotonation of tyramine, (c)  
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nucleophilic attack of deprotonated tyramine at the carbonyl of the acetyl-CoA thioester to form 
a zwitterionic tetrahedral intermediate, (d) collapse of the tetrahedral intermediate with the 
concomitant protonation of CoA, and (e) ordered product release with CoA-SH departing last to 
regenerate AANATA for the next round of catalysis.    Our only evidence for the ordered product 
release is the data showing that CoA-SH binds to AANATA in the absence of N-acetyltyramine 
(Figure 7) and is consistent with the ordered binding of substrates, acetyl-CoA binding first.  The 
release of CoA-SH is partially-rate determining resulting from AANATA conformation that has 
relatively high affinity for CoA-SH.  The Arg-153/Asp-46 salt bridge is critical to maintaining 
AANATA in this conformation and the affinity for CoA-SH increases as the  
CoA-S
-
 thiolate forms at higher pH. 
One issue remaining with this mechanism is the roles played by Ser-182 and Ser-186 in 
catalysis, given that Ser-186 was proposed to serve as the general acid in AANATA catalysis.
37
   
A preponderance of the data for the S182A, S186A, and S182A/S186A mutants seem to rule out 
a direct catalytic role for both Ser-182 and Ser-186, plus proton transfer from a serine hydroxyl 
to a thiol is thermodynamically unfavorable.  Instead, we suggest that Ser-182 and Ser-186 are 
involved in an elaborate network of hydrogen bonds that function in both substrate binding and 
catalysis (Figure 5).  Mutation of Ser-182 and/or Ser-186 to alanine alters the hydrogen-bonding 
network, changing the active site architecture.  This alteration of the active site is reflected in the 
changes observed in the kcat,app and Km,app values for the S182A, S186A, and S182A/S186A 
mutants.     
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Conclusions 
We identified that D. melanogaster AANATA will catalyze the formation of 
N-acylarylalkylamides from a broad array of corresponding acyl-CoA and arylalkylamine 
substrates.  These data validate the potential role of N-acyltransferases in fatty acid amide 
biosynthesis and provide structure-activity data for the future development of inhibitors to this 
class of enzymes.  A chemical mechanism for AANATA, consistent with all the data available 
for this enzyme,
21, 37
 is illustrated in Scheme 1.  Substrate binding is sequential ordered with 
acetyl-CoA binding first, meaning that that catalysis only occurs after the formation of a 
AANAT•acetyl-CoA•arylalkylamine ternary complex.  We identified Glu-47 as the general base 
involved in the water-assisted deprotonation of the positively charged amino group of the donor 
substrate via an active site “proton wire”.  The deprotonation of a species with a pKa,app of 9.8 
was attributed to the formation of the tightly bound CoA thiolate.    Finally, our mutagenesis data 
suggest that protein dynamics regulate substrate binding and catalysis in AANATA.  The active 
site amino acids, Asp-46, Pro-48, Arg-153, and His-220, seem critical to the regulatory dynamics 
of the enzyme. 
 
Acknowledgments 
Support for this work has been provided by Mass Spectrometry and Peptide Facility, Department 
of Chemistry, University of South Florida.   The authors thank Elisabeth Nevins Caswell for a 
thorough reading and revision of the manuscript. 
 
  
184 
 
Supporting Information 
The supporting information section contains three tables and six figures.  The three tables consist 
of mutant PCR primers, LC/QTOF-MS data for product characterization, and a list of arginines 
found in other GNAT enzymes that are conserved with Arg-153.  The six figures consist of 
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Table 1. 
Steady-state kinetic constants for AANATA and AANATB with different acyl-CoAs. 
AANATA
a,b 
Substrate
c
 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
Relative (kcat/Km)app 
Benzoyl-CoA 65 ± 13 0.37 ± 0.03 (5.7 ± 1.2) × 10
3
 1.0 ± 0.3  
Acetyl-CoA 39 ± 12  16 ± 1  (4.1 ± 1.3) × 10
5
 72 ± 27  
Butyryl-CoA 36 ± 2  9.9 ± 0.4  (2.8 ± 0.2) × 10
5
 49 ± 11  
Hexanoyl-CoA 23 ± 3  1.6 ± 0.1  (6.8 ± 0.9) × 10
4
 12 ± 3  
Octanoyl-CoA 18 ± 3 0.26 ± 0.01 (1.4 ± 0.2) × 10
4
 2.5 ± 0.6 
Decanoyl-CoA 220 ± 60 0.04 ± 0.01  (1.7 ± 0.5) × 10
2
 0.04 ± 0.01 
AANATB
d 
Benzoyl-CoA 80 ± 6 0.12 ± 0.04 (1.6 ± 0.5) × 10
3
 1.0 ± 0.4 
Acetyl-CoA 64 ± 9  8.3 ± 0.4  (1.3 ± 0.2) × 10
5
 81 ± 31 
Butyryl-CoA 19 ± 3  4.4 ± 0.2  (2.3 ± 0.3) × 10
5
 150 ± 55  
Hexanoyl-CoA 23 ± 6  0.88 ± 0.04  (3.8 ± 1.0) × 10
4
 25 ± 10 
a
Relative (kcat/Km)app values for AANATA amino acceptor substrates were indexed to benzoyl-CoA. 
b
Kinetic constants are reported as ± standard error (n = 3). 
c
Reaction condition – 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 1.0 mM tyramine, and varying 
concentration of acyl-CoA. 
d
Relative (kcat/Km)app value for AANATB amino acceptor substrates were indexed to benzoyl-CoA. 
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Table 2. 
AANATA IC50 values for long-chain acyl-CoAs 
Inhibitor
a,b
 Carbon Skeleton 
IC50 
(nM) 
Oleoyl-CoA  18:1 (9)  380 ± 5  
Palmitoleoyl-CoA  16:1 (9)  430 ± 40 
Myristoyl-CoA  14:0  580 ± 70 
Lauroyl-CoA  12:0  1100 ± 130 
a
Reaction was fixed at the Km,app values for both acetyl-CoA (39 µM) and tyramine (12 µM) while varying 
the concentration of the long-chain acyl-CoA inhibitor. 
b
Kinetic constants are reported as ± standard error (n = 3). 
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Table 3. 
AANATA steady-state kinetic constants for different arylalkylamines 
Substrate
a,b
 Structure 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
Tyramine 
 
12 ± 1  19 ± 1  (1.6 ± 0.2) × 10
6
 
5-Benzyloxytryptamine 
 
18 ± 3  27 ± 2  (1.5 ± 0.3) × 10
6
 
Octopamine 
 
10 ± 2  13 ± 1  (1.3 ± 0.3) × 10
6
 
Dopamine 
 
25 ± 2  17.6 ± 0.4  (7.0 ± 0.4) × 10
5
 
Tryptamine 
 
33 ± 3  22 ± 1  (6.5 ± 0.7) × 10
5
 
3-(Trifluoromethyl)phenethylamine 
 
110 ± 10  71 ± 3  (6.5 ± 0.8) × 10
5
 
5-Methoxytyrptamine 
 
54 ± 6  35 ± 1  (6.4 ± 0.7) × 10
5
 
Norepinephrine 
 
32 ± 6  20 ± 1  (6 ± 1) × 10
5
 
Phenethylamine 
 
56 ± 13  30 ± 3  (5 ± 1) × 10
5
 
-Methylphenethylamine 
 
47 ± 11  15 ± 1  (3.2 ± 0.8) × 10
5
 
3-Methoxyphenethylamine 
 
120 ± 30  38 ± 4  (3.2 ± 0.9) × 10
5
 
Serotonin 
 
110 ± 8  29.7 ± 0.7  (2.7 ± 0.2) × 10
5
 
7-Methyltryptamine 
 
130 ± 9  21.2 ± 0.4  (1.6 ± 0.1) × 10
5
 
3,4-Methylenedioxyphenethylamine 
 
340 + 10  26 + 1  (7.8 ± 0.4) × 10
4
 
4-Methoxyphenethylamine 
 
780 ± 60  41 ± 1  (5.2 ± 0.4) × 10
4
 
4-Phenylbutylamine 
 
270 ± 20  3.7 + 0.1  (1.4 ± 0.1) × 10
4
 
3,4-Dimethoxyphenethylamine 
 
3200 ± 300  30 ± 1  (10 ± 1) × 10
3
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a
Reaction condition – 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 500 µM acetyl-CoA, and varying 
concentration of arylalkylamine. 
b
Kinetic constants are reported as ± standard error (n = 3). 
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Table 4. 
Steady-state kinetic constants for AANATA site-directed mutants. 
Mutant
a,b
 
Acetyl-CoA 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
           
 
    
  
              
     
% 
Wild-type 39 ± 12  16 ± 1 (4.1 ± 1.3) × 10
5
 100 
E47A 32 ± 3  1.26 ± 0.04 (3.9 ± 0.6) × 10
4
 9.5 
P48A 190 ± 10 1.4 ± 0.1 (7.3 ± 0.5) × 10
3 
1.8 
Y64A 81 ± 5 8.6 ± 0.2 (1.1 ± 0.1) × 10
5 
27 
D142A 80 ± 6 27.5 ± 0.6 (3.4 ± 0.3) × 10
5 
83 
R153A 430 ± 60 106 ± 6 (2.5 ± 0.4) × 10
5 
61 
H178A 120 ± 7 17.9 ± 0.4 (1.5 ± 0.1) × 10
5 
37 
C181A 26 ± 1 19.1 ± 0.2 (7.3 ± 0.3) × 10
5 
178 
S186A 29 ± 5  5.0 ± 0.3 (1.7 ± 0.3) × 10
5
 41 
S182A/S186A 43 ± 4 8.9 ± 0.3 (2.1 ± 0.2) × 10
5 
51 
H220A 160 ± 20  4.2 ± 0.2 (2.6 ± 0.3) × 10
4
 6.3 
Mutant
a,c
 
Tyramine 
Km, app 
(µM) 
kcat, app 
(s
-1
) 
(kcat/Km)app 
(M
-1
s
-1
) 
 
    
  
           
 
    
  
              
     
% 
Wild-type 12 ± 1 19 ± 1 (1.6 ± 0.2) × 10
6
 100 
E47A 160 ± 50  1.0 ± 0.1 (6 ± 2) × 10
3
 0.38 
P48A 470 ± 50 0.86 ± 0.04 (1.84 ± 0.2) x 10
3 
0.12 
Y64A 87 ± 17 8.8 ± 0.4 (1.0 ± 0.2) × 10
5 
6.3 
D142A 17 ± 1 25 ± 1 (1.5 ± 0.1) × 10
6 
94 
R153A 290 ± 20 98 ± 2 (3.4 ± 0.3) × 10
5 
21 
H178A 25 ± 3 14.7 ± 0.5 (5.9 ± 0.8) × 10
5 
37 
C181A 17 ± 2 22 ± 1 (1.3 ± 0.1) × 10
6 
81 
S186A 73 ± 12  5.0 ± 0.1 (6.9 ± 0.6) × 10
4
 4.3 
S182A/S186A 190 ± 20 8.3 ± 0.2 (4.3 ± 0.3) x 10
4
 2.7 
H220A 82 ± 9 4.1 ± 0.2 (4.9 ± 0.6) × 10
4
 3.1 
a
Kinetic constants are reported as ± standard error (n = 3). 
b
The reaction rate was measured at a fixed saturating concentration of tyramine while varying the 
concentration of acetyl-CoA. 
c
The reaction rate was measured at a fixed saturating concentration of acetyl-CoA while varying the 
concentration of tyramine. 
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Figure Legends 
 
Figure 1. Double reciprocal plot of initial velocities for acetyl-CoA and tyramine.  (A) Velocities 
measured at a fixed concentration of tyramine: 50 µM (●), 25 µM (o), 10 µM (▼), 5 µM (Δ).   
(B) Velocities measured at a fixed concentration of acetyl-CoA: 100 µM (●), 60 µM (o), 40 µM (▼),  
20 µM (Δ). 
 
Figure 2.  Dead-end inhibition analysis of AANATA. (A) Velocities measured at a fixed concentration of 
tyramine (12 µM), varying the concentration of acetyl-CoA, and varying the concentration of the 
inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 375 nM (▼); Ki = 78 ± 8 nM.  (B) Velocities measured at a 
fixed concentration of acetyl-CoA (39 µM), varying the concentration of tyramine, and varying the 
concentration of the inhibitor, oleoyl-CoA: 0 nM (●), 200 nM (o), 375 nM (▼); Ki = 150 ± 7 nM. (C) 
Velocities measured at a fixed concentration of tyramine (12 µM), varying the concentration of 
acetyl-CoA, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 100 µM (o), 580 µM (▼); 
Ki = 260 ± 10 µM.  (D) Velocities measured at a fixed concentration of acetyl-CoA (39 µM), varying the 
concentration of tyramine, and varying the concentration of the inhibitor, tyrosol: 0 µM (●), 100 µM (o), 
580 µM (▼); Ki = 302 ± 34 µM.   
 
Figure 3. AANATA pH rate profile. (A) kcat,app-acetyl-CoA. (B) kcat,app-tyramine. (C) (kcat/Km)app-acetyl-CoA. (D) 
(kcat/Km)app-tyramine. 
 
Figure 4. (A). Determination of the coenzyme A dissociation constant by fluorescence titration for 
wild-type enzyme. (B) Determination of the coenzyme A dissociation constant by fluorescence titration 
for R153A mutant. 
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Figure 5. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA identifying the possible 
general base residues.  Stick model showing the proximity of Glu-47, His-178, and Asp-142 to 
acetyl-CoA.  Red circles represent water molecules.  
 
Figure 6. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA bound identifying the 
possible general acid residues.  Stick model showing the proximity of Tyr-64, Cys-181, Ser-182, Ser-183, 
and Ser-186 to acetyl-CoA.  Red circles represent water molecules. 
 
Figure 7. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA showing a possible 
“proton wire” involving the general base, Glu-47. 
 
Figure 8. Crystal structure of D. melanogaster AANATA depicting structural importance of His220. 
CPK schematic of His-220 found in AANATA along with secondary structure highlighting van der Waals 
interactions between H220:Y185 and H220:P48.    
 
Figure 9. Crystal structure of D. melanogaster AANATA with bound acetyl-CoA depicting the 
Asp-46/Arg-153 salt bridge.  Stick model showing the proximity of Asp-46 and Arg-153 to acetyl-CoA.  
Red circles represent water molecules. 
 
Scheme Legend 
 
Scheme 1. Proposed chemical mechanism for D. melanogaster AANATA.  R = different acyl chain 
length for acyl-CoA.  The dashed arrows represent ambiguities in the position of the irreversible step due 
to differences between the pH rate profiles reported herein and those by Cheng et al.
37
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Supporting Information 
Table S1. 
Site-directed Mutagenesis Primers 
Mutant 
Forward or 
Reverse Primer 
Primer Sequence 
E47A 
Forward CTT TTT CTT CAA GGA TGC ACC GCT GAA CAC CTT CC 
Reverse GGA AGG TGT TCA GCG GTG CAT CCT TGA AGA AAA 
AG 
P48A 
Forward AGG TGT TCA GCG CTT CAT CCT TGA AGA AAA AGG 
TCT 
Reverse AGA CCT TTT TCT TCA AGG ATG AAG CGC TGA ACA 
CCT 
Y64A 
Forward GAA GCG GTT TCA GGG AGG CCT TCT CCA GCT CCT 
TGC 
Reverse GCA AGG AGC TGG AGA AGG CCT CCC TGA AAC CGC 
TTC 
D142A 
Forward ACA GGA TCT TGC CGG CCA GGA TGA GCT CC 
Reverse GGA GCT CAT CCT GGC CGG CAA GAT CCT GT 
R153A 
Forward GTG GAC ACC AAC TAC GCG GGC CTG GGC A 
Reverse TGC CCA GGC CCG CGT AGT TGG TGT CCA C 
H178A 
Forward GGC TGG AAC AGA GAA CGG CGT ACA CAT TGA TGC 
CGT 
Reverse ACG GCA TCA ATG TGT ACG CCG TTC TCT GTT CCA 
GCC 
C181A 
Forward ATG TGT ACC ACG TTC TCG CTT CCA GCC ACT ACT CCG 
Reverse CGG AGT AGT GGC TGG AAG CGA GAA CGT GGT ACA 
S186A 
Forward CCA GCC ACT ACG CCG CCC GGG TG 
Reverse CAC CCG GGC GGC GTA GTG GCT GG 
S182A/S186A 
Forward TCA ATG TGT ACC ACG TTC TCT GTG CCA GCC ACT 
ACG 
Reverse CGT AGT GGC TGG CAC AGA GAA CGT GGT ACA 
H220A 
Forward CCG GCG GCC CCG GCC GTA GGC ATC CA 
Reverse TGG ATG CCT ACG GCC GGG GCC GCC GG 
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Table S2. 
AANATA product characterization. 
Sample 
Retention Time 
(min) 
Mass/Charge 
[M + H] (m/z) 
N-acetylserotonin Standard 0.78 219.1132  
AANAT A Enzyme Assay
 a
 0.78  219.1133 
a
 Reaction condition – 300 mM Tris-HCl pH 8.0, 500 µM acetyl-CoA, 1 mM serotonin, 15 µg AANATA. 
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Table S3. 
Conserved D. melanogaster AANATA Arg153 Found in other GNAT Enzymes 
Organism Enzyme 
PDB Data Base ID for 
Crystal Structure 
Conserved Arginine 
Drosophila AANATA 3TE4 R153 
Sheep SNAT 1CJW R131 
Human SSAT 2JEV R101 
Tuberculosis AgNAT 1M4G R91 
Yeast HAT (Hpa2) 1QSM R100 
Human NMT 3JTK R255 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
215 
 
 
 
 
Figure S1. Cloning of AANATA and AANATB from D. melanogaster.  (Lane 1) 1 kb DNA ladder (New 
England Biolabs), (Lane 2) AANATB; 828 bp band, (Lane 3) AANATA; 723 bp band. 
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Figure S2.  SDS-PAGE gel for purified AANATA and AANATB.  (Lane 1) Precision Plus Protein™ 
Kaleidoscope™ Standards (Biorad), (Lane 2) AANATA; 27 kDa, (Lane 3) AANATB; 31 kDa. 
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Figure S3.  Primary sequence alignment of AANATA with putative AANATL enzymes found in D. 
melanogaster using clustalW2. 
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Figure S4. SDS-PAGE gel of purified AANATA mutants.  (Lane 1) PageRuler™ Prestained protein 
ladder (Thermo Scientific), (Lane 2) E47A, (Lane 3) R153A, (Lane 4) S186A, (Lane 5) H220A.  
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Figure S5. SDS-PAGE gel of purified AANATA mutants.  (Lane 1) PageRuler™ Prestained protein 
ladder (Thermo Scientific), (Lane 2) P48A, (Lane 3) Y64A, (Lane 4) D142A, (Lane 5) H178A, (Lane 5) 
C181A, (Lane 5) S182A/S186A.  
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Figure S6.  D. melanogaster AANATA Pro-48 (PDB: 3TE4) showing general location with respect to 
amine binding pocket and bound actey-CoA. 
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Abstract 
Arylalkylamine N-acyltransferase-like 2
2
 (AANATL2) from Drosophila melanogaster 
was expressed and shown to catalyze the formation of long-chain N-acylserotonins and  
N-acydopamines.  Subsequent identification of endogenous amounts of N-acylserotonins and 
colocalization of these fatty acid amides and AANATL2 transcripts gives supporting evidence that 
AANATL2 has a role in the biosynthetic formation of these important cell signalling lipids. 
 
 
 
Keywords: Arylalkylamine N-acyltransferase; Arylalkylamine N-acetyltransferase;  
N-acyldopamines; N-acylserotonins; Drosophila melanogaster; thorax-abdomen; steady-state 
kinetics 
 
 
Abbreviations: AANATL2, arylalkylamine N-acyltransferase like 2; FAAH, fatty acid amino 
hydrolase; ATP, adenosine triphosphate; AANAT, arylalkyamine N-acetyltransferase;  
D. melanogaster, Drosophila melanogaster; E. coli, Escherichia coli; SDS-PAGE, sodium 
dodecyl sulfate polyacrylamide gel electrophoresis; 5,5’-dithiobis(2-nitrobenzoic acid), DTNB; 
RT-PCR, reverse transcription polymerase chain reaction; LC/QTOF-MS, liquid 
chromatography/quadrupole time-of-flight mass spectrometry  
 
2
The authors recommend the change of arylalkylamine N-acetyltransferase to arylalkylamine 
N-acyltransferase due to the discovery of acyl-CoA substrates longer than C2 (acetyl). 
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1. Introduction 
Fatty acid amides are an emerging class of cell signalling lipids. This family of bioactive 
amides consists of N-acyl amino acids, N-acylarylalkylamines, N-acylethanolamines, 
N-monoacylpolyamines, and primary fatty acid amides. The N-acylarylalkylamines can be 
subdivided into two groups called the N-acyldopamines and the N-acylserotonins. With the 
exception of the N-acylethanolamines, the biosynthetic routes to these long-chain fatty acids 
amides in vivo is largely unknown [1-2]. 
The N-acylserotonins were originally synthesized as inhibitors of fatty acid amino 
hydrolase (FAAH), the primary focus being N-arachidonoylserotonin with an IC50 = 12 µM [3].  
Following this discovery, N-arachidonoylserotonin was shown to act as a vanilloid TRPV1 
receptor antagonist [4], as an inhibitor of soybean lipoxygenase [5],  as a regulator for gastric 
emptying [6], and also exhibited  analgesic, anxiolytic, and anti-allergic activity in various model 
systems [4,7-8]. The biological roles for the other known long-chain N-acylserotonins have yet 
to be determined.  Recently, Verhoeckx et al. [9] identified and quantified the endogenous 
amounts of long-chain N-acylserotonins in the different regions of the porcine gastrointestinal 
tract, including the ileum.  Like the N-acylserotonins, activities have been ascribed to the  
N-acyldopamines, as the N-acyldopamines regulate pain perception, body temperature, and 
locomotion in mammals [10-13].  Little is known about the in vivo production of the  
N-acylserotonins and N-acyldopamines except for data showing that these could be produced by 
the direct conjugation of serotonin or dopamine to a fatty acid [9,14]. One set of biosynthetic 
reactions consistent with these data would be the initial formation of the acyl-CoA in a reaction 
requiring ATP, followed by a reaction between the resulting acyl-CoA and serotonin or 
dopamine to form the long-chain N-acylarylalkylamide (Fig. 1). Acyl-CoA formation is 
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catalyzed by an acyl-CoA synthetase, a known enzyme [15], while the enzyme catalyzing the 
second reaction is reported here for the first time.  This chemistry is consistent with reactions 
catalyzed by the arylalkylamine N-acetyltransferases (AANATs) and other enzymes of the 
GCN5-related N-acetyltransferase (GNAT) family enzymes [16-18]. 
AANATs from a number of organisms have been shown to catalyze the production of 
different N-acetylarylalkylamines like N-acetyldopamine and N-acetylserotonin [16-18].  Other 
than a single report that propionyl-CoA and butyryl-CoA are relatively poor substrates for 
human serotonin N-acetyltransferase [19], it has not been determined if the known AANATs will 
utilize long-chain acyl-CoA thioesters as substrates to generate the corresponding long chain 
N-acylarylalkylamides [19]. Eight putative arylalkylamine N-acetyltransferase-like (AANATL) 
enzymes [20] were identified in Drosophila melanogaster and we hypothesized that one of these 
enzymes would have a role in the formation of the long-chain N-acylserotonins.  
Herein, we provide evidence that AANATL2, an AANATL enzyme from  
D. melanogaster (CG9486), will catalyze the formation of long-chain N-acylserotonins. We 
further define the expression of AANATL2 transcripts in different anatomical regions of the flies 
and find measureable levels of the endogenous N-acylserotonins in regions that overlap with the 
expression of the AANATL2 transcripts.  While the N-acylserotonins are the major focus of this 
report, we also demonstrate that arylalkylamines other than serotonin are AANATL2 substrates, 
including dopamine, octopamine, and tyramine.  These data suggest that AANATL2 could serve 
broadly in the cellular production of numerous different N-acylarylalkylamides. 
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2. Materials and Methods 
2.1. Materials 
Codon optimized AANATL2 was purchased from Genscript.  Oligonucleotides were 
purchased from Eurofins MWG Operon.  BL21(DE3) Escherichia coli  competent cells and 
pET-28a(+) vector were purchased from Novagen. Probond™ nickel-chelating resin, Ambion 
MicroPoly(A) Purist, and Ambion Retroscript kit were purchased from Invitrogen.  NdeI, XhoI, 
Antarctic Phosphatase, and T4 DNA ligase were purchased from New England Biolabs. 
Ampicillin sodium salt and IPTG were purchased from Gold Biotechnology.  Long-chain 
acyl-CoAs were purchased from Sigma-Aldrich.  D. melanogaster (Oregon R) and 4-24 Instant 
Medium were supplied by Carolina Biological.  Silica was purchased from Suppelco.  
Long-chain N-acylserotonins and N-arachidonoylglycine-d8 standards were purchased from 
Cayman Chemical.  All other reagents were of the highest quality available from either 
Sigma-Aldrich or Fisher Scientific. 
 
2.2. Molecular cloning 
AANATL2 (CG9486; Accession No. NM_135161.3) was codon optimized for expression 
in E. coli and purchased from Genscript.  The codon optimized gene was inserted into a 
pET28a(+) vector using the  NdeI and XhoI restriction sites.  The AANATL2-pET28a vector was 
then transformed into E. coli BL21(DE3) competent cells and plated on a LB agar plate 
supplemented with 40 µg/mL kanamycin.  A single colony from the transformation was then 
used for the expression of AANATL2. 
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2.3. Protein expression and purification 
The BL21(DE3) E. coli cells containing the D. melanogaster AANATL2-pET28a vector 
were cultured in LB media supplemented with 40 µg/mL kanamycin and induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside at an OD600 of 0.6 for 4 hrs at 37°C.  The final culture 
was then harvested by centrifugation at 5,000 g for 10 min at 4
o
C and the pellet was collected.   
The pellet was then resuspended in 20 mM Tris, 500 mM NaCl, 5 mM imidazole; lysed 
by sonication; and then centrifuged at 10,000 g for 15 min at 4°C.  The resulting supernatant was 
loaded onto 6 mL of Probond™ nickel-chelating resin.  The column was first washed with  
10 column volumes of 20 mM Tris-HCl, 500 mM NaCl, 5 mM imidazole, pH 7.9, then washed 
with 10 column volumes of 20 mM Tris-HCl, 500 mM NaCl, 60 mM imidazole, pH 7.9, and 
lastly  eluted in 1 mL fractions of 20 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 7.9.  
The AANATL2 within these fractions were analyzed for purity using a 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel, visualized using Coomassie stain, 
and pooled together.   The pooled fractions are dialyzed overnight at 4°C in 20 mM Tris, 200 
mM NaCl, pH 7.4 and stored at -80°C.   
 
2.4. Activity assay 
Steady-state kinetic characterization of AANATL2 was performed in 300 mM Tris-HCl, 
pH 8.0, 150 µM 5,5’-dithiobis(2-nitrobenzoic acid) (DTNB) [21], and varying concentrations of 
substrates.  Initial rates were measured continuously at 412 nm.  Kinetic constants for long-chain 
acyl-CoA substrates were determined by holding the initial serotonin concentration constant at 5 
mM.  Kinetic constants for the short-chain acyl-CoA substrates, acetyl-CoA and butyryl-CoA, 
were determined by holding the initial serotonin concentration constant at 100 M.  The steady-
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state kinetic constants for serotonin, dopamine, octopamine, and tyramine were delineated by 
holding the initial acyl-CoA concentration at 50 µM.  Steady-state kinetic constants were 
obtained by fitting the data to the Michaelis-Menten equation in SigmaPlot 12.0. 
 
2.5. AANATL2 product characterization 
The product of the AANATL2-catalyzed reaction was generated by incubating 36 µg of 
the enzyme for 1 hour in 300 mM Tris-HCl, pH 8.0, 50 mM serotonin or dopamine, and 500 µM 
oleoyl-CoA.  The reaction mixture was passed through a 10 kDa ultrafilter (Millipore) to remove 
the AANATL2 and resulting protein-free solution injected on an Agilent 6540 liquid 
chromatography/quadrupole time-of-flight mass spectrometer (LC/QTOF-MS) in positive ion 
mode.  A Kinetex™ 2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column was used for 
AANATL2 product separation.  Mobile phase A consisted of water with 0.1% formic acid and 
mobile phase B consisted of acetonitrile with 0.1% formic acid.  A linear gradient of 10% B 
increasing to 100% B over the course of 5 min, followed by a hold of 3 min at 100% B was used 
for the LC analysis of the reaction product.  The reverse phase column was equilibrated with 
10% B for 8 minutes after the run to prepare the column for the subsequent injections.       
2.6. AANATL2 transcript localization 
D. melanogaster were grown on 4-24 Instant Medium from Carolina Biological, flash 
frozen for decapitation, and the heads were separated from thorax-abdomens using a wired mesh.  
Ambion MicroPoly(A) Purist kit was used to purify the mRNA and Ambion Retroscript kit was 
used to generate the cDNA library for subsequent RT-PCR localization of AANATL2 from  
D. melanogaster head and thorax-abdomen.  Identification of AANATL2 transcripts was 
completed by RT-PCR (45 cycles of 95°C for 30 s; 60°C for 30 s; 72°C for 1 min).  The primers 
235 
 
used to amplify a 247 bp region of AANATL2 (forward – ATGACAATCGGGGATTACGA, 
reverse - CCTCCTGGTACTCCCTCTCC) were designed and synthesized by Eurofins MWG 
Operon.  Amplified product from the RT-PCR reaction was analyzed by a 0.6 % agarose gel and 
the band visualized by 0.5 µg/mL ethidium bromide under ultraviolet light.  The positive bands 
at 247 bp were cut out of the gel, purified by the Promega Wizard
®
 SV Gel and PCR Clean-up 
system, and sequenced by Eurofins MWG Operon.  
 
2.7. Endogenous quantification of long-chain N-acylserotonins 
Four separate cultures of D. melanogaster were used for the analysis of endogenous 
levels of long-chain N-acylserotonins.   Lipids were extracted using organic solvents followed by 
the solid phase purification of Farrell et al. [22].  The purified extracts were dried under N2, 
reconstituted in HPLC grade methanol, and injected on an Agilent 1260 connected to an Agilent 
6540 LC/QTOF-MS in positive ion mode.  Injected lipid extracts were separated by a Kinetex™ 
2.6 µm C18 100 Å (50 × 2.1 mm) reverse phase column at 0.6 mL/min.  Mobile phase A 
consisted of water with 0.1% formic acid and mobile phase B consisted of acetonitrile with 0.1% 
formic acid.  A linear gradient was used for the separation of the injected lipid extracts by 
reverse phase chromatography starting at 10% B and increasing to 100% B over the course of 5 
min, followed by a hold of 3 min at 100% B.  The reverse phase column was equilibrated with 
10% B for 8 minutes after the run to prepare the column for subsequent injections.  
N-Arachidonoylglycine-d8, 1 pmole per 10 µL injection, was spiked into each extraction to 
measure instrument performance and for data normalization.  The four extractions from separate 
cultures of D. melanogaster were analyzed in triplicate for a total of 12 runs.  Standard curves of 
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commercially available N-acylserotonins and N-arachidonoylglycine-d8 were analyzed in 
triplicate with a linear range of 100 fmoles to 5 pmoles (r
2
 values >0.99). 
 
3. Results and Discussion 
The codon optimized D. melanogaster AANATL2 gene was prepared commercially by 
Genscript and cloned into a pet28a(+) vector that encodes for an N-terminal His6-tag protein.  
Recombinant D. melanogaster AANATL2 was expressed in Escherichia coli BL21(DE3) cells 
and purified using Probond™ nickel-chelating resin.  The purified AANATL2 was then analyzed 
by SDS-PAGE (Fig. 2), yielding a single band at 25 kDa.  
 Potential substrates for AANATL2 were identified using Ellman’s reagent [21] by 
measuring the acyl-CoA dependent release of CoA-SH which yields 2-nitro-5-thiobenzoate at 
412 nm.  Activity was observed with serotonin and oleoyl-CoA from our substrate screening 
studies which was evaluated in greater detail with subsequent steady-state kinetic analysis of 
AANATL2 with a set of acyl-CoA thioesters and serotonin.  We found that acyl-CoA thioesters 
from acetyl-CoA to arachidonoyl-CoA are AANATL2 substrates with some variability in the 
apparent kinetic constants at saturating serotonin.  The (KM,acyl-CoA)app values for all the acyl-CoA 
thioesters included in our study were approximately the same, ranging from ~2 M for  
butyryl-CoA and arachidonoyl-CoA to ~ 10 M for palmitoyl-CoA.  Greater variability was 
observed for the (kcat,acyl-CoA)app and (kcat/KM)acyl-CoA,app values with a range of 20-30-fold.  Based 
on our data, the short-chain acyl-CoA thioesters are, in general, substrates with higher 
(kcat/KM,acyl-CoA)app values than the long-chain acyl-CoA thioesters (Table 1).  Amherd et al. [20] 
expressed D. melanogaster AANATL2 in COS-7 cells and report a (KM,acyl-CoA)app for  
acetyl-CoA of 7.2 ± 0.6 M with tryptamine as a co-substrate that is similar to the value we 
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measure using serotonin as the co-substrate.  A comparison of (kcat,acyl-CoA)app and (kcat/KM)acyl-
CoA,app values we measure (Table 1) to those reported by Amherd et al. [20] is difficult as these 
researchers did not purify recombinant AANATL2 from the COS-7 cells.    
We have also evaluated biologically relevant arylalkylamines other than serotonin as 
substrates for AANATL2, namely dopamine, octopamine, and tyramine.  Ahmerd et al. [20] 
have already demonstrated that tryptamine is a substrate for D. melanogaster AANATL2.    
Neither tyramine nor octopamine were substrates when the acyl acceptor was oleoyl-CoA as the 
observed rate of CoA release from oleoyl-CoA was equivalent to the background rate of 
hydrolysis obtained in the absence of the arylalkylamine.  However, both were substrates when 
the acyl acceptor was acetyl-CoA. The kinetic constants for the AANATL2-catalyzed formation 
of N-acetyltyramine and N-acetyloctopamine are similar to those determined for the formation of  
N-acetylserotonin except for a relatively high (KM,amine)app for octopamine of 78 ± 3.9 M  
(Table S1, supplementary materials).   Dopamine is a substrate for AANATL2 when the co-
substrate is acetyl-, palmitoyl-, or oleoyl-CoA (Table 2).  Again, the kinetic constants for the 
formation of N-acetyldopamine are similar to those determined for the generation of the other  
N-acetylarylalkylamides. 
We evaluated the relationship between the (KM,amine)app for serotonin or dopamine as a 
function of acyl chain length for the acyl-CoA substrates (Table 2) because both of these were 
substrates when acetyl-CoA and the long-chain acyl-CoA were co-substrates. The pattern in the 
data was the same for both serotonin and dopamine, the (KM,amine)app increased, the (kcat,amine)app 
decreased, and the (kcatKM)amine,app decreased as the acyl chain length increased from acetyl to 
arachidonoyl.  The ratio of (kcatKM          
          /(kcatKM          
                
  is 3,400 for dopamine and 
5,000 for serotonin indicating that acetyl-CoA is substantially preferred by AANATL2.   
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Side-by-side comparisons of the acyl-CoA thioesters between serotonin and dopamine show that 
AANATL2 exhibits a slight preference for serotonin as the amine donor substrate.   
An examination of our kinetic data reveals some patterns:  (a) limited variation in the  
(KM,acyl-CoA)app values for the acyl-CoA substrates as all are in the range of 2-10 M, (b) limited 
variation (kcat,amine)app and (kcat/KM)amine,app values on the amine substrate, (c) an increase in the 
(KM,amine)app values for the amine substrates as the length of the acyl chain increases for the  
acyl-CoAs, and (d) a decrease in the (kcat,amine)app and (kcat/KM)amine,app values as the length of the 
acyl chain increases for the acyl-CoAs.  These data suggest that the long-chain acyl group either 
interferes with the binding of the arylalkylamine substrates or that the binding of the long-chain 
acyl-CoAs results in an AANATL2 conformation that is less optimal for catalysis.  An X-ray 
structure of AANATL2 with bound acetyl-CoA or oleoyl-CoA could differentiate between these 
two possibilities.  We also note the relatively low kcat,app values [(kcat,acyl-CoA)app and (kcat,amine)app] 
values for the long-chain acyl-CoA substrates; however, low kcat,app values are not surprising 
since the long-chain N-acyl- serotonins and dopamines likely serve as potent cell signaling lipids 
[9-13].  The cellular function of AANATL2 may be the generation of the long-chain  
N-acylarylalkylamides and the measured kcat,app values are sufficient to supply the cellular needs 
of these potent lipid amides. Saghatelian and Cravatt [23] have shown in their studies of  
FAAH(-/-) that in vitro measurements of kinetic constants may not provide a complete 
understanding of the functional role of an enzyme in vivo.    
The products from the AANATL2 catalyzed reaction between oleoyl-CoA and serotonin 
or dopamine were positively identified as N-oleoylserotonin and N-oleoyldopamine (Table 3).  
AANATL2 was incubated with serotonin or dopamine and oleoyl-CoA for one hour, the enzyme 
was removed by ultrafiltration using a 10 kDa cutoff filter, followed by product analysis by 
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liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/QTOF-MS).  
AANATL2-generated N-oleoylserotonin or N-oleoyldopamine was compared to a commercial 
standard.  Positive identification was delineated by a comparable retention time and molecular 
ion m/z for the AANATL2 product and the standard (Table 3).  
The in vitro data we obtained using purified AANATL2 (substrate specificity and product 
characterization) lead to questions such as: (a) are the long-chain N-acylarylalkylamides found in 
D. melanogaster, (b) if so, what are the steady-state endogenous levels of these fatty acid 
amides, and (c) would we find colocalization of endogenous N-acylarylalkylamides and 
AANATL2?  To address these intriguing questions, we first identified the localization of the 
AANATL2 transcripts by RT-PCR.  Primers were designed and synthesized commercially to 
generate a 247 bp AANATL2-derived RT-PCR product from the cDNA libraries generated from 
D. melanogaster head and thorax-abdomen.  The RT-PCR experiments show that AANATL2 
transcripts were only found in the thorax-abdomen of D. melanogaster (Fig. 3). 
AANATL2 was positively identified by the 247 bp RT-PCR product generated from the  
D. melangaster thorax-abdomen cDNA library; however, a similar RT-PCR product was not 
observed from the head cDNA library.  The sequence of the 247 bp product from the 
thorax-abdomen library was confirmed as AANATL2 by DNA sequencing.  These data are in 
slight contrast to the report a faint band for AANATL2 from D. melanogaster head by Northern 
analysis [20].  Together, our data and that from Amherd et al. [20] indicate that AANATL2 
transcripts are found at substantially higher levels in the thorax-abdomen relative to the head in 
D. melanogaster.  
 Our identification of the AANATL2 transcripts in the thorax-abdomen and the relatively 
high levels of serotonin in the mammalian gastrointestinal tract [9,24] strongly suggested to us 
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that the long-chain N-acylserotonins would exist endogenously in the thorax-abdomen of D. 
melanogaster.  Four long-chain N-acylserotonins were identified in the thorax-abdomen by 
molecular ion m/z and retention time comparisons to commercially available standards (Table 4) 
by LC/QTOF-MS in positive ion mode.  Endogenous amounts of N-acylserotonins were not 
identified in the heads, consistent with our RT-PCR data in which the AANATL2 transcripts were 
not found.  Standard curves with a linear range of 100 fmoles to 5 pmoles (r
2
 values >0.99) were 
used to quantify the endogenous amounts of N-acylserotonins in the thorax-abdomen.  
N-Stearoylserotonin was the most abundant followed by N-palmitoylserotonin, 
N-arachidonoylserotonin, and N-oleoylserotonin (Table 4).  The N-acylserotonin levels that we 
found in the thorax-abdomen of D. melanogaster are similar to that reported for these fatty acid 
amides in porcine gastrointestinal tract [9].   In contrast to the long-chain N-acylserotonins, the 
long-chain N-acyldopamines are found in both the thorax-abdomen and the heads of D. 
melanogaster [25].  The dissimilarities in the localization of the long-chain N-acylserotonins 
relative to the long-chain N-acyldopamines are likely the result of differences in biosynthesis, 
degradation, and/or transport of these different N-acylarylalkylamides.    
In summary, AANATL2 from D. melanogaster was shown to catalyze the formation of a 
diverse set of N-acylarylalkylamides with the most intriguing products being the long-chain  
N-acylserotonins and N-acyldopamines.  Colocalization of AANATL2 transcripts and endogenous 
long-chain N-acylserotonins to the thorax-abdomen points to an important role for this enzyme in 
the biosynthesis of these cell signalling long-chain N-acylarylalkylamides.  Future work to 
expand our understanding of biosynthesis and degradation of the N-acylserotonins,  
N-acyldopamines, and other long-chain N-acylarylalkylamides involving the inhibition of key 
enzymes is ongoing.   
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Figure Legends 
 
Figure 1. Proposed reaction for the formation of long-chain N-acylserotonins catalyzed by 
AANATL2. 
 
Figure 2. SDS-PAGE analysis of purified D. melanogaster AANATL2. Left lane is 
PageRuler™ Prestained Protein Ladder. Right lane is purified AANATL2. 
 
Figure 3. RT-PCR of AANATL2 in D. melanogaster head and thorax-abdomen. Lane 1-4  
is data generated from the D. melanogaster head cDNA library at 45°C, 50°C, 55°C, and 60°C 
annealing temperatures respectively.  Lane 5 is 100 bp DNA ladder from New England Biolabs.  
Lane 6-9 is data generated from the D. melanogaster thorax-abdomen cDNA library at 45°C, 
50°C, 55°C, and 60°C annealing temperature respectively.  Lane 10 is a 1 kb DNA ladder from 
New England Biolabs. 
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Figure 3. 
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Table 1 
Acyl-CoA Specificity for AANATL2 
a
Background rates of acyl-CoA hydrolysis were obtained at each CoA concentration in the absence of 
serotonin and subtracted from the rate obtained in the presence of serotonin.  The non-serotonin 
background rates were ≤15% of rates obtained in the presence of serotonin, with exception of steroyl-
CoA.  For stearoyl-CoA, the background hydrolysis rates were ≤30%. 
 
 
 
 
 
 
 
 
 
 
Substrate
a
 
(KM,acyl-CoA)app (kcat,acyl-CoA)app (kcat/KM)acyl-CoA,app 
µM s
-1
 M
-1
s
-1
 
Acetyl-CoA 6.1 ± 0.27 1.3 ± 0.012 (2.2 ± 0.020) × 10
5
 
Butyryl-CoA 1.8 ± 0.17 0.53 ± 0.011 (2.9 ± 0.058) × 10
5
 
Palmitoyl-CoA 9.9 ± 1.6 0.16 ± 0.0090 (1.6 ± 0.091) × 10
4
  
Stearoyl-CoA 6.0 ± 0.75 0.059 ± 0.0023 (9.8 ± 0.39) × 10
3
 
Oleoyl-CoA 3.6 ± 0.58 0.075 ± 0.0033 (2.1 ± 0.091) × 10
4
  
Arachidonoyl-CoA 1.9 ± 0.25 0.043 ± 0.0013 (2.3 ± 0.068) × 10
4
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Table 2 
Apparent Kinetic Constants for Serotonin and Dopamine using Different Acyl-CoA Substrates 
Substrate
a
 
(KM,amine)app (kcat,amine)app (kcat/KM)amine,app 
µM s
-1
 M
-1
s
-1
 
Serotonin 
Acetyl-CoA 7.2 ± 1.1 2.4 ± 0.097 (3.3 ± 0.13) × 10
5
 
Butyryl-CoA 2.9 ± 0.33 0.52 ± 0.011 (1.8 ± 0.040) × 10
5
 
Palmitoyl-CoA 870 ± 60 0.15 ± 0.0034 (1.7 ± 0.039) × 10
2
  
Stearoyl-CoA 350 ± 35 0.057 ± 0.0014 (1.6 ± 0.040) × 10
2
  
Oleoyl-CoA 490 ± 86 0.085 ± 0.0059 (1.7 ± 0.12) × 10
2
  
Arachidonoyl-CoA 460 ± 69 0.030 ± 0.0014 66 ± 3.0 
Substrate
a
 
(KM,amine)app (kcat,amine)app (kcat/KM)amine,app 
mM s
-1
 M
-1
s
-1
 
Dopamine 
Acetyl-CoA 0.042 ± 0.0097 6.5 ± 0.67 (1.6 ± 0.16) × 10
5
 
Palmitoyl-CoA 1.1 ± 0.13 0.14 ± 0.0050 (1.2 ± 0.045) × 10
2
 
Oleoyl-CoA 1.2 ± 0.20 0.058 ± 0.0033 47 ± 2.7 
a
Background rates of acyl-CoA hydrolysis were obtained at a saturating CoA concentration in the absence 
of the arylalkylamine and subtracted from the rate obtained in the presence of arylalkylamine.  The non-
arylalkylamine (background rates) were ≤20% of rates obtained in the presence of arylalkylamine. 
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Table 3 
Standards used for identification of endogenous long-chain N-acylserotonins and  
the AANATL2 product characterization 
N-Acylarylalkylamine Standard 
Retention Time 
Min 
Molecular Ion 
[M+H]
+
 
m/z 
N-Oleoylserotonin  6.132 441.3878 
N-Palmitoylserotonin  6.038 415.3344 
N-Stearoylserotonin  6.368 443.3620 
N-Arachidonoylserotonin  5.900 463.3291 
N-Oleoyldopamine 5.929 418.3326 
   
AANATL2 Product
a
 6.130 441.3464 
AANATL2 Product
b
 5.929 418.3325 
a 
Reaction conditions: 300 mM Tris-HCl, pH 8.0, 50 mM serotonin, and 500 µM oleoyl-CoA was 
incubated with 36 µg of AANATL2 for one hour. 
b
Reaction conditions: 300 mM Tris-HCl, pH 8.0, 50 mM dopamine, and 500 µM oleoyl-CoA was 
incubated with 36 µg of AANATL2 for one hour. 
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Table 4 
Endogenous amounts of N-acylserotonins found in D. melanogaster head and thorax-abdomen 
N-Acylserotonin 
Head
a
 Thorax-abdomen
b
 
Extracted 
amount 
Extracted 
amount 
Retention 
Time 
Molecular Ion 
pmoles g
-1
  pmoles g
-1
  min [M+H]
+
 
m/z 
N-Oleoylserotonin nd
c
 0.42 ± 0.55 
6.147 441.2633 
6.009 441.2684 
6.149 441.2666 
6.180 
 
441.2622 
 
N-Palmitoylserotonin nd
c
 1.16 ± 0.12 
6.036 415.3249 
6.032 415.3237 
6.023 415.3203 
6.040 
 
415.3243 
 
N-Stearoylserotonin nd
c
 53.5 ± 33.3 
6.367 443.3143 
6.244 443.2986 
6.368 443.3167 
6.262 
 
443.2993 
 
N-Arachidonoylserotonin nd
c
 0.25 ± 0.15 
5.907 463.2998 
5.906 463.3022 
5.882 463.3478 
5.940 463.3138 
a
Identification and quantification of endogenous amounts extracted from one gram of  
D. melanogaster heads. 
b
Identification and quantification of endogenous amounts extracted from one gram of  
D. melanogaster thorax-abdomen. 
c
nd indicates that these N-acylserotonins were “not detected” in one gram of this anatomical 
location of D. melanogaster. 
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Supporting Information 
Table S1 
Amino Donor Specificity for AANATL2 
a
Reaction conditions: 300 mM Tris-HCl pH 8.0, 150 µM DTNB, 50 µM acetyl-CoA, and varying 
concentration of different amino donors. 
b
Each amino donor was screen under two reaction conditions to determine if AANATL2 will catalyze the 
formation of long-chain N-acyl amino donor.  Reaction condition 1: 300 mM Tris-HCl pH 8.0, 150 µM 
DTNB, 50 µM oleoyl-CoA, and 5 mM amino donor.  Reaction condition 2: 300 mM Tris-HCl pH 8.0, 
150 µM DTNB, 500 µM oleoyl-CoA, and 50 mM amino donor.  A rate was not observed above the 
background rate of oleoyl-CoA hydrolysis for each amino donor. 
 
Substrate
a,b
 
Km, app kcat, app (kcat/Km) app 
µM s
-1
 M
-1
s
-1
 
Octopamine 78 ± 3.9 2.3 ± 0.038 (3.0 ± 0.049) × 10
4
 
Tyramine 3.9 ± 0.30 0.81 ± 0.013 (2.1 ± 0.033) × 10
5
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Supplementary Information 
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Figure S.1. 
AANATL7 – 
500 µM 
acetyl-CoA and 
varied 
histamine. 
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Figure S.2. AANATL7 – 500 µM acetyl-CoA and varied tyramine. 
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Figure S.3. AANATL7 – 500 µM acetyl-CoA and varied ethanolamine. 
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Figure S.4. AANATL7 – 500 µM acetyl-CoA and varied tryptamine. 
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Figure S.5. AANATL7 – 500 µM acetyl-CoA and varied serotonin. 
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Figure S.6. AANATL7 – 500 µM acetyl-CoA and varied octopamine. 
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Figure S.7. AANATL7 – 500 µM acetyl-CoA and varied phenethylamine. 
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Figure S.8. AANATL7 – 500 µM acetyl-CoA and varied 3-methoxyphenethylamine. 
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Figure S.9. AANATL7 – 500 µM acetyl-CoA and varied 3,4-methylenedioxyphenethylamine. 
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Figure S.10. AANATL7 – 500 µM acetyl-CoA and varied 4-phenylbutylamine. 
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Figure S.11. AANATL7 – 500 µM acetyl-CoA and varied β-methylphenethylamine. 
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Figure S.12. AANATL7 – 500 µM acetyl-CoA and varied dopamine. 
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Figure S.13. AANATL7 – 500 µM acetyl-CoA and varied norephinephrine. 
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Figure S.14. AANATL7 – 500 µM acetyl-CoA and varied 5-benzyloxytryptamine. 
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Figure S.15. AANATL7 – 500 µM acetyl-CoA and varied 3-(trifluoromethyl)phenethylamine. 
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Figure S.16. AANATL7 – 500 µM acetyl-CoA and varied 5-methoxytryptamine. 
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Figure S.17. AANATL7 – 500 µM acetyl-CoA and varied benzylamine. 
 
[Agmatine (µM)]
0 1000 2000 3000 4000 5000 6000
V
o
 (
µ
m
o
l/
m
in
/m
g
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
 
 
Figure S.18. AANATL7 – 500 µM acetyl-CoA and varied agmatine. 
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Figure S.19. AANATL7 – 500 µM acetyl-CoA and varied putrescine. 
 
[4-methoxyphenethylamine (µM)]
0 200 400 600 800 1000 1200
V
o
 (
µ
m
o
l/
m
in
/m
g
)
0
5
10
15
20
25
30
35
 
 
Figure S.20. AANATL7 – 500 µM acetyl-CoA and varied 4-methoxyphenethylamine. 
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Figure S.21. AANATL7 – 7.5 mM histamine and varied acetyl-CoA. 
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Figure S.22. AANATL7 – 7.5 mM histamine and varied butyryl-CoA. 
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Figure S.23. AANATL7 – 7.5 mM histamine and varied hexanoyl-CoA. 
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Figure S.24. AANATL7 – 750 µM tyramine and varied acetyl-CoA. 
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Figure S.25. AANATL7 – 750 µM tyramine and varied butyryl-CoA. 
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Figure S.26. AANATL7 E26A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.27. AANATL7 E26A - 500 µM acetyl-CoA and varied histamine 
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Figure S.28. AANATL7 P27A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.29. AANATL7 P27A – 1.0 mM acetyl-CoA and varied histamine. 
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Figure S.30. AANATL7 P27A – 1.0 mM acetyl-CoA and varied agmatine. 
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Figure S.31. AANATL7 R138A - 50 mM histamine and varied acetyl-CoA. 
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Figure S.32. AANATL7 R138A – 2.5 mM acetyl-CoA and varied histamine. 
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Figure S.33. AANATL7 T167A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.34. AANATL7 T167A – 2.0 mM acetyl-CoA and varied histamine. 
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Figure S.35. AANATL7 S171A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.36. AANATL7 S171A – 500 µM acetyl-CoA and varied histamine. 
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Figure S.37. AANATL7 T167A/S171A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.38. AANATL7 T167A/S171A – 500 µM acetyl-CoA and varied histamine. 
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Figure S.39. AANATL7 H206A – 50 mM histamine and varied acetyl-CoA. 
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Figure S.40. AANATL7 H206A – 2.0 mM acetyl-CoA and varied histamine. 
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Figure S.41. AANATL2 – 50 µM acetyl-CoA and varied tryptamine. 
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Figure S.42. AANATL2 – 50 µM acetyl-CoA and varied norepinephrine. 
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Figure S.43. AANATL2 – 50 µM acetyl-CoA and varied phenethylamine. 
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Figure S.44. AANATL2 – 50 µM acetyl-CoA and varied 3-(trifluoromethyl)phenethylamine. 
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Figure S.45. AANATL2 – 50 µM acetyl-CoA and varied 3,4-methylenedioxyphenethylamine. 
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Figure S.46. AANATL2 – 50 µM acetyl-CoA and varied histamine. 
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Figure S.47. AANATL2 – 50 µM acetyl-CoA and varied 3-methoxyphenethylamine. 
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Figure S.48. AANATL2 – 50 µM acetyl-CoA and varied β-methylphenethylamine. 
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Figure S.49. AANATL2 – 50 µM acetyl-CoA and varied 4-methoxyphenethylamine. 
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Figure S.50. AANATL2 – 50 µM acetyl-CoA and varied ethanolamine. 
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Figure S.51. AANATL2 – 50 µM acetyl-CoA and varied 5-benzyloxytryptamine. 
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Figure S.52. AANATL2 – 50 µM acetyl-CoA and varied 4-phenylbutylamine. 
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Figure S.53. AANATL2 – 50 µM acetyl-CoA and varied 5-methoxytryptamine. 
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Figure S.54. AANATL2 – 50 µM acetyl-CoA and varied benzylamine. 
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Figure S.55. AANATL2 – 50 µM acetyl-CoA and varied tyramine. 
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Figure S.56. AANATL2 – 100 µM tyramine and varied acetyl-CoA. 
 
 
 
282 
 
[Acetyl-CoA (µM)]
0 10 20 30 40 50 60
V
o
 (
µ
m
o
l/
m
in
/m
g
)
0.0
0.2
0.4
0.6
0.8
1.0
 
 
Figure S.57. AANATL2 E29A – 1.0 mM tyramine and varied acetyl-CoA. 
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Figure S.58. AANATL2 E29A – 50 µM acetyl-CoA and varied tyramine. 
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Figure S.59. AANATL2 P30A – 2.5 mM tyramine and varied acetyl-CoA. 
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Figure S.60. AANATL2 P30A – 50 µM acetyl-CoA and varied tyramine. 
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Figure S.61. AANATL2 R138A – 500 µM tyramine and varied acetyl-CoA. 
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Figure S.62. AANATL2 R138A – 50 µM acetyl-CoA and varied tyramine. 
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Figure S.63. AANATL2 S167A – 100 µM tyramine and varied acetyl-CoA. 
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Figure S.64. AANATL2 S167A – 500 µM acetyl-CoA and varied tyramine. 
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Figure S.65. AANATL3 – 10 mM tyramine and varied acetyl-CoA. 
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Figure S.66. AANATL3 – 1.0 mM acetyl-CoA and varied tyramine. 
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Figure S.67. AANATL3 – 1.0 mM acetyl-CoA and varied serotonin. 
 
 
 
[Octopamine (µM)]
0 2000 4000 6000 8000 10000 12000
V
o
 (
µ
m
o
l/
m
in
/m
g
)
0.0
0.1
0.2
0.3
0.4
0.5
0.6
 
 
Figure S.68. AANATL3 – 1.0 mM acetyl-CoA and varied octopamine. 
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Figure S.69. Cloning and Purification of AANATL7 from D. melanogaster.  (A) Lane 1 - 1 kb 
DNA ladder (New England Biolabs), Lane 2 - AANATL7; 687 bp band. (B) Lane 1 - 
PageRuler™ Prestained protein ladder (Thermo Scientific), Lane 2 – Purified AANATL7; 26 
kDA. 
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Figure S.70. SDS-PAGE gel of purified AANATL7 mutants.  Lane 1 - PageRuler™ Prestained 
protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL7, Lane 3 – E26A, Lane 4 – 
P27A, Lane 5 - R138A, Lane 6 – T167A, Lane 7 - S171A, Lane 8 – H206A.  
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Figure S.71. SDS-PAGE gel of purified AANATL7 mutants.  Lane 1 - PageRuler™ Prestained 
protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL7, Lane 3 – T167A/S171A. 
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Figure S.72. SDS-PAGE gel of purified AANATL2 site-directed mutants.  Lane 1 - PageRuler™ 
Prestained protein ladder (Thermo Scientific), Lane 2 – Wildtype AANATL2, Lane 3 – E29A, 
Lane 4 – P30A, Lane 5 - R138A, Lane 6 – S167A, Lane 7 - S171A, Lane 8 - H206A.  
 
 
 
 
 
 
 
 
 
 
 
